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SUMMARY 
Comparing biological activities and thermodynamic profiles obtained for one compound toward 
proteins, differing only in few residues is a promising strategy to increase the knowledge of 
protein-ligand interactions and active site topologies thereby enabling rational drug design. 
For this purpose, wild type proteins and their mutants carrying a set of point mutations can 
be used. Such an approach was applied in the present study to guide the development of small-
molecule antagonists targeting PqsR, a novel target to limit Pseudomonas aeruginosa 
pathogenicity. It resulted in two chemically divers fragments with antagonistic activity and 
provided insights into their binding modes. The latter can be used to assist fragment 
optimization and therefore the identified PqsR antagonists are promising scaffolds for further 
drug design efforts against this important pathogen. 
Alternatively, proteins from various species, which are highly conserved in sequence and 
differ only in few residues, might be considered. This line of attack was also utilized employing 
human and marmoset monkey 17β-HSD1, a promising target for the treatment of estrogen-
dependent diseases. By means of in silico methods a better understanding of 17β-HSD1 active 
site topologies and inhibitor binding modes was achieved that guided the elaboration of a lead 
compound.  
The described strategy was successfully applied for hit identification and lead optimization 
reflecting its benefit in drug design. 
  
VII 
ZUSAMMENFASSUNG 
Die möglichst genaue Kenntnis der räumlichen Gestalt der Ligand Bindungsstelle und der damit 
verbundenen Protein-Ligand-Wechselwirkungen ist eine Voraussetzung für rationales 
Wirkstoffdesign. Eine aussichtsreiche Strategie um diese Informationen zu erhalten, ist es 
biologische/biophysikalische Daten einer Verbindung gegenüber Proteinen zu vergleichen, die 
sich nur in wenigen Aminosäuren unterscheiden. 
Einerseits können dazu Wildtyp und Mutanten genutzt werden, was in dieser Studie zur 
Entwicklung von PqsR Antagonisten geführt hat. PqsR ist ein neues Target zur Limitierung der 
Pseudomonas aeruginosa Pathogenität. Zwei chemisch verschiedene, antagonistische 
Fragmente wurden entdeckt und Aufschlüsse über deren Bindungsmodi erhalten, die zur 
weiteren Optimierung genutzt werden können. Somit stellen die entdeckten Liganden 
vielversprechende Grundgerüste zur weiteren Wirkstoffentwicklung gegen dieses relevante 
Pathogen dar. 
Alternativ können hochkonservierte Proteine verschiedener Spezies in Betracht gezogen 
werden. Unter Verwendung von humaner und marmoset 17β-HSD1, einem 
erfolgversprechenden Target zur Behandlung estrogenabhängiger Erkrankungen, wurden durch 
in silico Methoden das aktive Zentrum der 17β-HSD1 sowie Bindungsmodi ausgewählter 
Hemmstoffe untersucht. Anhand der erstellten Modelle wurde eine Leitverbindung 
weiterentwickelt.  
Diese Strategie wurde erfolgreich für das Wirkstoffdesign bei der Hit Identifizierung sowie 
der Lead Optimierung angewendet. 
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1 Introduction 
1.1 Rational Drug Design 
Besides cardiovascular and infectious diseases, cancer is the leading cause of death worldwide 
(WHO, 2008). As those diseases constantly threaten human life, new drugs are always in great 
demand for prevention and treatment. However, it is generally acknowledged that drug 
discovery and development are time (Myers and Baker, 2001) and resources (DiMasi et al., 
2003) consuming processes. 
From early on, the discovery of new drugs involved a trial-and-error approach on naturally 
derived materials and substances. This was expanded by systematic pharmacological 
evaluations of both natural and synthetic compounds in the first half of the twentieth century. 
However, most new drugs until the 1970s were discovered by serendipity (Kaul, 1998; Rester, 
2008). Over the past 30 years the route of drug discovery has been changed. With advances in 
computational techniques and molecular biology as well as with the development of biophysical 
methods, that is, mainly X-ray crystallography, nuclear magnetic resonance (NMR) 
spectroscopy, isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR) 
spectroscopy, it became possible to place drug discovery on a rational basis (Mavromoustakos 
et al., 2011). The use of complementary experimental and computational techniques provides a 
lot of information on the system under study. This knowledge can be utilized in a positive way 
to streamline drug discovery, which is characteristic for a rational drug design approach. The 
latter has the potential to increase the chances of success in many stages of the discovery 
process, from the identification of novel targets and elucidation of their function to the 
discovery and development of lead compounds with desired properties (Bajorath, 2001). 
1.1.1 Isothermal titration calorimetry in drug design 
Isothermal titration calorimetry (ITC) provides a rapid route to a full thermodynamic 
characterization of a molecular interaction – for example, a protein and a small-molecule ligand. 
A single ITC experiment provides the changes in free energy (ΔG), enthalpy (ΔH) and entropy 
(ΔS) as well as the stoichiometry N of the reaction. While ΔH, N, and the association constant 
KA are directly measured (Figure 1), ΔG and ΔS are calculated from Eq. (1) 
 
ΔG = ΔH - TΔS = RTlnKA = -RTlnKD (1) 
 
Determination of the thermodynamic parameters offers detailed information on a molecular 
interaction: ΔG reports on the affinity, ΔH is the heat associated with the number and the 
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strength of non-covalent bonds, ΔS reports on the overall change in the degrees of freedom of 
the system (Ladbury, 2010). 
 
 
Figure 1. Typical titration data. a) raw data. b) binding isotherm created by plotting the 
integrated heat peaks against the molar ratio of the ligand. 
In the drug discovery process, affinity (ΔG, KD) can be used as criteria for hit or lead 
identification. But as in the optimization process, increasing affinity of a candidate is usually 
accompanied by an increase in molecular mass (Lipinski, 2000) screening for affinity alone can 
result in compounds with lower molecular mass being discarded. In order to deal with this 
problem, efficiency indices should be used as guideposts (Abad-Zapatero and Metz, 2005). This 
is a way of normalizing the affinity and molecular size of a compound to provide a useful 
comparison between compounds with a range of molecular weight and affinity. A measure that 
includes affinity is the ligand efficiency (LE). It is calculated as the binding energy of the ligand 
ΔG per heavy atom (Hopkins et al., 2004). However, to account for heteroatoms the binding 
efficiency index (BEI), which engages the total molecular weight instead of the number of non-
hydrogen atoms is superior (Abad-Zapatero and Metz, 2005). 
Favorable ΔH values indicate a good non-covalent bond complementary between proteins 
and small molecules and compounds with more favorable ΔH values make additional or 
stronger interactions (Figure 2). Therefore ΔH provides also a viable measure with which 
medicinal chemists can rank compounds, in particular using the accordant efficiency index, the 
enthalpy efficiency (EE; EE = ΔH /number of non-hydrogen atoms; Ladbury et al., 2010). 
The ΔS value is constituted by the solvation entropy change and the conformational entropy 
change. The solvation entropy change is favorable and originates from the release of water 
molecules as the drug and the binding cavity undergo complete or partial desolvation upon 
binding. The conformational entropy change, by contrast, is almost always unfavorable as the 
binding process involves the loss of conformational degrees of freedom of both the drug 
molecule and the protein (Figure 2). During the drug design process the loss in conformational 
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entropy can be minimized by introducing conformational constraints in the drug molecule such 
that fewer conformational degrees of freedom are lost upon binding (Freire, 2004). 
In summary, thermodynamic parameters can aid decision making in hit or lead selection and 
particularly in combination with structural data it can streamline the optimization process and 
provides new insights into the energetic characteristics of protein-ligand interactions. 
Accordingly, integrating calorimetric data delivers a valuable tool in the drug discovery process.  
 
 
Figure 2. The binding affinity of a small molecule to its target (blue) is determined by the 
balance of the magnitude of its interactions with the target and those with the solvent water as 
well as the solvation and conformational entropy changes. H-bonds are indicated as dashed 
lines; modified from Freire (2004). 
1.1.2 Computational techniques in drug design 
Computer-aided drug design (CADD) involves all computer-assisted techniques used to 
discover, design and optimize biologically active compounds with a putative use as drugs 
(Wermuth et al., 1998). These in silico methods are being utilized in many steps of the drug 
discovery process including hit identification, hit-to-lead selection, lead optimization, and 
ADMET (absorption, distribution, metabolism, excretion, and toxikology) prediction. 
Commonly used computational approaches comprise statistical mathematical methods that are 
based on structural properties (quantitative structure-activity/property relationships) as well as 
those techniques, which employ the three-dimensional (3D) structure of either ligands (ligand-
based drug design) or the biological target (structure-based drug design; Wermuth et al., 1998). 
1.1.2.1 Statistical methods 
Quantitative structure-activity relationship (QSAR) models are quantitative regression methods 
that attempt to correlate physicochemical properties (descriptors) of chemical substances with 
their biological activity to obtain a reliable statistical model for prediction of the activities of 
new compounds within a series (Hansch, 1969). The term quantitative structure-property 
relationship (QSPR) is used when instead of the biological activity other properties like 
4 
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solubility, permeability or toxicology are concerned as dependent variables (Bradbury, 1994). 
Given that the descriptors characterizing steric, topological, electronic, and hydrophobic 
properties of molecules (Taft et al., 2008) could efficiently be determined by experimental or 
computational means, QSAR can decrease the number of compounds to be synthesized by 
facilitating the selection of the most promising candidates. Beyond the prediction capacity, 
QSAR models assist drug discovery by leveraging existing structure-activity data, providing 
insights into mechanism or identifying an alternative mechanism of action, recognizing 
important structural characteristics, and suggesting new design strategies (Perkins et al., 2003). 
1.1.2.2 Ligand-based drug design 
Ligand-based drug design is a popular approach for drug discovery, which is applied in the 
absence of the 3D structure of the macromolecular target. It is based on analyzing known 
molecules that bind to the drug target thereby highlighting those chemical features responsible 
for the biological activity (Kurogi and Güner, 2001). Pharmacophore modeling and 3D QSAR 
are the most important and widely used tools in ligand-based drug design.  
According to the definition by IUPAC (Wermuth et al., 1998), a pharmacophore model is an 
ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular 
interactions with a specific biological target and to trigger (or block) its biological response. 
Pharmocophore modelling from multiple ligands involves two main steps: (1) creating the 
conformational space for each ligand to represent conformational flexibility and aligning the 
multiple ligands; (2) determination of the essential common chemical features. In ligand-based 
pharmacophore modeling handling conformational flexibility of ligands and conducting 
molecular alignment represent the key techniques and also the main difficulties (Yang, 2010). 
Once a pharmacophore model is generated it is mostly used for querying 3D chemical databases 
to search for potential ligands, which is the so-called pharmacophore-based virtual screening or 
for incremental construction of completely novel candidate structures that conform to the 
requirements of a given pharmacophore, which is termed as de novo design (Wermuth et al., 
1998; Yang, 2010). 
3D QSAR has emerged as a natural extension to the classical QSAR models and as the 
name suggests, it employs descriptors derived from the spatial representation of the ligands to 
predict their biological activities (Wermuth et al., 1998). The Comparative Molecular Field 
Analysis (CoMFA; Cramer et al., 1988) has become a prototype of 3D QSAR methods 
(Podlogar and Ferguson, 2000). The idea underlying this methodology is that differences in 
biological activity are often related to differences in the magnitudes of molecular fields 
surrounding the investigated ligands. Close to pharmacophore modeling, the selected ligand 
molecules are first aligned in 3D space and subsequently placed in a 3D grid box. The values of 
steric and electrostatic potential energies are calculated with different probe groups at each grid 
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point. Finally, the 3D QSAR model is generated by partial-least-squares (PLS) analysis of the 
resulting interaction field values and allows identifying the quantitative influence of specific 
molecular features on the biological activity (Verma et al., 2010). 
Clearly, ligand-based drug design is an effective method that can provide both predictive 
models suitable for compound optimization and crucial insights into the nature of the 
interactions between drug targets and ligand molecules. 
1.1.2.3 Structure-based drug design 
The knowledge of the 3D structure of the macromolecular target is a prerequisite to carry out a 
structure-based drug design strategy (Wermuth et al., 1998). The structural information is 
generally obtained by X-ray crystallography or NMR. However, in the case of targets with no 
experimentally determined structures, homology modeling is the most reliable alternative to 
predict the target structure (Kalyaanamoorthy and Chen, 2011). Structure-based design 
approaches aim at evaluating the complementarities and predicting the possible binding modes 
and affinities between small molecules and their targets (Zhang, 2011) in order to develop 
compounds that perfectly match the binding site and simultaneously incure energetically 
favorable interactions. Besides homology modeling that enables structure-based drug design 
against protein targets with unknown structures commonly used computational techniques are 
molecular docking, pharmacophore modeling, and de novo design. 
Homology modeling is based on the general observation that evolutionarily related 
sequences have similar 3D structures (Chothia and Lesk, 1986). As a consequence, the 3D 
structure of a given protein sequence (target) can be built employing one or more proteins of 
known structure (templates) that share statistically significant sequence similarity. The 3D 
structure prediction process involves several consecutive steps: template identification, target-
template alignment, model building, and model refinement and evaluation (Martí-Renom et al., 
2000). Although each step can introduce errors that affect the modeled structure, optimal use of 
structural information from available templates and correctness of sequence-to-structure 
alignment are the most significant determinants of final model quality (Ginalski, 2006). 
Molecular docking is a process of predicting the ligand conformation and its orientation 
inside the target structure (Kalyaanamoorthy and Chen, 2011). It is carried out in two parts 
starting with the determination whether a given conformation and orientation of a ligand fits the 
active site, which is so-called posing. In the second step an energy-based score is provided to 
order the poses (Kitchen et al., 2004). These scoring functions are features that aid in 
investigating the interactions between the small molecule and the biological target, thereby 
providing information about biological activity (Kalyaanamoorthy and Chen, 2011). Docking is 
applied at different stages of the drug discovery process for three main purposes: (1) predicting 
the binding mode of a known active ligand; (2) identifying new ligands using virtual screening; 
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(3) predicting the binding affinities of related compounds from a known active series. Of these 
three challenges, successful prediction of a ligand binding mode is the area where most success 
has been achieved but accurate prediction of binding affinities for a set of molecules turns out to 
be genuinely difficult (Leach et al., 2006). The latter is mainly due to the major drawbacks of 
molecular docking that are the lack or poor flexibility of the protein, which is not permitted to 
adjust its conformation upon ligand binding, and the absence of a unique and widely applicable 
scoring function, which precisely calculates solvation energies (Alonso et al., 2006; Leach et al., 
2006). A strategy to deal with this problem is combining moleculer docking with moleculer 
dynamics (MD) simulations. MD simulations are a computational approach in which Newton’s 
equations of motions are solved for an atomistic representation of a molecular system to obtain 
information about its time-dependent properties. They can treat both ligand and protein in a 
flexible way, allowing for an induced fit of the binding site around the newly introduced ligand. 
In addition, the effect of explicit water molecules can be studied directly, and very accurate 
binding free energies can be obtained. Further MD simulations can be used during the 
preparation of the experimental or homology modeling derived 3D structure before docking, to 
optimize it and account for protein flexibility (Alonso et al., 2006). 
The 3D structure of a macromolecular target or a macromolecule-ligand complex can also 
be used to build a pharmacophore model. So termed structure-based pharmacophore modeling 
involves an analysis of the complementary chemical features of the active site and their spatial 
relationships, and a subsequent pharmacophore model assembly with selected features. As 
described for the ligand-based pharmacophore model, a structure-based pharmacophore model 
can be used for virtual screening and de novo design (Yang, 2010). 
In addition to employing a pharmacophore model, small fragments can also be placed by 
docking in the target binding site. Such a target-based de novo design can be carried out by 
fragment linking or growing techniques. In the linking process different small fragments are 
added simultaneously to different active site residues of the target and connected to a final 
single compound wheres in the growing technique a single fragment is placed in the active site 
and grown well complementarily against the binding site (Kalyaanamoorthy and Chen, 2011). 
In summary, the role of computational models is to increase prediction based on existing 
knowledge. In silico methods are very useful tools in rational drug design to minimize the time 
for identification, characterization and structure-optimization for novel drug candidates.  
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1.2 Pseudomonas Quinolone Signaling as Drug Target 
1.2.1 Pseudomonas aeruginosa: an important opportunistic pathogen 
Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium capable of surviving in a 
broad range of natural environments and known to infect a wide range of animal and plant hosts 
(Rahme et al., 1995). In humans, the opportunistic pathogen is the most common bacterium 
found in nosocomial infections. It is responsible for 16% of nosocomial pneumonia cases, 12% 
hospital acquired urinary tract infections, 8% of surgical wound infections (van Delden and 
Iglewski, 1998), and 10% of bloodstream infections (Gordon et al., 1998). Further, it causes 
life-threatening infections in immunocompromised persons, such as patients with AIDS, where 
P. aeruginosa bacteremia is associated with 50% of deaths (Mendelson et al., 1994).  
Beyond this, P. aeruginosa plays an important role in cystic fibrosis (CF) patients. The latter 
are characteristically susceptible to chronic infection by P. aeruginosa, which is responsible for 
high rates of illness and death in this population (Govan and Deretic, 1996). CF results from a 
mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which 
encodes a chloride channel involved in the transport of electrolytes across epithelial and other 
cell membranes (Riordan, 2008). The defect leads to highly viscous mucus and a failure in the 
airway mucociliary clearance mechanisms. Hence, the normally sterile lower airways are 
compromised by the accumulation of mucous and trapped bacteria (Hart and Winstanley, 2002).  
The major reason for the persistence of P. aeruginosa, which is rarely eradicated despite 
even intensified antibiotic therapy, is the ability of forming biofilm structures. A biofilm is a 
structured consortium of bacteria, embedded in a biopolymer matrix consisting of 
polysaccharides, extracellular DNA and other macromolecular components such as proteins, 
lipids and biosurfactants. The pattern of biofilm development involves initial attachment to a 
solid surface, the formation of microcolonies, and finally differentiation of microcolonies into 
mature biofilms (Costerton et al., 1999; Figure 3).  
 
Figure 3. Model of the development of a mature P. aeruginosa biofilm from planktonic cells. 
Flagella (red) are involved in attachment, and Type IV pili (black) are required for twitching 
motility on a surface and the formation of microcolonies in the attached monolayer. Quorum 
sensing serves as a maturation signal leading to the formation of differentiated, thick mature 
biofilm structures; modified from Costerton et al. (1999). 
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Characteristically, gradients of nutrients and oxygen exist from the top to the bottom of biofilms 
and these gradients are associated with decreased bacterial metabolic activity and increased 
doubling times of the bacterial cells. It is these more or less dormant cells that are responsible 
for some of the tolerance to antibiotics (Høiby et al., 2010). Further, the mutation frequency of 
biofilm-growing bacteria is significantly increased compared to planktonically growing isogenic 
bacteria (Driffield et al., 2008) and there is increased horizontal gene transmission in biofilms 
(Molin and Tolker-Nielsen, 2003). Thus, bacterial cells in biofilms may simultaneously produce 
enzymes that degrade antibiotics, have antibiotic targets of low affinity and overexpress efflux 
pumps that have a broad range of substrates. Besides the ability of a biofilm to work as a 
protection shield against antibiotics and adverse conditions, be they phage or amoeba in nature 
or biocides in industrial settings (Costerton et al., 1999), it counterworks the human immune 
response (Bjarnsholt et al., 2010). 
Moreover, the capacity of P. aeruginosa to produce such diverse, often overwhelming 
infections is due to the exceptional adaptability to variable and frequently adverse 
environmental conditions (Vasil, 1986) as well as the aptitude to express an arsenal of virulence 
factors. The latter includes both cell-associated and extracellular products, which play an 
important pathological role in the colonization, the survival of the bacteria, and the invasion of 
tissues (Bjarnsholt et al., 2010; Figure 4). 
 
Figure 4. P. aeruginosa virulence factors. P. aeruginosa has both cell-associated (flagellum, 
pillus, nonpilus adhesins, alginate/ biofilm, lipopolysaccharide (LPS)) and extracellular virulence 
factors (proteases, hemolysins, exotoxin A, exoenzyme S, pyocyanin); modified from van 
Delden et al. (1998). 
The coordinated production and secretion of these virulence factors as well as the biofilm 
formation (Figure 3) are controlled by a complex cell density dependent cell-to-cell 
communication system known as quorum sensing (QS; Swift et al., 2001). 
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1.2.2 The Pseudomonas aeruginosa quorum sensing network 
Until recently, bacteria were considered autonomous single-cell organisms with little capacity 
for collective behaviours. However, now it is appreciated that bacterial cells are highly 
communicative and possess an extraordinary capacity for social behaviors. Termed as quorum 
sensing (QS; Fuqua et al., 1994), bacterial cell-to-cell communication involves producing, 
releasing, detecting, and responding to small hormone-like molecules (Swift et al., 2001). The 
latter are referred to as autoinducers as they induce their own synthesis. The signal molecules 
increase in concentration as a function of cell density and activate or repress corresponding 
transcriptional regulators (Gram–negative bacteria) or sensor kinases (Gram-positive bacteria) 
after a threshold concentration has been reached (Miller and Bassler, 2001; Waters and Bassler, 
2005).  
Thereby, QS allows bacteria to monitor the environment for other bacteria and to alter 
behavior on a population-wide scale in response to changes in the number and/or species present 
in a community. Most QS-controlled processes are unproductive when undertaken by individual 
bacteria acting alone but become beneficial when carried out simultaneously by a large number 
of cells. Thus, QS confuses the distinction between prokaryotes and eukaryotes because it 
enables bacteria to act as multicellular organisms (Waters and Bassler, 2005).  
The first described QS system is that of the bioluminescent marine bacterium Vibrio fischeri 
that colonizes the light organ of the Hawaiian squid Eupryma scolopes (Nealson and Hastings, 
1979). LuxI is the signal synthase, which produces the N-acylhomoserine lactone (AHL) 
autoinducer N-(3-oxo-hexanoyl)-L-homoserine lactone (3-oxo-C6-HSL). After a critical 
threshold concentration has been reached, the latter interacts with the transcriptional regulator 
LuxR and activates the transcription of the luciferase operon (Engebrecht and Silverman, 1984). 
Importantly, as luxI is encoded in the luciferase operon its expression is also induced creating a 
positive feedback loop (Stevens et al., 1994). In Gram-negative bacteria, most QS systems 
consist of a LuxR-type transcriptional regulator (R) and an acylated homoserine lactone 
autoinducer (AI) by what LuxRI QS systems are considered as the paradigm for QS in Gram-
negative bacteria (Fuqua et al., 1996; Figure 5). 
P. aeruginosa employs the las and rhl communication systems, which use AHL 
autoinducers. Both systems consist of two pairs of LuxRI homologs, LasRI and RhlRI, 
respectively. In the las system, the lasI gene product directs the synthesis of N-(3-oxo-
dodecanoyl)-L-homoserine lactone (3-oxo-C12-HSL), which interacts with the transcriptional 
regulator LasR and activates target promoters (Gambello and Iglewski, 1991; Passador et al., 
1993). 
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Figure 5. Generalized model for QS in Gram-negative bacteria. The key components of any QS 
module are the transcriptional regulator R, the signal synthase I, and the autoinducer molecule 
AI. The R and I proteins are expressed from their respective R and I genes; modified from Swift 
et al. (2001). 
In the rhl system, rhlI directs the synthesis of N-(butanoyl)-L-homoserine lactone (C4-HSL), 
which interacts with the cognate regulator RhlR and stimulates the transcription of target genes 
(Ochsner et al., 1994; Ochsner and Reiser, 1995; Figure 6).  
 
Figure 6. Structures of the P. aeruginosa QS signal molecules 3-oxo-C12-HSL, C4-HSL, PQS, 
HHQ, the QS inhibitor C-30, and the HHQ-derived PqsR antagonists. 
The las and rhl systems are organized as a hierarchy placing the las system above the rhl system 
(Latifi et al., 1996). Further, they have been found to regulate the timing and production of 
multiple virulence factors including elastase, alkaline protease, exotoxin A, rhamnolipids, 
pyocyanin, lectins, superoxide dismutases and biofilm formation (Smith and Iglewski, 2003; 
Figure 7). 
While both AHL-mediated QS systems are widespread among Gram-negative bacteria, the 
occurrence of a third pqs QS system (Pesci et al., 1999) is rather unique and restricted to 
particular Pseudomonas and Burkholderia strains (Diggle et al., 2006). It functions via the 4-
hydroxy-2-alkylquinolone (HAQ) signal molecules PQS (Pseudomonas quinolone signal; 2-
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heptyl-3-hydroxy-4(1H)-quinolone) and its precursor HHQ (2-heptyl-4(1H)-quinolone; Figure 
6). Both interact with their receptor PqsR, also known as multiple virulence factor regulator 
(MvfR), which is essential for full P. aeruginosa pathogenicity (Cao et al., 2001; Xiao et al., 
2006; Figure 7). In common with the AHL-dependent QS systems, the pqs system is involved in 
the regulation of P. aeruginosa virulence including pyocyanin biosynthesis (Dubern and Diggle, 
2008), biofilm formation and maturation (Allesen-Holm et al., 2006), the production of 
exoproducts like elastase, alkaline proteases, rhamnolipids, and hydrogen cyanide (Déziel et al., 
2005), and the expression of efflux pumps (Diggle et al., 2003). Further, PQS itself can 
downregulate the host innate immune response (Kim et al., 2010). 
The biosynthesis of HHQ involves the condensation of anthraniloyl-coenzyme A (CoA) 
with a β-ketodecanoyl moiety and requires the pqsABCD gene products (Gallagher et al., 2002; 
Pistorius et al., 2011). PqsA was identified as an anthranilate-CoA ligase involved in 
anthranilate activation (Coleman et al., 2008), while PqsB, PqsC, and PqsD show similarities 
with β-keto-acyl-acyl carrier protein synthetases (Dubern and Diggle, 2008). PqsD catalyzes the 
decarboxilative Claisen condensation of the β-keto fatty acid and the activated anthraniloyl-
CoA, followed by heterocycle formation via intramolecular condensation under elimination of 
water. Based on the fact, that PqsB and PqsC are absolutely required for HHQ biosynthesis, 
these two enzymes probably produce an activated form of the β-ketodecanoic acid, which 
exhibits a higher affinity to PqsD (Pistorius et al., 2011).  
HHQ is already active as a signaling molecule (Xiao et al., 2006) but it can be converted 
intracellularly into PQS through the action of PqsH. The latter is a probable FAD-dependent 
monoxygenase, which is located outside of the pqsABCDE operon and under control of the las 
system. Thereby it provides a link between AHL- and HAQ-signaling (Gallagher et al., 2002)  
while the pqs system is placed in between the las-rhl hierarchy (McKnight et al., 2000; Figure 
7). Along with HHQ and PQS, P. aeruginosa produces more than 50 different HAQs that vary 
in the substitution at position 3 and the length and saturation of their alkyl side chain, and most 
are present only in small amounts (Lépine et al., 2004). 
In addition to the biosynthetic enzymes PqsA-D, the pqs operon contains a fifth gene, pqsE 
(Gallagher et al., 2002), which does not take part in the biosynthesis of PQS. The function of the 
pqsE gene is not known, but it is required for the production of multiple PQS-controlled 
virulence factors (Farrow et al., 2008; Rampioni et al., 2010; Figure 7).  
The regulation of the HAQ biosynthetic genes including the phnAB (encodes the 
anthranilate synthases) and pqsABCDE operons occurs through PqsR, a LysR-type 
transcriptional regulator (LTTR; Cao et al., 2001) that is encoded slightly downstream of the 
pqs operon. It is positively controlled by LasR and negatively regulated by RhlR (Wade et al., 
2005). PqsR was predicted to be membrane associated and it binds the promoter of pqsABCDE. 
This binding increases dramatically in the presence of PQS and HHQ (Xiao et al., 2006), 
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thereby the latter trigger their own biosynthesis and function similar to other AI molecules 
(Figure 7). 
 
Figure 7. P. aeruginosa cell-to-cell signaling. HAQ and AHL-dependant quorum sensing are 
intimately linked since LasR/3-oxo-C12-HSL is required for full expression of pqsH. The 
transcription of pqsR is positively regulated by LasR and negatively regulated by RhlR. HHQ is 
produced via pqsA-D itself regulated by pqsR. Both PQS and HHQ induce the expression of 
pqsA-E in a PqsR- dependant manner. The production of lectin and pyocyanin also require 
PqsE. Furthermore, PQS released from the cell is capable of binding iron, forming a PQS-Fe3+ 
complex. The removal of iron from the extra-cellular environment by PQS induces expression of 
genes involved in siderophores production in an independent manner from cell-to-cell signaling. 
Grey arrows represent positive regulation; red lines represent negative regulation; modified from 
Dubern & Diggle (2008).  
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1.2.3 Jamming pqs quorum sensing as a new approach for the treatment of 
Pseudomonas aeruginosa infections 
Since the introduction of antibiotics in clinical therapy, the deployment of any novel antibiotic 
has been followed by the evolution of clinically significant resistance to that antibiotic in as 
little as a few years (Palumbi, 2001). This has led to the appearance and spread of bacteria that 
are resistant to practically all antimicrobial drugs available on the market, so-called superbugs. 
P. aeruginosa has joined the ranks of superbugs due to its enormous capacity to engender 
resistance (Breidenstein et al., 2011). Yet the development of new classes of therapeutics to treat 
P. aeruginosa infections has lagged far behind the growing need for such drugs.  
Traditional antibiotics work by either inhibiting bacterial growth (bacteriostatic) or killing 
the cell (bacteriocidal; Figure 8). However, these modes of action impose selective pressure that 
fosters the selection of antibiotic-resistant strains. Therefore, we must consider developing 
antimicrobials that have novel modes of action and exhibit less evolutionary pressure. 
 
 
Figure 8. Traditional targets of antibacterial compounds. Traditional antibiotics function by 
inhibiting DNA or RNA synthesis, inhibiting protein synthesis, inhibiting cell wall synthesis, 
inhibiting folate synthesis, or depolarizing membrane potential. 
Alternatives are disrupting the interaction between the host and the pathogen or the specific 
attenuation of bacterial virulence, which can be attained by targeting key regulatory systems that 
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mediate the expression of virulence factors (Clatworthy et al., 2007; Klein et al., 2010). One of 
the target regulatory systems, currently being discussed as drug target, is quorum sensing 
(Rasmussen and Givskov, 2006; Bjarnsholt and Givskov, 2007). Given that QS does not affect 
bacterial growth, jamming bacterial communication is generally believed to be unlikely to pose 
harsh selective pressure, thus minimizing the risk of resistance development (Defoirdt et al., 
2010).  
Over the last decade disruption of AHL-dependent QS came up as a novel target aiming at 
the reduction of bacterial virulence (Hentzer et al., 2002). Recently, it was shown that 
combination treatment of C-30, a synthetic furanone, which interferes with AHL-dependent QS 
(Hentzer et al., 2003; Figure 6), and tobramycin resulted in an increased clearance of P. 
aeruginosa in a infection mouse model (Christensen et al., 2012). However, AHL-dependent QS 
systems are widespread among Gram-negative bacteria, thereby precluding the selective 
disruption of cell-to-cell communication in a single species. In addition, P.aeruginosa lasR 
mutants emerged in the airway of a CF patient and resulted in increased fitness under certain 
growth conditions (Heurlier et al., 2005; Sandoz et al., 2007; Wilder et al., 2009). The relative 
prevalence of lasR mutants in the CF airway is likely to influence the efficacy of new drugs 
targeting AHL-dependent QS. 
Therefore, we consider the pqs system that is characteristic for P. aeruginosa as a highly 
attractive target for drug development to interfere with P. aeruginosa pathogenicity and biofilm 
formation. The general validity of this approach is supported by the fact that pqsR, pqsA, pqsH, 
and pqsE mutants display attenuated virulence in mice (Cao et al., 2001; Déziel et al., 2005; 
Xiao et al., 2006). Further, pqsA mutants formed flat, altered biofilms that were more 
susceptible to treatment with the biocide sodium dodecyl sulphate than the P. aeruginosa wild-
type biofilms (Allesen-Holm et al., 2006). A reduced pathogenicity was also observed in a 
mouse infection model when animals infected with the wild-type strain were treated with 
halogenated anthranilic acid derivatives that inhibit PQS biosynthesis. This treatment led to a 
significant increase in survival in comparison to the control group (Lesic et al., 2007). Based on 
the fact that PQS is produced in high amounts in the sputum of the CF patients (Palmer et al., 
2005), it can be assumed that blocking the pqs QS system should make the P. aeruginosa lung 
infection in CF patients better treatable. 
Two options to target pqs QS are: (1) inhibition of PqsD, a key enzyme in the biosynthesis 
of the signal molecules HHQ and PQS or (2) antagonizing PqsR, thereby avoiding the 
transcription of PqsR controlled genes. So far no PqsD inhibitors are reported in literature while 
the first PqsR antagonists were recently derived from the natural effector HHQ (Lu et al, 2012; 
Figure 6). 
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1.3 17β-Hydroxysteroid Dehydrogenase Type 1 as Drug Target 
1.3.1 Biochemical communication in eukaryotes: hormones as signal 
transmitter 
Chemical communication between cells ensures coordination of behaviour and activities. As 
described above, in prokaryotes cell to cell signaling results from autoinducers and is usually 
referred to as quorum sensing. Intercellular communication in eukaryotes is also based on 
diffusible chemical signals, in fact neurotransmitters and hormones (Voet and Voet, 1994). In 
the classical view, hormones are chemical substances, which are synthesized by specialized 
glands for release into the general blood circulation and transport to distant target tissues, where 
they unfold their effects. Hormones are essential for nearly all functions of the human body like 
regulation of metabolism, stimulation or inhibition of growth, control of the reproductive cycle, 
regulation of the blood pressure, or preparation of the body for mating, fighting, fleeing and 
other activity. In order to exert these effects in the target cells, hormones interact with specific 
receptors involving ion channels, G-protein coupled receptors (GPCRs), transcription factors, 
and receptors with independent or associated enzyme activity, i.e. receptor-tyrosin-kinases. 
Hormone production, release, and effect interact with each other and for many hormones 
this process is regulated by a hirachical three-step system: the hypothalamic-pituitary axis 
(Figure 9). 
 
Figure 9. Negative feedback regulation. The secretory activity of the hypothalamic-pituitary axis 
is dependent on the concentration of the accordant effector hormone. 
The hypothalamus is the central regulator, which delivers a releasing hormone thereby 
stimulating the production of a glandotropic hormone in the pituitary. The latter induces the 
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formation of an effector hormone in a peripheral gland that is finally responsible for the cellular 
effect. The concentration of the effector hormone in the blood circulation is detected by the 
hypothalamus and accordingly it regulates the distribution of the releasing hormone. Increasing 
hormone concentration results in a reduced and decreasing hormone concentration in an 
enhanced disposal of the releasing hormone constituting a negative feedback regulation 
(Mutschler, 2001; Aktories et al., 2011). 
Considering their chemical nature hormones can be devided into steroid hormones (i.a. sex 
hormones and adrenal corticoids), hormones that are derived from amino acids (i.a. adrenaline, 
dopamine, thyroxine (T4), and triiodothyronine (T3)), and peptide hormones (i.a. insuline, 
antidiuretic hormone (ADH), and adrenocorticotropic hormone (ACTH)) including 
glycoproteins, which bear additional carbohydrate side-chains (i.a. luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH; Aktories et al., 
2011). Given that hormones function across different distances various types of signal 
transmission can be distinguished (Labrie, 1991; Voet and Voet, 1994; Figure 10):  
 endocrine function matches the classical definition of hormones 
 paracrine hormones are released from one cell and influence neighbouring cells 
 autocrine hormones excert an action on the producing cell 
 intracrine activity describes the formation of active hormones which perform their action in 
the same cells without release into the pericellular compartment 
 
Figure 10. Schematic representation of a) endocrine, b) paracrine, c) autocrine, and d) 
intracrine secretion; modified from Labrie et al. (1991). 
Besides the well known endocrine, paracrine, and autocrine modes of signal transmission the 
term of intracrine activity was first coined in 1988 (Labrie et al.) for describing the fact that 
“locally produced androgens and/or estrogens exert their action in the cells where synthesis took 
place, without release in the extracellular space”. In classical endocrine systems only a small 
amount of the secreted hormones is utilized in the target tissues or exerts their effects while the 
great majority is actually degraded. In contrast, an intracrine system requires minimal amounts 
of biologically active hormones to carry out their maximum hormonal effects since the 
hormones act at the same place as they are produced. Therefore, the intracrine system is 
considered a markedly efficient mode of hormone action. Converting inactive precursor 
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hormones to their corresponding active forms and vice versa provides autonomous control to 
target tissues which are thus able to adjust the formation and metabolism of sex steroids 
according to local requirements (Labrie, 1991). 
1.3.1.1 Signaling by estrogens: a class of sex steroid hormones 
Together with the adrenal corticosteroids the sex steroids are grouped as steroid hormones, 
which are sterane derivatives. The biosynthesis of steroid hormones starts from cholesterol as a 
common precursor and employs dehydrogenases and cytochrome P450 (CYP) enzymes (Figure 
11). The corticosteroids can be devided in mineralocorticoids (e.g. aldosterone) and 
glucocorticoids (e.g. cortisol) that regulate the electrolyte and fluid homeostasis and glucose 
levels, respectively. Further, the glucocorticoids typically exert anti-inflammatory, immune-
modulating as well as bone-catabolizing functions (Schäcke et al., 2002). 
The group of sex steroids comprises androgens, gestagenes, and estrogens. Androgens, the 
male sex steroids, are responsible for sexual differentiation and development in men, as well as 
the maintenance and support of sexual tissues in adults (Dehm and Tindall, 2007). The naturally 
occurring androgens are C19-steroids that are generally synthesized in the testis but also in the 
adrenals and in the ovaries. The predominantly circulating androgen in men is testosterone that 
is converted to the most potent androgen 5α-dihydrotestosterone (DHT) in target tissues. 
Androstendione and dehydroepiandrosterone (DHEA), however, are the most important 
androgens, which are produced in ovaries. 
The femal sex steroids include gestagenes and estrogenes that regulate essential biological 
processes in the organism i.a. development of the female sex organs and secondary sex 
characteristics, the regulation of the menstrual cycle and reproduction (Travis and Key, 2003). 
Gestagenes are C21-steroids based on a pregnane core with progesterone being the 
physiologically occurring gestagene that is mainly produced in the ovary. In premenopausal 
women the latter is also the main source of the biologically appearing estrogens estrone (E1), 
estradiol (E2), and estriol (E3; Sasano et al., 1989) that are C18-steroids. Though, in 
postmenopausal women, the estrogen production moves to peripheral tissues such as adipose 
tissue or skin (Bulun et al., 2001) and almost all of the sex steroids are synthesized from 
precursors of adrenal origin (Jansson, 2009). 
In general, the synthesis of the most potent estrogen E2 from androstendione involves 17β-
hydroxysteroid dehydrogenase (17β-HSD) and aromatase (CYP19) and can follow two 
pathways: (1) reversible reduction of androstendione to testosterone (17β-HSD3) succeeded by 
irreversible aromatization of the steroidal A-ring; (2) aromatization of the A-ring and 
subsequent reduction of of E1 to E2 (17β-HSD1; Figure 11). Interestingly, the principal 
substrate for extra-ovarian aromatase activity in women is androstenedione (Bulun et al., 2000). 
In the target tissue 17β-HSD1 catalyzes the activation of E1 to the highly potent E2 (Gangloff et 
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al., 2001), thus in the context of intracrinology it constitutes the molecular switch that allows 
pre-receptor modulation. 
Steroid hormones act via intracellular receptors that function as transcriptional regulators 
and alter the transcription of specific target genes. Accordingly, estrogenic effects are mediated 
by steroid hormone receptors: the estrogen receptors (ER) ERα (Walter et al., 1985) and ERβ 
(Kuiper et al., 1996) that show considerable sequence similarity (96 % in the DNA-binding 
domaine and 53 % in the hormone-binding domaine) and share the common structure of steroid 
hormone nuclear receptors (Mendelsohn and Karas, 1999). Estrogens have widespread effects 
on both genital and extragenital systems. Genital target tissues are the uterus, the cervix, the 
vagina, and the mamma where estrogens are responsible for i.a. proliferation of the 
endometrium and development of endometrial glands, production and physical properties of the 
cervical mucus as well as maintainance of gravidity (Aktories et al., 2011). Further estrogens 
influence bone formation (Turner et al., 1994), cause vasodilatation, and induce water retention 
(Mendelsohn and Karas, 1999), to name but a few extragenital effects. Besides its physiological 
functions the most potent estrogen E2 is involved in the developmet of diseases such as breast 
cancer, endometriosis and endometrial hyperplasia. Increased E2/E1 ratios as well as high levels 
of 17β-HSD1 mRNA in diseased tissues point out the pivotal role of 17β-HSD1, which 
catalyzes the activation of E1 to E2. 
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Figure 11. Biosynthetic pathway of steroid hormones. CYP11A1: cholesterol desmolase; 
CYP17: 17α-hydroxylase/17,20-lyase; 3β-HSD: 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 
isomerase; CYP21A: 21-hydroxalyse; CYP11B1: 11β-hydroxylase; CYP11B2: 11β/18-
hydroxylase; CYP19: aromatase; 17β-HSD: 17β-hydroxysteroid dehydrogenase; S5AR: 5α-
reductase. 
HO
HO
O
Cholesterol
Pregnenolone
O
Progesterone
O
HO
O
17α-Hydroxypregnenolone
OH
O
17α-Hydroxyprogesterone
O
OH
O
HO
Dehydroepiandrosterone
(DHEA)
HO
OH
3β,17β-Dihydroxy-5-androstene
4-Androsten-3,17-dione
O
O
Testosterone
O
OH
5α-Dihydrotestosterone
O
OH
H
Estradiol
(E2)
HO
OH
Estrone
(E1)
HO
O
O
Aldosterone
O
HO
OH
O
O
Cortisol
O
OHHO
OH
CYP19
CYP19
CYP21A
CYP21A
CYP11B1
CYP17CYP17
3β−HSD
3β−HSD
3β−HSD
3β−HSD
CYP17 CYP17
17β−HSD117β−HSD217β−HSD317β−HSD217β−HSD117β−HSD2
S5AR
CYP11A1
CYP11B2
20 1 INTRODUCTION 
 
 
1.3.1.2 17β–Hydroxysteroid Dehydrogenase Type 1: a key player in estradiol 
biosynthesis 
17β-HSD1 is a cytosolic enzyme that belongs to the short-chain dehydrogenases/reductases 
(SDRs) protein family (Jornvall et al., 1995) as most of the fourteen identified 17β-HSDs (Luu-
The, 2001; Moeller and Adamski, 2009; Prehn et al., 2009). The only exception known so far is 
17β-HSD5, which belongs to the aldo-ketoreductases (AKR; Persson et al., 2009). 17β-HSD1 
consists of 327 amino acid residues (34.9 kDa) and the active form exists as homodimer 
(Peltoketo et al., 1988). To date 22 crystal structures of 17β-HSD1 are available in the protein 
data bank (PDB) as: apoform (1bhs), holoform (1fdv, 1qyv), binary complex with E2, 
androgens or inhibitors (1fds, 1fdw, 1dht, 3dhe, 1jtv, 1iol, 3dey, 1i5r, 3hb4, 3klm, 3klp) and 
ternary complex with cofactor and E2, androstenediol or inhibitors (1fdt, 1equ, 1fdu, 1a27, 
1qyw, 1qyx, 3hb5, 3km0). Remarkably, no crystal structure with the substrate E1 exists. All 
crystals reveal an overall identical tertiary structure: a seven-stranded parallel β-sheet (βA to 
βG), surrounded by six parallel α-helices (αB to αG), three on each side of the β-sheet. The 
basic fold of the segment βA to βF is a doubly wound α/β motif, with alternating β-strands and 
α-helices. Whereas the βA to βF segment is the classic 'Rossmann fold', associated with 
nicotinamide adenine dinucleotide binding, the βD to βG segment, in addition to being partly in 
the Rossmann fold, forms the substrate binding domain (SBD; Figure 12a; Ghosh et al., 1995). 
The latter is described as a hydrophobic tunnel with polar residues at each end: His221/Glu282 
on the C-terminal side, and Ser142/ Tyr155 on the other side. E2 is stabilized by hydrogen 
bonds between the O3 and His221/Glu282, as well as between the O17 and Tyr155/Ser142. The 
apolar residues of Leu149, Val225, Phe226, and Phe259 are also involved in steroid binding by 
forming hydrophobic contacts (Azzi et al., 1996). Apart from this, Leu149 with its forke-like 
structure controls substrate specificity of 17β-HSD1 by C18/C19-steroid discrimination (Han et 
al., 2000; Gangloff et al., 2003; Figure 12b). 
Major differences in the crystal structures have been identified only for the highly flexible 
βFαG’-loop. It is not resolved in ten crystal structures, while the remaining twelve showed high 
b-factor values for this area, which is an additional hint for the flexibility of the βFαG’-loop. 
The latter can occupy three possible orientations, dependent on the presence of cofactor and 
ligands: an opened, a semi-opened and a closed enzyme conformation (Negri et al., 2010). 
Given that the βFαG’-loop is located at the interface between the cofactor binding site (COF) 
and the SBD it delimits the shape and volume of both cavities (Figure 12a). 
In human 17β-HSD1 the amino acid residues Asn114, Ser142, Tyr155 and Lys159 form the 
catalytic tetrad that is present in the majority of the SDR enzymes. Together with a conserved 
water molecule, which is stabilized by a H-bond with Asn114 it plays a critical role for the 
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enzymatic reaction of 17β-HSD1 (Filling et al., 2002): a reversible hydride transfer from 
NADPH to E1, which is attended by a proton shift for charge equalization. 
 
 
Figure 12. Structural insights into human 17β-HSD1. a) Tertiary structure of 17β-HSD1 (PDB 
entry 1a27); the COF is coloured in orange, the SBD in green, and the βFαG’-loop in cyan 
(closed conformation); the βFαG’-loop in the opened conformation (PDB entry 1iol) is coloured 
in magenta and in the semi-opened conformation (PDB entry 1i5r) in red. b) Binding modes of 
E2 (light green) and NADPH (yellow) in the SBD and the COF, respectively; H-bonds are drawn 
as black dashed lines. 
Three catalytic mechanisms are proposed for 17β-HSD1 (Penning, 1997; Ghosh and Vihko, 
2001) including one concerted (simultaneous transfer of hydride and proton) and two stepwise 
mechanisms (Figure 13). The latter differ in the intermediate presence of either an oxyanion or a 
carbocation. Despite the availability of numerous structural data, it has not yet been clarified 
which mechanism is the most likely one (Marchais-Oberwinkler et al., 2010). 
In vitro 17β-HSD1 is able to catalyze both the reduction and oxidation depending on which 
redox state of cofactor is added. However, under in vivo conditions, such as in living cells, the 
catalysis is unidirectional due to distinct affinities of 17β-HSD1 for nicotinamide cofactors and 
existing cofactor gradients. Structural and mutagenesis studies revealed that in the Rossmann 
fold of 17β-HSD1 the positively charged side-chain of Arg37 forms a salt bridge with the 2’-
phosphate group of NADP(H) (Figure 12b; Huang, 2001) that consequently led to a favored 
binding of the phosphorylated cofactors. Further NADP+ is preferably abundant in its reduced 
form (NADPH/NADP+ > 500), whereas NAD+ is mainly present in its oxidized form 
(NAD+/NADH > 700) and these ratios are homeostatically maintained by glucose metabolism 
and O2 supply (Sherbet et al., 2007; 2009). 
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Figure 13. Two possible stepwise catalytic mechanisms of 17β-HSD1. a) In the first step the 
pro-S hydride of NADPH is transferred to the β–face of E1 at the planar C17 carbon (ai), 
resulting in an energetically favorable aromatic system; subsequently the resultant oxyanion is 
protonated by the acidic OH group of Tyr155 (aii). b) In the first step the keto oxygen of E1 is 
protonated by the acidic OH of Tyr155 (bi); then the resultant carbocation accepts the pro-S 
hydride of NADPH at the β-face (bii). The proton relay is facilitated by a H-bond network 
involving Lys159, two water molecules and Asn114, an electrostatic interaction between the 
protonated side chain of Lys159 and the phenyl ring of Tyr155 (Ghosh and Vihko, 2001) as well 
as T-stacking between Phe192 and Tyr155 (Negri et al., 2010). Hydrogen bonds are 
represented in dashed lines; modified from Marchais-Oberwinkler et al. (2010). 
1.3.2 Estrogen-dependent diseases 
Estrogens influence many physiological processes in mammals such as reproduction, 
cardiovascular health, or bone integrity to name but a few. Given this widespread role for 
estrogens in human physiology, it is not surprising that estrogens are also implicated in the 
development and progression of numerous diseases, which include but are not limited to breast 
cancer, endometriosis, and endometrial hyperplasia (Deroo and Korach, 2006). 
1.3.2.1 Breast cancer 
Breast cancer is a type of cancer originating from the epithelial cells that line the terminal duct 
lobular unit. Cancer cells that remain within the basement membrane of the elements of the 
terminal duct lobular unit are classified as non-invasive. An invasive breast cancer is one in 
which there is dissemination of cancer cells outside the basement membrane of the ducts and 
lobules into the surrounding adjacent normal tissue (Sainsbury et al., 2000). It is by far the most 
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frequent cancer among women with an estimated 1.38 million new cancer cases diagnosed in 
2008 (23% of all cancers), and ranks second in both sexes (10.9% of all cancers) after lung 
cancer (12.7% of all cancers; Ferlay et al., 2010). Data from both clinical and animal studies 
demonstrated that estrogens, particularly E2, are implicated in the etiology of human breast 
cancer. Among the most widely accepted risk factors for breast cancer are early menarche, late 
menopause, post-menopausal obesity, and hormone replacement therapy, which can be thought 
as measures of the cumulative ‘dose’ of estrogens that the breast epithelium is exposed to over 
time (Henderson and Feigelson, 2000). However, the responsible mechanism by which E2 
contributes to the development of mammary cancer remains incompletely understood. The 
generally accepted hypothesis is that estrogens bind to ERα or ERβ and stimulate the 
transcription of genes encoding growth factors. Cell proliferation is essential for carcinogenesis 
because cell division increases the risk of errors during DNA replication, which if not corrected, 
can lead to cancer (Yue et al., 2005). In this context the expression pattern of ERα or ERβ plays 
an important role. ERs are present in extremely low quantities in normal breast epithelial cells. 
In contrast, 30% of premenopausal and 60% of postmenopausal breast cancers have measurable 
ERs and are determined as estrogen receptor positive (ER+; Cotterchio et al., 2003). 
The estrogen-dependent proliferation and progress of breast cancer is further enhanced by 
the increased E2/E1 ratio. This is due to increased expression of 17β-HSD1 in breast tumors 
compared to normal breast epithelium (Jansson, 2009). On the other hand, the expression of 
17β-HSD2, which catalyzes the reverse reaction (oxidation of E2 to E1), is not increased (Vihko 
et al., 2004), in some cases it is even reduced (Sasano et al., 2000). 
1.3.2.2 Endometriosis 
Endometriosis is is a chronic estrogen dependent gynecological condition that is defined as the 
presence of endometrial glands and stroma outside of the uterine cavity. It affects at least 3.6% 
of women (Ferrero et al., 2010) and causes pain symptomes, including dysmenorrhea, deep 
dyspareunia, and chronic pelvic pains, as well as infertility. Endometriosis is pathohistologically 
a benign disease. However, it is characterized by a malignant tumor-like nature in that it grows, 
infiltrates and adheres to the surrounding tissues (Kitawaki et al., 2002). Although its exact 
etiology and pathogenesis are unclear, the most widely accepted theory for the pathogenesis has 
been proposed by Sampson (1927) and assumes that metastatic implantation occurs after the 
reflux of endometrial cells through the fallopian tubes. Given that endometriosis is highly 
estrogen dependent the aberrant expression of aromatase, the overexpression of 17β-HSD1, and 
the deficiency in 17β-HSD2 in endometriotic tissues may result in accumulation of E2 and thus 
promote the formation and growth of endometriosis (Tsai et al., 2001). Further, in endometric 
lesions the highly potent E2 favours its own formation by establishing a positive feedback loop: 
E2 induces cyclooxygenase-2 (COX-2) giving rise to elevated concentrations of prostaglandin 
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E2 (PGE2; Bulun et al., 2000); PGE2 in turn, is the most potent known stimulator of aromatase 
in endometriotic stromal cells (Noble et al., 1997). 
1.3.2.3 Therapeutic options 
The mainstay for breast cancer treatment is surgery. Depending on the stage of the cancer it can 
be an excision of the tumour with surrounding normal breast tissue (breast conservation 
surgery) or removal of the entire breast (mastectomy; Sainsbury et al., 2000). In general, after 
surgery patients receive radiotherapy to reduce the risk of recurrence (Maughan et al., 2010). In 
the post-operative treatment, also termed as adjuvant therapy (Liu et al., 2010), also 
chemotherapy is a component that decreases cancer recurrence and disease-specific death 
(Maughan et al., 2010). Further chemotherapy is an integral part of preoperative (neoadjuvant) 
systemic therapy to convert inoperable cancers into candidates for surgical resection or to 
reduce the size of the tumor in relation to the breast to make breast conservation surgical 
therapy feasible (Liu et al., 2010).  
An alternative therapeutical approach is settled on the endocrine level. Endocrine therapies 
aim at inhibiting estrogen production or blocking estrogen receptor action, thereby preventing 
stimulation of an estrogen-sensitive tumor (Maughan et al., 2010). In the adjuvant treatment of 
pre- and postmenopausal women with ER+ breast cancer endocrine therapy is an inherent part 
(Stuart-Harris and Davis, 2010) and it is increasingly being employed in the neoadjuvant 
therapy of postmenopausal women with with ER+ mammary carcinoma to improve surgical 
options. However, for premenopausal women, neoadjuvant endocrine therapy remains 
investigational (Chia et al., 2010). 
The biosynthesis of estrogens can be inhibited by gonadotropin-releasing hormone (GnRH) 
analoga, which interfere with the hypothalamic-pituitary-gonadal axis. Both GnRH agonists 
(e.g. busereline) and antagonists (e.g. cetrorelix) can be used and lead to a suppression of 
ovarian estrogen production, a state called reversible medical castration. A continuous 
application of GnRH agonists leads to the down-regulation of pituitary gonadotropin secretion 
by establishing a negative feedback mechanism (Figure 9; Emons et al., 2003). GnRH 
antagonists compete with natural GnRH for binding to the GnRH receptors and in contrast to 
GnRH agonists they avoid an initial stimulation of the gonadotropin secretion (Aktories et al., 
2011). 
Another strategy to interfere with estrogen biosynthesis is inhibiting aromatase that 
catalyzes the conversion of androgens to estrogens (Figure 11). Currently, aromatase inhibitors 
of the third generation are available including both steroidal (e.g. formestane) and nonsteroidal 
(e.g. anastrazole; Aktories et al., 2011). 
Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to ER 
and can modulate its transcriptional capabilities in different ways in diverse estrogen target 
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tissues (Peng et al., 2009). In other words they can both act as agonists and antagonists. For 
example, tamoxifen, one of the first generation SERMs, inhibits the growth of breast cancer 
cells while it stimulates the profileration of the endometrium. 
Pure ER antagonists completely inhibit the estrogen dependent gene transcription and 
compared to SERMs no agonistic activity is observed. Fluvestrant is on the market for the 
treatment of tamoxifen-resistant ER+ breast cancer in postmenopausal woman (Aktories et al., 
2011). 
Surgical treatment of endometriosis is widely done and can be performed using laparoscopy. 
But considering the regression aspect of the lesions, ovaryectomy is the most effective therapy 
(Kitawaki et al., 2002). Nonselective non-steroidal antiinflammatory drugs (NSAIDs) inhibit the 
synthesis of prostaglandins at both the COX-1 and COX-2 sites, and their use for the treatment 
of endometriosis has been largely studied, even though it is associated with various side effects. 
In the mild stage of endometriosis some NSAIDs acting on the pain symptomatology are used 
for long-term treatment (Cobellis et al., 2004). The selective inhibition of COX-2 is an effective 
therapeutic approach to endometriosis-associated pelvic pain (Cobellis et al., 2004), however 
due to side effects and the actual state of clinical data it can only be recommended for patients 
with severe endometriosis under clearly defined conditions (Ebert et al., 2005). 
Further medical treatments for endometriosis focus on the hormonal alteration of the 
menstrual cycle attempting to produce a pseudo-pregnancy or pseudo-menopause. In this 
context GnRH analoga, oral contraceptives, and androgens are employed (Olive and Pritts, 
2001). So far aromatase inhibitors and SERMs are not integrated into the therapeutic concept to 
treat endometriosis but recent studies showed promising results (Racine et al., 2010; Kulak et 
al., 2011).  
1.3.3 17β-HSD1 as promising target for the treatment of estrogen-dependent 
diseases 
Estrogen-dependent diseases (EDDs) such as breast cancer or endometriosis are a severe threat 
for women (Ferlay et al., 2010; Ferrero et al., 2010). Consequently the treatment of these 
diseases is a major therapeutic challenge. Besides surgery and chemotherapy suppression of the 
estrogenic effects is a major therapeutic approach to accomplish this task. However, the 
endocrine therapies that are currently used in the clinic such as GnRH analoga, SERMs or 
aromatase inhibitors cause unwanted side effects. Strong reduction of estrogen levels in the 
whole body or blockade of estrogen action lead to adverse events largely mimicking 
menopausal symptoms, including hot flashes, losses in bone mineral density, gynecologic 
symptoms, and arthralgias (Abdulhaq and Geyer, 2008). Due to their tissue specific 
functionality, SERMs carry the risk to induce cancer in different tissues such as the 
endometrium, where they act as ER agonists (Angela DeMichele, 2008). Another drawback of 
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the presently applied endocrine therapies is the development of resistance that is observed for 
both antiestrogens and aromatase inhibitors (Urruticoechea, 2007). Further, the applicability of 
the latter is limited to postmenopausal women. In women with functioning ovaries suppression 
of estrogen synthesis can trigger a reflex increase in gonadotropins, which in turn causes an 
increase in ovarian production of aromatase and estrogens (Figure 9), as well as stimulation of 
estrogen-dependent tumor cells (Ortmann et al., 2009). 
Therefore, we must consider developing novel therapeutical strategies for the treatment of 
estrogen-dependent diseases that predominantly affect intracellular E2 production in the 
diseased tissues. Such an intracrine approach has already been proved successful for the 
treatment of androgen dependent diseases such as benign prostatic hyperplasia and alopecia by 
using 5α-reductase (S5AR) inhibitors (Picard et al., 2002; Aggarwal et al., 2009). A promising 
target to locally reduce E2 levels in diseased tissues is 17β-HSD1 that catalyzes the intracellular 
activation of E1 into E2. Both hormone-dependent breast cancer and endometriosis are 
estrogen-dependent diseases, with an increase in the ratio of 17β-HSD1 to 17β-HSD2 (Sasano et 
al., 2000; Tsai et al., 2001; Jansson, 2009) expression resulting in an increased E2/E1 ratio. 
Therefore inhibition of 17β-HSD1 has the potential to balance the increased E2/E1 ratio thereby 
reducing the E2 dependent proliferating effect. Further, this strategy is not expected to cause the 
unwanted effects that are characteristic for the endocrine therapies, as it does not interfere with 
the E1 biosynthesis. Hence, E1 is able to unfold its weak estrogenic activity. 
Different animal models support the general validity of this approach. In immunodeficient 
mice that were inoculated with T-47D breast cancer cells stably expressing human 17β-HSD1 
and 17β-HSD2 a decrease of tumor growth could be demonstrated by application of a steroidal 
17β-HSD1 inhibitor (Day et al., 2008). Further, endometrial hyperplasia of transgenic mice 
ubiquitously expressing high levels of human 17β-HSD1 could be reversed using of a steroidal 
17β-HSD1 inhibitor (Saloniemi et al., 2010). 
In the past ten years a great deal of work was invested in the development of 17β-HSD1 
inhibitors. Most of the inhibitors of 17β-HSD1 reported are based on the steroid scaffold 
including E1 and E2 derivatives. There are also hybrid inhibitors that consist of a steroidal 
scaffold linked to an adenosine moiety to cover both the SBD and COF (Poirier, 2003; 2009; 
Day et al., 2010; Marchais-Oberwinkler et al., 2010). However, as the steroidal inhibitors are 
close to the natural ER ligands E1 and E2 it cannot be exluded that steroidal inhibitors show 
affinity to human ERs or other steroid receptors. In order to reduce the risk of undesired side 
effects caused by interaction with steroid receptors the development of non-steroidal inhibitors 
has come into focus. Several classes of non-steroidal inhibitors have been discovered including 
gossypol derivatives (Brown et al., 2003), phytoestrogens (Poirier, 2003), 
thiophenepyrimidinones (Messinger et al., 2006; Karkola et al., 2008; Lilienkampf et al., 2009), 
and biphenyl ethanones (Allan et al., 2008). In the effort to identify a lead structure, that can be 
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optimized as selective 17β-HSD1 inhibitor for the treatment of estrogen-dependent diseases the 
group of Prof. Hartmann has made an important contribution to the field of non-steroidal 17β-
HSD1 inhibitors. So far five different classes of potent and selective non-steroidal 17β-HSD1 
inhibitors have been identified: the (hydroxyphenyl)naphthols (Frotscher et al., 2008; Marchais-
Oberwinkler et al., 2008; 2009; 2011; Henn et al., 2012), the bis(hydroxyphenyl) substituted 
arenes (Bey et al., 2008a; 2008b; 2009), the heterocyclic substituted biphenylols (Oster et al., 
2010b), the bicyclic substituted hydroxyphenylmethanones (Oster et al., 2010a), and the 
hydroxybenzothiazoles (Spadaro et al., 2012a; 2012b; Figure 14). 
 
Figure 14. Representative structures of non-steroidal 17β-HSD1 inhibitor classes. a) 
(hydroxyphenyl)naphthols; b) bis(hydroxyphenyl) substituted arenes; c) heterocyclic substituted 
biphenylols; d) bicyclic substituted hydroxyphenylmethanones; e) hydroxybenzothiazoles. 
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2 Aim of the Thesis 
Corpora non agunt nisi fixata (drugs do not act unless they are bound) – in 1913, it was Paul 
Ehrlich who first proposed the concept of highly specific interactions between drugs and their 
macromolecular targets, which usually are proteins. A detailed knowledge of the specific 
protein-ligand interactions is essential to understand physiological processes on a molecular 
level and to modulate pathophysiological states. Very importantly it enables rational drug 
design. The latter has the potential to increase the chances of success in many stages of the drug 
discovery process, from the identification of novel targets and elucidation of their function to 
the design and development of lead compounds with desired properties. Therefore, this thesis is 
aimed at increasing the body of knowledge of protein-ligand interactions and active site 
topologies as well as understanding structure-activity relationships (SAR) by thermodynamic 
and structural profiling to aid the drug discovery process. In doing so, the comparison of 
affinities, inhibitory potencies, and thermodynamic signatures obtained for one compound 
toward proteins, differing only in few amino acid residues is a promising strategy. For this 
purpose, wild type proteins and their mutants carrying a set of point mutations can be used. 
Alternatively, ortholog, highly conserved proteins from various species might be considered. In 
the present study, both approaches were applied to investigate in particular the P. aeruginosa 
transcriptional regulator PqsR and human 17β-HSD1 that are promising targets for limiting P. 
aeruginosa pathogenicity and the treatment of estrogen-dependent diseases, respectively. Given 
that infectious and estrogen-dependent diseases are a constant threat for humans not least due to 
the development of resistances or unsatisfying current therapies there is an urgent need for drugs 
with novel modes of action. 
We consider antagonizing PqsR as a novel, promising strategy to attenuate PqsR-dependent 
virulence of P. aeruginosa without affecting bacterial viability. Thus, we believe that this 
approach is unlikely to pose harsh selective pressure thereby minimizing the risk of resistance 
development. In 6-position substituted HHQ derivatives constitute a class of potent PqsR 
antagonists. However, an important drawback of the HHQ-derived antagonists is the insufficient 
physicochemical properties. Hence, one major goal of this thesis was the identification of small, 
druglike molecules targeting the QS key player PqsR. To achieve this goal, we followed a 
rational design strategy combined with a fragment screening approach. Thermodynamic 
profiling of ligands binding to wild-type PqsR and site-directed mutants was applied as 
guidepost for hit selection and optimization. This approach is particularly suitable as it provides 
insights into ligand binding modes and the energetic characteristics of protein-ligand 
interactions. 
17β-HSD1 catalyzes the activation of E1 to the most potent estrogen E2, which is known to 
have a crucial role in the development and proliferation of estrogen-dependent diseases. 
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Consequently, inhibition of 17β-HSD1 is considered as a valuable therapeutic approach for their 
treatment. In the past, several steroidal and non-steroidal inhibitors of 17β-HSD1 have been 
described but so far none of the candidates has entered clinical trials. Furthermore, there is no 
cocrystal structure of a non-steroidal inhibitor in complex with 17β-HSD1 indicating a lack of 
understanding the underlaying protein-ligand interactions. Therefore, the present study is 
targeted at increasing the knowledge of active site topologies and protein-ligand interactions in 
order to facilitate structure-based drug design and optimization. To achieve this goal, inhibitory 
potencies of selected non-steroidal inhibitors toward human and marmoset 17β-HSD1, which 
are highly conserved in sequence, were determined, compared and rationalized on a structural 
basis employing a set of computational methods. The obtained binding mode models were used 
to assist the design and synthesis of novel 17β-HSD1 inhibitors. 
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Abstract: The Gram-negative opportunistic pathogen Pseudomonas aeruginosa produces an 
intercellular alkyl quinolone signaling molecule, the Pseudomonas quinolone signal. The pqs 
quorum sensing communication system that is characteristic for P. aeruginosa regulates the 
production of virulence factors. Therefore, we consider the pqs system a novel target to limit P. 
aeruginosa pathogenicity. Here, we present small molecules targeting a key player of the pqs 
system, PqsR. A rational design strategy in combination with surface plasmon resonance 
biosensor analysis led to the identification of PqsR binders including four top candidates with 
good ligand efficiencies. Determination of thermodynamic binding signatures using isothermal 
titration calorimetry and functional characterization in a heterologous reporter gene assay in E. 
coli guided the optimization of the best hit that resulted in the potent hydroxamic acid-derived 
PqsR antagonist 11 (IC50 = 12.5 µM). This compound showed a KD value of 4.1 µM, displayed a 
similar potency in P. aeruginosa (IC50 = 23.6 µM) and reduced the production of the virulence 
factor pyocyanin. Beyond this, site-directed mutagenesis together with thermodynamic analysis 
provided insights into the energetic characteristics of protein-ligand interactions suggesting the 
presence of hydrogen bonds and CH/π interactions. Thus the identified PqsR antagonists are 
promising scaffolds for further drug design efforts against this important pathogen. 
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Introduction 
Pseudomonas aeruginosa is an environmental highly adaptable opportunistic pathogen that is 
one of the leading causes for nosocomial infections1 and is responsible for chronic lung 
infections in the majority of cystic fibrosis patients.2 It coordinates group behaviours via a cell 
density dependent cell-to-cell communication system known as quorum sensing (QS).3 Beside 
the las4, 5 and the rhl6, 7 communication systems, which use N-acyl homoserine lactones as 
autoinducers, P. aeruginosa employs a characteristic pqs QS system.8 It functions via the signal 
molecules PQS (2-heptyl-3-hydroxy-4-quinolone) and its precursor HHQ (2-heptyl-4-
quinolone) that interact with their receptor PqsR to control the production of a number of 
virulence factors such as pyocyanin and biofilm formation.9-11 Due to growing antibiotic 
resistance there is an urgent need for therapeutics with novel modes of action. Targeting 
bacterial virulence or disrupting the interaction between the host and the pathogen are attractive 
options that are increasingly being explored.12 Therefore we consider PqsR a novel, promising 
target to disrupt PqsR-dependent gene expression thereby limiting P. aeruginosa pathogenicity 
without affecting bacterial viability.13 Recently, we reported on the discovery of the first PqsR 
antagonists.14 However, as their structures are derived from the natural effector HHQ they have 
insufficient physicochemical properties to be used as a drug. Here, we describe the discovery 
and optimization of small molecules targeting the transcriptional regulator PqsR using a rational 
design strategy guided by biophysical methods. Combination of site-directed mutagenesis and 
thermodynamic analysis enabled us to study protein-ligand interactions in detail.  
 
Results and Discussion 
The κ-opioid receptor agonist (±)-trans-U50488 (1) was recently found to stimulate the 
transcription of pqsABCDE in P. aeruginosa PAO1 indicating that it could act via PqsR.15 
Employing surface plasmon resonance (SPR) biosensor analysis and isothermal titration 
calorimetry (ITC) we confirmed that 1 binds to PqsR (Figure 1; Supplementary Figures S1 and 
S2) thereby providing a promising starting point for the identification of small-molecule PqsR 
ligands. 
We applied a rational design strategy that involves the simplification of 1 into smaller 
fragments and analogues. In the context of antibacterial drug discovery, fragment-based design 
is a promising strategy since it allows to address the key issues namely insufficient 
physicochemical properties and lack of chemical diversity.16, 17 The derived in house library 
included (i) N-heteroaromatic substituted benzamides, (ii) substituted benzyl- and benzamides, 
and (iii) N-phenyl substituted isonicotin- and nicotinamides (Figure 1).  
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Figure 1. Ligand-based design strategy. Structure of the PqsR ligand (±)-trans-U50488 1 (top) 
and general structures i-iii of the derived focused library (below). KD value and ligand efficiency 
(LE) were determined using ITC. 
Screening of the focussed library (106 compounds) in a SPR biosensor assay monitoring the 
affinity toward PqsR (biotinylated PqsR was immobilized on a streptavidin coated sensorchip) 
revealed binders including four top candidates with outstanding ligand efficiencies (LE, Figure 
2).  
 
Figure 2. SPR screening data analysis. a) Compound data overlay for binding, referenced for 
blanks, DMSO calibration and streptavidin reference flow cell; blue dots represent calculated LE 
for compounds; red squares represent calculated LE for positive control 1 (referring surface 
stability); orange circles represent screening hits. Compounds were injected at 100µM. b) 
Chemical structures of the top four hits. 
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The major drawback of screening small simple molecules is that the binding affinity is usually 
low.17 Therefore, LE, which is calculated as the binding energy of the ligand per heavy atom 
thereby normalizing the affinity and molecular size of a compound, was used for effective hit 
selection.18 To account for heteroatoms the binding efficiency index (BEI), that engages the 
total molecular weight instead of the number of non-hydrogen atoms19 is superior but here the 
ranking did not change. To verify and further characterize the best hit 4, we carried out a 
thermodynamic analysis and evaluated its agonistic and antagonistic activity (Table 1).  
Table 1. Thermodynamic parameters of ligands 1, 4, and 6-12 binding to PqsR and their 
agonistic and antagonistic activities. 
 
 
Ligand R KD 
[µM] 
ΔG 
[kcal mol-1] 
ΔH 
[kcal mol-1] 
-TΔS 
[kcal mol-1] 
LE 
[kcal mol-1] 
Agonistic  
activity [%] 
Antagonistic  
activity [%] 
1  3.6±0.4 -7.4±0.1 -4.7±0.1 -2.7±0.1 0.31 n.a. 18±3★ 
4 Cl 25.5±2.5 -6.3±0.1 -4.1±0.2 -2.1±0.2 0.63 n.a. 53±7★ 
6 Me 31.2±3.4 -6.1±0.1 -2.2±0.1 -3.9±0.1 0.62 33±2☆ n.i. 
7 Et 7.3±0.6 -7.0±0.1 -4.6±0.3 -2.4±0.3 0.64 122±13☆ n.i. 
8 iPr 3.0±0.4 -7.5±0.1 -6.3±0.3 -1.3±0.4 0.63 111±10☆ n.i. 
9 tBu 0.9±0 -8.3±0 -9.7±0.3 1.5±0.3 0.63 43±3☆ 48±1☆ 
10 iBu 5.7±0.9 -7.2±0.2 -7.9±0.4 0.7±0.1 0.55 32±3★ 45±8★ 
11 tBu 4.1±0.6 -7.4±0.1 -8.9±0.2 1.5±0.3 0.53 n.a. 78±12★ 
12 Et 19.7±1.2 -6.4±0 -4.8±0.2 -1.6±0.2 0.54 n.a. 50±9☆ 
ITC titrations were performed at 298 K. Data represent mean ± SD from at least three independent experiments. 
Agonistic activity was determined by measuring the PqsR stimulation induced by 100 µM of the test compound 
compared to 50 nM PQS (= 100%); n.a. = no agonism (agonistic activity ≤ 10%). Antagonistic activity was determined 
by measuring the inhibition of the PqsR stimulation induced by 50 nM PQS in the presence of 100 µM test compound 
(full inhibition = 100%); n.i. = no inhibition (antagonistic activity ≤ 10%). Mean value of at least two independent 
experiments with n = 4, standard deviation less than 25%. Significance: For the agonist test, induction compared to the 
basal value; for the antagonist test, decrease of the PQS-induced induction. ☆ p < 0.003; ★ p < 0.05. 
Using ITC a dissociation constant (KD) of 25.5 µM was determined for 4 binding to PqsR and 
the LE of 0.63 kcal/mol confirmed the high potential of 4 as starting point for optimization. 
Further, we examined the PqsR-mediated transcriptional effect in a reporter gene assay by 
measuring the β-galactosidase activity in E. coli harbouring the pEAL08-2 plasmid containing 
the tacP-pqsR and pqsAP-lacZ fusion genes.20 E.coli was used as it provides a system to 
characterize the functionality of PqsR ligands independent of the entire pqs system present in P. 
aeruginosa.21 Remarkably, in the E. coli reporter gene assay 1 did not stimulate the transcription 
of pqsABCDE as described,15 rather it acts as a weak PqsR antagonist. 
More important, for ligand 4 a significant reduction of the PqsR stimulation was observed.  
Considering the promising LE and the antagonistic activity compound 4 was chosen as starting 
point for structural modifications. 
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Variation of the length of the alkyl chain in PQS21, 22 as well as in HHQ and its derivatives14 
had demonstrated a chain length dependency of agonistic and antagonistic activities revealing 
the alkyl chain as a key feature. Therefore, alkyl chains varying from C1 to C4 were introduced 
in the para-position of the benzamide core that led to compounds 6-10 (Table 1; Figure 3). 
 
Figure 3. Flexible alignment of 7, 8, and 9 (magenta) with the natural ligand PQS (green). 
Alignment was done using the flexible alignment utility of MOE2010.10 (Chemical Computing 
Group Inc., Montreal, Canada). 
Compared to 4 (KD = 25.5 µM) the tert-butyl substituted benzamide (9, KD = 0.9 µM) showed a 
29-fold increase in binding affinity and the LE remained constant at a value of 0.63 kcal/mol. 
However, changing the constitution from tert- to iso-butyl (compound 10, KD = 5.7 µM) 
reduced the affinity again. Analysis of the thermodynamic signatures revealed that ligands 7-10 
are enthalpy driven binders indicating a good non-covalent bond complementary between the 
protein and the compounds.23 However, with increasing enthalpic contribution in this series the 
entropic terms became more unfavorable, thereby partially compensating the enthalpic gain 
(Figure 4). 
 
Figure 4. Plot of enthalpy (ΔH) vs entropy (-TΔS). ΔH and –TΔS are highly correlated thereby 
clearly evidencing an enthalpy-entropy compensation effect in the protein-ligand complexes of 
the current study. 
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The replacement of the Cl-substituent in para-position of 4 by alkyl-residues (compounds 6-10) 
inverted the functional properties from antagonistic (4) to agonistic activity (6-10). 
Interestingly, the ligands with the bulkiest substituents 9 and 10 showed in addition to their 
moderate agonistic activity a significant reduction of the PqsR stimulation. These findings 
demonstrate the impact of the alkyl moiety on binding affinity as well as on functional 
properties. 
In order to elucidate the role of the amide function, we exchanged it by a hydroxamic acid in 
the ligand with the highest affinity and the most favorable enthalpic contribution (compound 9). 
The resulting compound 11 (KD = 4.1 µM) displayed a 4.6-fold reduced affinity compared to 9 
that is due to a decrease in ΔH. Interestingly, the antagonistic potency was improved and the 
agonistic activity was completely lost. To investigate whether in the alkyl-substituted series the 
replacement of the amide by a hydroxamic acid in general can turn agonists into antagonists the 
corresponding derivative of 7 (compound 12) was synthesized. Indeed, 12 (KD = 19.7 µM) is 
also a pure PqsR antagonist. 
Combining ITC with site-directed mutagenesis provides a valuable thermodynamic tool to 
identify the effects of specific residues in interaction with ligands.24 Gln194, the only polar 
residue in the PQS-binding pocket,25, 26 was mutated and the binding of 1, 8, 9, and 11 to the 
resulting PqsR Q194A mutant was analyzed by ITC (Table 2). 
Table 2. Effect of the Q194A mutation on the thermodynamic parameters of ligand binding. 
Ligand ΔΔG 
[kcal mol-1] 
ΔΔH 
[kcal mol-1] 
-TΔΔS 
[kcal mol-1] 
1 0.0±0.1 0.1±0.1 -0.1±0.1 
8 -1.3±0.3☆ -4.0±0.3☆ 2.7±0.4☆ 
9 -1.3±0☆ -4.4±0.3☆ 3.1±0.3☆ 
11 -0.5±0.1☆ -4.1±0.4☆ 3.6±0.4☆ 
ΔΔG, ΔΔH, and –TΔΔS are ΔGWT – ΔGmutant, ΔHWT – ΔHmutant, and –T(ΔSWT – ΔSmutant), respectively. Negative values 
indicate a loss; positive values, a gain compared to wild-type. Errors indicate SD calculated via Gaussian error 
propagation. Significance: effect of the Q194A mutation on the thermodynamic parameters of ligand binding compared 
to the wild-type. ☆ p < 0.003. 
While the point mutation of Gln194 to Ala did not affect the binding of 1, the affinity of 8, 9, 
and 11 was significantly decreased. The latter reveals that Gln194 is only involved in the 
binding of 8, 9, and 11, but ITC and SPR competition experiments though confirmed that 1 and 
11 bind to the same binding site (Figure 5).  
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Figure 5. Competitive binding of ligands to PqsRC87 as measured by ITC and SPR. a) Raw ITC 
data (top) and integrated normalized data (bottom) for titrations of 94 µM H6SUMO-PqsRC87 with 
900 µM 11 (■) in the absence of 1 and in the presence of 1 mM compound 1 (Δ). b) Overlay of 
sensorgrams for compound 1 in competition with 11 to H6SUMO-PqsRC87 measured in 
duplicates at 12°C; double referenced and DMSO calibrated. c) Blue line: Fit of the duplicate 
(±)-trans-U50488 equilibrium response data from the H6SUMO-PqsRC87 surface to a 1:1 
interaction; black line: Fit of the duplicate (±)-trans-U50488 equilibrium response data from the 
H6SUMO-PqsRC87 surface to a 1:1 interaction in the presence of 100µM of compound 11.  
Interestingly, for the interaction of 8, 9, and 11 with the Q194A mutant a comparable loss in ΔH 
was observed with values ranging from 4.0 to 4.4 kcal/mol. Considering that a well-placed H-
bond can make a favorable enthalpic contribution in the order of -4 to -5 kcal/mol,27 the results 
suggest that Gln194 forms H-bonds with 8, 9, and 11. Further, the binding of the latter ligands 
to the Q194A mutant showed positive -TΔΔS values relative to those of the wild-type. This 
might be due to the increased conformational flexibility both of the ligand and the protein in the 
absence of the H-bond. 
As shown in Table 1, variation of the alkyl chain (compounds 6-10) affects the enthalpy ΔH 
demonstrating that the alkyl chain is involved in the formation of non-covalent interactions like 
CH/π hydrogen bonds. The latter have their origin in dispersion forces, which have an impact on 
the enthalpic term of free energy.28 To probe for CH/π interactions Phe221 that is lining the 
PQS-binding pocket25, 26 was mutated to Ala. Ligand 9, which showed the highest affinity 
toward PqsR (KD = 0.9 µM) was selected for analysis and the thermodynamic signatures for the 
binding of 9 to wild-type and F221A mutant PqsR are shown in Figure 6.  
Indeed, the F221A point mutation affected the binding of 9 and with a deficit of 7.6 
kcal/mol the enthalpic contribution was significantly reduced compared to the wild-type. A 
salient feature of the CH/π hydrogen bond is that it works cooperatively and for cases involving 
aliphatic CH groups as the hydrogen donor, the energy of a CH/π hydrogen bond is between -
1.5 and -2.5 kcal/mol.29  
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Figure 6. Thermodynamic profiles determined by ITC for the binding of ligand 9 to wild-type and 
F221A mutant PqsR. Data shown are mean ± SD, n = 3. 
This indicates that Phe221 might form three CH/π bonds with the tBu-moiety of 9 as described 
for the interaction of benzene with isobutane.30 
Given that P. aeruginosa is characterized by a synergy between drug efflux pumps with 
broad substrate specificity and low outer membrane permeability31 we examined whether the 
most potent antagonist 11 also shows an effect when tested in a P. aeruginosa background. 
Remarkably, the antagonistic activity could be confirmed (IC50 in E. coli = 12.5 µM vs. IC50 in 
P. aeruginosa = 23.6 µM; Figure 7).  
 
Figure 7. Determination of IC50 values in E.coli and P. aeruginosa. IC50 values were determined 
in the reporter gene assays. Compound 11 was tested at seven concentrations in competition 
with 50 nM PQS. IC50 value in E.coli: 12.5 µM; mean value of three experiments. IC50 value in P. 
aeruginosa: 23.6 µM; mean value of two experiments with n = 4. The log (inhibitor) vs. response 
model (Prism 5.0) was applied for nonlinear regression and determination of IC50-values; the Hill 
slope was constrained equal to 1.0. 
Two possible explanations for this encouraging finding might be that the penetration of the 
hydrophilic hydroxamic acid 11 (logP = 2.1; calculated with MOE2010.10) across the outer 
membrane exceeds its efflux or that the antagonist 11 is no substrate of the efflux pumps. 
Additionally, 11 is able to reduce the production of the virulence factor pyocyanin in P. 
aeruginosa (IC50 = 87.2 µM; Figure 8). 
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Figure 8. Effect of 11 on the pyocyanin production in P. aeruginosa PA14. For the 
determination of the IC50 value the pyocyanin levels in P. aeruginosa PA14 were 
spectrophotometrically determined at A520 nm in the presence of compound 11 at six 
concentrations. IC50 value in: 87.3 µM; mean value of three experiments. The log (inhibitor) vs. 
response-variable slope model (Prism 5.0) was applied for nonlinear regression and 
determination of the IC50-value. 
Conclusion 
In summary, through application of rational design and biophysical methods, we developed to 
the best of our knowledge the first small-molecule PqsR ligands. LEs and functional properties 
were used to guide the elaboration process that resulted in the potent hydroxamic acid-derived 
PqsR antagonist 11. Compared to the recently described HHQ analogues14 compound 11 is a 
less potent antagonist but, as a consequence of its low molecular weight and its activity in P. 
aeruginosa, it has high potential for further optimization. Beyond this, site-directed mutagenesis 
together with thermodynamic analysis disclosed that Gln194 and Phe221 are involved in ligand 
binding, probably by making hydrogen bonds and CH/π interactions, respectively. The rational 
simplification strategy in combination with biophysical methods, using LE as a primary filter, 
revealed promising hits. Accordingly, this approach is a valuable tool in drug design. Future 
experiments will address hit to lead optimization to open the door for antibiotics with novel 
modes of action for the treatment of P. aeruginosa infections. 
 
Methods 
Construction of pSUMO3_ck4_pqsRC87. For generation of pSUMO3_ck4_pqsRC87 containing 
the truncated pqsRC87 gene of P. aeruginosa PA14, the pqsR gene from nucleotide 259 to the 
stop codon was PCR-amplified from genomic DNA using the forward primer 5’-
TATGAGTACTAATCTCAACAAGGGTCCGCGC-3′ and reverse primer 5′-
TGTACAATTGCTACTCTGGTGCGGCGCGCT-3′ (ScaI/MfeI sites underlined) and 
subsequently cloned into the ScaI/MfeI sites of the pSUMO3_ck4 vector in order to express it as 
a H6SUMO-fusion protein. The construct was confirmed by DNA sequencing. This plasmid 
adds 104 amino acids to the N-terminus of the PqsR sequence starting at N87. 
Preparation of pSUMO3_ck4_Q194ApqsRC87 and pSUMO3_ck4_F221ApqsRC87. The 
Q194A and the F221A mutants was generated using the QuikChange Site-Directed Mutagenesis 
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Kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions using the pSUMO3-
ck4-pqsRC87 plasmid as an template. Briefly, the forward primer 5’-
CTGGCCAATTACCGGGCGATCAGCCTCGGCAGC-3’ (A194 underlined) and the reverse 
primer 5’-GCTGCCGAGGCTGATCGCCCGGTAATTGGCCAG-3’ (A194 underlined) were 
used to amplify the Q194A gene through 16 cycles of PCR (35 s denaturation at 95 °C, 60 s 
annealing at 55 °C, and 6.5 min extension at 68 °C). The forward primer 5' 
CTCTTCGTGGAAAACGCGGACGACATGCTGCGTCTG 3' (A221 underlined) and the 
reverse primer 5' CAGACGCAGCATGTCGTCCGCGTTTTCCACGAAGAG 3' (A221 
underlined) were used to amplify the F221A gene through 16 cycles of PCR using the same 
conditions as described above. After treatment with DpnI, the PCR product was transformed 
into E. coli strain XL1-Blue. Plasmid DNA was then purified from transformants using the 
GenEluteTM HP Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO) and sequenced to 
confirm the Q194A and the F221A mutations.  
Protein Expression and Purification. Wild-type, Q194A mutant, and F221A mutant 
H6SUMO-PqsRC87 were expressed in E. coli and purified using a single affinity chromatography 
step. Briefly, E. coli BL21 (DE3) cells containing the pSUMO3_ck4_pqsRC87, the 
pSUMO3_ck4_Q194ApqsRC87 or the the pSUMO3_ck4_F221ApqsRC87 plasmid were grown in 
LB medium containing 50 µg ml-1 kanamycin at 37 °C to an OD600 of approximately 0.8 and 
induced with 0.2 mM IPTG for 16 h at 16 °C. The cells were harvested by centrifugation (5000 
rpm, 10 min, 4 °C) and the cell pellet was resuspended in 100 ml binding buffer (50 mM Tris-
HCl, pH 7.8, 150 mM NaCl, 20 mM imidazole, 10% glycerol  (v/v)) and lysed by sonication for 
a total process time of 2.5 min. Cell debris were removed by centrifugation (13000 rpm, 30 min) 
and the supernatant was filtered through a syringe filter (0.2 µm). The clarified lysate was 
immediately applied to a Ni-NTA column (GE Healthcare), washed with 50 mM Tris-HCl, pH 
7.8, 150 mM NaCl, 20 mM imidazole, 10% glycerol (v/v), and eluted with 500 mM imidazole. 
The protein containing fractions were buffer-exchanged into 20 mM Tris, pH 7.4, 150 mM 
NaCl, 10% glycerol (v/v) for the wild-type and into 20 mM Tris, pH 7.8, 300 mM NaCl, 10% 
glycerol (v/v) for the Q194A and the F221A mutants, using a PD10 column (GE Healthcare) 
and judged pure by SDS-PAGE analysis. The H6SUMO-tagged proteins were stored at -80 °C 
and used for biophysical studies.  
Minimal biotinylation of H6SUMO-PqsRC87. Minimal biotinylation of the H6SUMO-
PqsRC87 was achieved by mixing 56 nmol of H6SUMO-PqsRC87 (1 eq.) with 28 nmol of EZ-link 
sulfoNHS LC-LC-biotin (0.5 eq.; Thermofisher Scientific) that was freshly dissolved in water. 
Biotinylation reaction mixture was incubated on ice for 2 hours. To remove unreacted biotin 
reagent, the entire biotinylation mixture was subjected to size exclusion chromatography on a 
Superdex200 HR (16/600) column equilibrated in storage buffer (1x PBS, pH 7.4, 10% glycerol 
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(v/v)). A protein peak containing biotinylated H6SUMO-PqsRC87 protein was collected (0.3 
mg/ml), stored at -80 °C and used for SPR studies.  
Surface Plasmon Resonance. SPR binding studies were performed using a Reichert 
SR7500DC instrument optical biosensor (Reichert Technologie, Depew, NY 14043 USA). 
SAD500 sensor chips from Xantec (Xantec Analytics, Düsseldorf) were used. Dimethyl 
sulfoxide (DMSO), biotin and (±)-trans-U50488 methanesulfonate were purchased from Sigma. 
Library collection consisted of 106 compounds with molecular weight range of 100 to 350 Da.  
Immobilization of biotinylated H6Sumo-PqsRC87. Biotinylated H6SUMO-PqsRC87 was 
immobilized on a SAD500 (Streptavidin coated) sensor chip at 25 °C. HEPES (50 mM HEPES, 
pH 7.4, 150 mM NaCl) was used as the running buffer. The streptavidin carboxymethyl dextran 
surface was preconditioned 30 min with running buffer until the baseline was stable. 
Biotinylated H6SUMO-PqsRC87was diluted into running buffer to a concentration of 100 µg/mL 
and coupled to the surface with a 2-min injection. Remaining streptavidin and the reference cell 
were blocked with a 3-min injection of biotin (3µg/mL). Biotinylated H6SUMO-PqsRC87 (39494 
Da) was immobilized at density of 2200 RU for the binding affinity experiment of (±)-trans-
U50488 methanesulfonate and at a density of 5506 RU for the library screen. 
 
Figure S1. Binding affinity for (±)-trans-U50488. a) Overlay of sensorgrams for confirmed hit 
binding to H6SUMO-PqsRC87 measured in duplicates at 12°C; double referenced. b) Fit of the 
duplicate (±)-trans-U50488 equilibrium response data from the H6SUMO-PqsRC87 surface to a 
1:1 interaction. 
Binding affinity for (±)-trans-U50488 methanesulfonate. The binding experiment was 
performed at 12°C at a constant flow rate of 80 µl/min in instrument running buffer (50 mM 
HEPES, 150 mM NaCl, pH 7.4, 5% DMSO (v/v), 0.05% P20 (v/v). A 10 mM stock of trans-
U50488 methanesulfonate in running buffer was directly diluted to a concentration of 1 mM and 
then diluted in a 3-fold dilution series from 111 µM down to 457 nM. Before starting the 
experiments 12 warm-up blank injections were performed. Zero-buffer blank injections and 
DMSO calibrations were included for double referencing. Individual concentrations were 
injected in duplicates from lowest to highest concentrations for 120 s association and 5 min 
dissociation time. Scrubber software was used for processing and analysing data. Equilibrium 
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dissociation constant (KD) was determined by locally fitting appropriate experimental data to a 
1:1 model using fitting procedure available within Scrubber software. Overlay plot of 
sensorgrams and affinity plot in adequate logarithmic units for the concentrations32 are shown in 
Supplementary Figure S1. 
Library Screening. Concentrations of ligand stock solutions in DMSO were determined by 
the weight of the compound. Compounds as 10 mM DMSO stocks were diluted in DMSO to 2 
mM. Final ligand concentrations (100 µM) were achieved by diluting 1:20 (v/v) in the 
experimental buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% P20 (v/v)) resulting in a 
final DMSO concentration of 5% (v/v). Binding experiments were performed at 12°C at a 
constant flow rate of 100 µl/min in instrument running buffer (50 mM HEPES, pH 7.4, 150 mM 
NaCl, 5% DMSO (v/v), 0.05% P20 (v/v). Each compound was injected for 26 s association - and 
120 s dissociation time. Positive control ((±)-trans-U50488 methanesulfonate) was injected 
each 25th injection at 20 µM to assess stability and reproducibility of the assay. 110 compounds 
were screened within 6 hours in 96 well plates. Data evaluation was performed using Scrubber 
(http://www.biologic.com.au) and Microsoft Excel software for data processing and analysis. 
Using Scrubber software, SPR signals in flow cell containing captured biotinylated protein were 
transformed, referenced against the blank surface (streptavidin) and further corrected for DMSO 
refractive index change (excluded volume effect). Compounds showing promiscuous binding 
response33 were removed from the screening data. Report binding points, taken for each 
fragment injection after a contact interval of 19-s were analyzed. KD values were estimated 
using Eq. (1) derived from the Langmuir adsorption isotherm.  
 
KD = (Rmax*C/R)-C (1) 
 
Rmax, R, and C correspond to the normalized saturation response of the compound, the 
normalized response of the test compound, and the concentration of the test solution, 
respectively. For the ranking of the best hits, the LE was calculated as previously described18, 34 
from Eq. (2), 
 
LE = -RTlnKD/(heavy atom count) (2) 
 
T is the absolute temperature, and R = 1.98 cal/mol/K. 
Competition experiments for (±)-trans-U50488 methanesulfonate and compound 11. 
The competition experiment was performed at 12°C at a constant flow rate of 25 µl/min in 
instrument running buffer (50 mM HEPES, 150 mM NaCl, pH 7.4, 5% DMSO (v/v), 0.05% P20 
(v/v), 100µM compound 11. A 10 mM stock of trans-U50488 methanesulfonate in running 
buffer was directly diluted to a concentration of 1 mM and then diluted in a 3-fold dilution 
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series from 333 µM down to 4,57 µM. Before starting the experiments 12 warm-up blank 
injections were performed. Zero-buffer blank injections and DMSO calibrations were included 
for double referencing. Individual concentrations were injected in duplicates from lowest to 
highest concentrations for 120 s association and 5 min dissociation time. Scrubber software was 
used for processing and analysing data. Equilibrium dissociation constant (KD) was determined 
by locally fitting appropriate experimental data to a 1:1 model using fitting procedure available 
within Scrubber software. Overlay plot of sensorgrams and affinity plot in adequate logarithmic 
units for the concentrations32 are shown in Figure 5. 
Isothermal titration calorimetry. ITC experiments were carried out using an ITC200 
instrument (Microcal Inc., GE Healthcare). Concentrations of ligand stock solutions in DMSO 
were determined by the weight of the compound. Final ligand concentrations were achieved by 
diluting 1:20 (v/v) in the experimental buffer resulting in a final DMSO concentration of 5% 
(v/v). Protein concentration was determined by measuring the absorbance at 280 nm using a 
theoretical molarity extinction coefficient of 22,900 M-1cm-1. DMSO concentration in the 
protein solution was adjusted to 5% (v/v). ITC measurements were routinely performed at 25 °C 
in 20 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol (v/v), 5% DMSO  (v/v) for the wild-type 
PqsRC87and in 20 mM Tris, pH 7.4, 300 mM NaCl, 10% glycerol (v/v), 5% DMSO (v/v) for the 
Q194A and the F221A mutants, respectively. The titrations were performed on 66-200 µM 
H6SUMO-PqsRC87, H6SUMO-Q194APqsRC87 or H6SUMO-F221APqsRC87 in the 200 µl sample 
cell using 2-2.7 µl injections of 0.7-2.5 mM ligand solution every 180 s. The competition 
experiment was performed on 94 µM H6SUMO-PqsRC87, which was incubated with 1mM 
compound 1 for 30 min at 25 °C. Raw data were collected and the area under each peak was 
integrated. To correct for heats of dilution and mixing the final base line consisting of small 
peaks of the same size at the end of the experiment was subtracted. The experimental data were 
fitted to a theoretical titration curve (one site binding model) using MicroCal Origin 7 software, 
with ΔH (enthalpy change in kcal/mol), KA (association constant in M−1), and N (number of 
binding sites) as adjustable parameters. Thermodynamic parameters were calculated from Eq. 
(3), 
 
ΔG = ΔH - TΔS = RTlnKA = -RTlnKD (3) 
 
where ΔG, ΔH, and ΔS are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R = 1.98 cal/mol/K. The LE for each compound 
was calculated from Eq. (4), 
 
LE = -ΔG/(heavy atom count)  (4) 
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where ΔG is the change in free energy and heavy atom count is the number of non-hydrogen 
atoms of the compound. For each ligand at least three independent experiments were performed. 
Representative ITC titrations of 1, 8, and 11 against H6SUMO-PqsRC87 and H6SUMO-
Q194APqsRC87 are shown in Supplementary Figure S2. Representative ITC titrations of 9 
against H6SUMO-PqsRC87, H6SUMO-Q194APqsRC87, and H6SUMO-F221APqsRC87 are shown 
in Supplementary Figure S3. Representative ITC titrations of 4, 6, 7, 10, and 12 against 
H6SUMO-PqsRC87 are shown in Supplementary Figure S4. 
 
 
Figure S2. Representative ITC titrations. a) ITC titration of 1 (1.4 mM) against H6SUMO-
PqsRC87 (111 µM). b) ITC titration of 8 (900 µM) against H6SUMO-PqsRC87 (83 µM). c) ITC 
titration of 11 (900 µM) against H6SUMO-PqsRC87 (94 µM). d) ITC titration of 1 (1 mM) against 
H6SUMO-Q194APqsRC87 (100 µM). e) ITC titration of 8 (2 mM) against H6SUMO-
Q194APqsRC87 (141 µM). f) ITC titration of 11 (1 mM) against H6SUMO-Q194APqsRC87 (95 
µM). The recorded change in heat is shown in units of µcal/sec as a function of time for 
successive injections of the ligand (upper row). Integrated heats (black squares) plotted against 
the molar ratio of the binding reaction. The continuous line represents the results of the non-
linear least squares fitting of the data to a binding model (lower row). 
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Figure S3. Representative ITC titrations. a) ITC titration of 9 (700 µM) against H6SUMO-
PqsRC87 (67 µM). b) ITC titration of 9 (700 µM) against H6SUMO-Q194APqsRC87 (66 µM). c) 
ITC titration of 9 (1 mM) against H6SUMO-F221APqsRC87 (124 µM). The recorded change in 
heat is shown in units of µcal/sec as a function of time for successive injections of the ligand 
(upper row). Integrated heats (black squares) plotted against the molar ratio of the binding 
reaction. The continuous line represents the results of the non-linear least squares fitting of the 
data to a binding model (lower row). 
 
Figure S4. Representative ITC titrations. a) ITC titration of 4 (2.5 mM) against H6SUMO-
PqsRC87 (200 µM). b) ITC titration of 6 (2.5 mM) against H6SUMO-Q194APqsRC87 (157 µM). c) 
ITC titration of 7 (900 µM) against H6SUMO-PqsRC87 (83 µM). d) ITC titration of 10 (900 µM) 
against H6SUMO-Q194APqsRC87 (83 µM). e) ITC titration of 12 (2 mM) against H6SUMO-
Q194APqsRC87 (158 µM). The recorded change in heat is shown in units of µcal/sec as a 
function of time for successive injections of the ligand (upper row). Integrated heats (black 
squares) plotted against the molar ratio of the binding reaction. The continuous line represents 
the results of the non-linear least squares fitting of the data to a binding model (lower row). 
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Reporter Gene Assay in E. coli. The ability of the compounds to either stimulate or antagonize 
the PqsR-dependent transcription was performed as previously described using a β-
galactosidase reporter gene assay20 in E. coli expressing PqsR with some modifications to 
enable a higher throughput35. PQS and PqsR ligands were diluted in ethyl acetate, added to the 
wells of a 96 deep well plate and the solvent was evaporated. Overnight cultures of E. coli 
DH5α cells containing the plasmid pEAL08-2 which encodes PqsR under the control of the tac 
promoter and the β-galactosidase reporter gene lacZ controlled by the pqsA promoter, were 
diluted 1:100 in Luria-Bertani medium with ampicillin (50 µg/ml). The culture was incubated at 
37 °C with shaking until it reached an OD600 of 0.2. For the determination of agonistic activities, 
1 ml aliquots were supplemented with either PQS (50 nM) or the test compound (100 µM). 
Ethyl acetate was used as control. Antagonistic effects of the compounds (100 µM) were 
evaluated in the presence of 50 nM PQS. The β-galactosidase activity was determined after a 
2.5 h incubation period at 37 °C with shaking (150 rpm). OD600, OD420 and OD550 were 
measured and the activity is expressed as ratio of the ethyl acetate control relative to the cultures 
that received either PQS, a test compound or both.  
Reporter Gene Assay in P. aeruginosa PA14. The ability of the compounds to either 
stimulate or antagonize the PqsR-dependent transcription was performed as previously 
described using a β-galactosidase reporter gene assay20 in PA 14ΔpqsA35. PQS and PqsR ligands 
were diluted in ethyl acetate, added to the wells of a 96 deep well plate and the solvent was 
evaporated. Overnight cultures of PA14 cells containing the plasmid pEAL08-2 which encodes 
PqsR under the control of the tac promoter and the β-galactosidase reporter gene lacZ controlled 
by the pqsA promoter, were diluted 1:100 in Luria-Bertani medium with carbenicillin (250 
µg/ml). The culture was incubated at 37 °C with shaking until it reached an OD600 of 0.2. For 
the determination of agonistic activities, 1 ml aliquots were supplemented with either PQS (50 
nM) or the test compound (100 µM). Ethyl acetate was used as control. Antagonistic effects of 
the compounds (100 µM) were evaluated in the presence of 50 nM PQS. The β-galactosidase 
activity was determined after a 2.5 h incubation period at 37 °C with shaking (150 rpm). After 
the incubation period the aliquots were shaked at least for 1 min (1000rpm). OD600, OD420 and 
OD550 were measured and the activity is expressed as ratio of the ethyl acetate control relative to 
the cultures that received either PQS, a test compound or both.  
Pyocyanin assay. Pyocyanin produced by P. aeruginosa PA14 was determined using the 
method of Essar et al.36 with some modifications: Cultures were inoculated with a starting OD600 
= 0.02 in 24 well plates (Greiner, Cellstar) containing 1.5 ml PPGAS medium per well. PPGAS 
medium (20 mM NH4C1, 20 mM KCl, 1.6 mM MgSO4, 120 mM Tris-HCl, pH 7.2, 0.5% (w/v) 
glucose, 1% (w/v) Bacto™ Tryptone)37 was found to enhance pyocyanin production. DMSO as 
a control or DMSO solutions of inhibitors were added to the cultures to a final DMSO 
concentration of 1%. Plates were incubated at 37 °C, 200 rpm and a humidity of 75% for 16 hrs. 
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For pyocyanin determination, 900 µl of each culture were extracted with 900 µl of chloroform. 
The solution was centrifuged (14.000 rpm, 15 min) to separate the phases. 800 µl of the organic 
phase were mixed with 250 µl of 0.2 M HCl. After centrifugation (14.000 rpm, 15 min), 80 µl 
of the aqueous phase was transferred to 96 well plates (Nunc U96 MicroWell™) for 
measurement of OD520 using FLUOstar Omega (BMG Labtech). For each sample, cultivation 
and extraction were performed in triplicates. 
Chemical and Analytical Methods. 1H and 13C NMR spectra were recorded on a Bruker 
DRX-500 instrument. Chemical shifts are given in parts per million (ppm), and 
tetramethylsilane (TMS) was used as internal standard for spectra obtained in CDCl3, MeOH-d4 
and DMSO-d6. Coupling constants (J) are given in hertz. Mass spectrometry (LC/MS) was 
performed on a MSQ® electro spray mass spectrometer (Thermo Fisher). The system was 
operated by the standard software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) 
column (Macherey-Nagel GmbH) was used as stationary phase with water/acetonitrile mixtures 
as eluents. All solvents were HPLC grade. Reagents were used as obtained from commercial 
suppliers without further purification. The reaction progress was determined by thin-layer 
chromatography (TLC) analyzes on silica gel 60, F254 (Merck). Visualization was accomplished 
with UV light. Melting points were measured using melting point apparatus SMP3 (Stuart 
Scientific). The apparatus is uncorrected. 
General procedure for the synthesis of amides.38 Synthesis of 4-ethylbenzamide39 (7). A 
solution of 4-ethylbenzoic acid (746 mg, 500 mmol), thionyl chloride (1 mL) and N,N-
dimethylformamide (3 drops) was heated at 80 °C for 1 h. The reaction mixture was evaporated 
under reduced pressure. The residue was redissolved in toluene (10 mL). At 0 °C the mixture 
was added to concentrated ammonia (20 mL). After stirring for 30 minutes the precipitate was 
collected by suction filtration, washed with water and n-hexane, and dried under reduced 
pressure at 50 °C. Recrystallization from ethyl acetate afforded compound 7 (0.41 g, 55%). Mp: 
164-165 °C. 1H-NMR (500 MHz, CDCl3): δ = 1.25 (t, J = 7.6 Hz, 3H), 2.69 (q, J = 7.6 Hz, 2H), 
6.12 (bs, 2H), 7.26 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ 
= 15.2, 28.8, 127.4, 128.1, 130.8, 148.7, 169.5. LC/MS: m/z = 150.06 (M + H)+, 191.13 (M + H 
+ CH3CN)+, tR = 8.77 min, 98.6% pure (UV). 
Synthesis of 4-isopropylbenzamide40 (8). Compound 8 was prepared from 4-
isopropylbenzoic acid according to the general procedure (0.24 g, 49%). Mp: 150.5-151.5 °C. 
1H-NMR (500 MHz, DMSO-d6): δ = 1.20 (d, J = 6.9 Hz, 6H), 2.92 (septet, J = 6.9 Hz, 1H), 
7.26 (bs, 1H), 7.30 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 8.2 Hz, 2H), 7.89 (bs, 1H). 13C-NMR (125 
MHz, DMSO-d6): δ = 23.6, 33.3, 126.1, 127.6, 131.9, 151.7, 167.8. LC/MS: m/z = 164.11 (M + 
H)+, 205.09 (M + H + CH3CN)+, tR = 8.54 min, >99% pure (UV).  
Synthesis of 4-isobutylbenzamide41 (10). Compound 10 was prepared from 4-
isobutylbenzoic acid according to the general procedure. The final product was crystallized 
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from ethyl acetate (0.45 g, 51%). Mp: 154-155 °C. 1H-NMR (500 MHz, CDCl3): δ = 0.89 (d, J 
= 6.6 Hz, 6H), 1.89 (nonet, J = 6.8 Hz, 1H), 2.52 (d, J = 7.2 Hz, 2H), 6.00 (bs, 2H), 7.21 (d, J = 
8.5 Hz, 2H), 7.73 (d, J = 8.1 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ = 15.2, 28.8, 127.4, 
128.1, 130.8, 148.7, 169.5. LC/MS: m/z = 178.18 (M + H) +, 219.05 (M + H + CH3CN)+, tR = 
10.72 min, 97.3% pure (UV). 
General procedure for the synthesis of hydroxamic acids.42 Synthesis of 4-(tert-butyl)-
N-hydroxybenzamide (11). O-(Tetrahydro-2-pyranyl)hydroxylamine (352 mg, 3.00 mmol) and 
sodium carbonate (159 mg, 1.50 mmol) were dissolved in a water-chloroform mixture (1:1, 10 
mL). 4-tert-Butylbenzoyl chloride (590 mg, 3.00 mmol) was added and the solution was stirred 
for 30 minutes at room temperature. Both layers were separated and the water layer was 
extracted with chloroform. The combined organic layers were evaporated under reduced 
pressure leaving a foam. The solid was dissolved in methanol (20 mL). 0.1 N aqueous HCl (20 
mL) was added and the solution was stirred overnight at room temperature. The solvent was 
removed under reduced pressure leaving compound 11 as a white solid (573 mg, 99%). Mp: 
135.3-136.8 °C (lit. 43 141-144 °C). 1H-NMR (500 MHz, MeOH-d4): δ = 1.28 (s, 9H), 7.45 (d, J 
= 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 11.14 (bs, 1H). 13C-NMR (125 MHz, MeOH-d4): δ = 
31.6, 35.8, 126.5, 128.1, 131.3, 156.4, 169.8. LC/MS: 235.04 (M + H + CH3CN)+, tR = 8.32 
min, 96.0% pure (UV). 
Synthesis of 4-ethyl-N-hydroxybenzamide (12). Compound 12 was prepared from 4-
ethylbenzoyl chloride according to the general procedure (258 mg, 52%). Mp: 103.0-104.8 °C 
(lit. 44 106.5-107 °C). 1H-NMR (500 MHz, CDCl3): δ = 1.17 (t, J = 7.6 Hz, 3H), 2.61 (q, J = 7.6 
Hz, 2H), 7.17 (d, J = 7.9 Hz, 2H), 7.66 (d, J = 7.9 Hz, 2H), 8.56 (bs, 1H), 10.66 (bs, 1H).  13C-
NMR (125 MHz, CDCl3): δ = 15.1, 28.6, 126.9, 127.8, 128.7, 148.1, 165.7. LC/MS: m/z = 
165.94 (M + H)+, 207.03 (M + H + CH3CN)+, 330.81 (2M + H)+ tR = 6.68 min, 95.0% pure 
(UV). 
 
Acknowledgement 
The authors thank S. Amann for her help in performing the reporter gene assay. We are very 
grateful to C. Cugini and D. Hogan (Dartmouth Medical School, Hanover, NH, USA) for kindly 
supplying the plasmid pEAL08-2. The P. aeruginosa PA14 strain was kindly provided by S. 
Häussler (Helmholtz Centre for Infection Research, Braunschweig, Germany). 
 
References 
(1) Blanc, D. S., Petignat, C., Janin, B., Bille, J., and Francioli, P. (1998) Frequency and molecular diversity of 
Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. Clin. 
Microbiol. Infect. 4, 242-247. 
(2) Koch, C., and Høiby, N. (1993) Pathogenesis of cystic fibrosis. Lancet 341, 1065-1069. 
48 3 RESULTS 
 
 
(3) Swift, S., Downie, J. A., Whitehead, N. A., Barnard, A. M., Salmond, G. P., and Williams, P. (2001) Quorum 
sensing as a population-density-dependent determinant of bacterial physiology. Adv. Microb. Physiol. 45, 199-270. 
(4) Gambello, M. J., and Iglewski, B. H. (1991) Cloning and characterization of the Pseudomonas aeruginosa lasR 
gene, a transcriptional activator of elastase expression. J. Bacteriol. 173, 3000-3009. 
(5) Passador, L., Cook, J. M., Gambello, M. J., Rust, L., and Iglewski, B. H. (1993) Expression of Pseudomonas 
aeruginosa virulence genes requires cell-to-cell communication. Science 260, 1127-1130. 
(6) Ochsner, U. A., Koch, A. K., Fiechter, A., and Reiser, J. (1994) Isolation and characterization of a regulatory gene 
affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J. Bacteriol. 176, 2044-2054. 
(7) Ochsner, U. A., and Reiser, J. (1995) Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in 
Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA 92, 6424-6428. 
(8) Pesci, E. C., Milbank, J. B., Pearson, J. P., McKnight, S., Kende, A. S., Greenberg, E. P., and Iglewski, B. H. 
(1999) Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc.  Natl. Acad. 
Sci. USA 96, 11229-11234. 
(9) Allesen-Holm, M., Barken, K. B., Yang, L., Klausen, M., Webb, J. S., Kjelleberg, S., Molin, S., Givskov, M., and 
Tolker-Nielsen, T. (2006) A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms. Mol. 
Microbiol. 59, 1114-1128. 
(10) Dubern, J.-F., and Diggle, S. P. (2008) Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas aeruginosa and 
other bacterial species. Mol. Biosyst. 4, 882-888. 
(11) Déziel, E., Gopalan, S., Tampakaki, A. P., Lépine, F., Padfield, K. E., Saucier, M., Xiao, G., and Rahme, L. G. 
(2005) The contribution of MvfR to Pseudomonas aeruginosa pathogenesis and quorum sensing circuitry regulation: 
multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-
homoserine lactones. Mol. Microbiol. 55, 998-1014. 
(12) Clatworthy, A. E., Pierson, E., and Hung, D. T. (2007) Targeting virulence: a new paradigm for antimicrobial 
therapy. Nat. Chem. Biol. 3, 541-548. 
(13) Xiao, G., Déziel, E., He, J., Lépine, F., Lesic, B., Castonguay, M.-H., Milot, S., Tampakaki, A. P., Stachel, S. E., 
and Rahme, L. G. (2006) MvfR, a key Pseudomonas aeruginosa pathogenicity LTTR-class regulatory protein, has 
dual ligands. Mol. Microbiol. 62, 1689-1699. 
(14) Lu, C., Kirsch, B., Zimmer, C., de Jong, J. C., Henn, C., Maurer, C. K., Müsken, M., Häussler, S., Steinbach, A., 
and Hartmann, R. W. (2012) Discovery of Antagonists of PqsR, a Key Player in 2-Alkyl-4-quinolone-Dependent 
Quorum Sensing in Pseudomonas aeruginosa. Chem. Biol. 19, 381-390. 
(15) Zaborina, O., Lepine, F., Xiao, G., Valuckaite, V., and Chen, Y. (2007) Dynorphin activates quorum sensing 
quinolone signaling in Pseudomonas aeruginosa. PLoS Pathog. 
(16) Mochalkin, I., Miller, J. R., Narasimhan, L., Thanabal, V., Erdman, P., Cox, P. B., Prasad, J. V. N. V., Lightle, 
S., Huband, M. D., and Stover, C. K. (2009) Discovery of antibacterial biotin carboxylase inhibitors by virtual 
screening and fragment-based approaches. ACS Chem. Biol. 4, 473-483. 
(17) Waldrop, G. L. (2009) Smaller is better for antibiotic discovery. ACS Chem. Biol. 4, 397-399. 
(18) Hopkins, A. L., Groom, C. R., and Alex, A. (2004) Ligand efficiency: a useful metric for lead selection. Drug 
Discov. Today 9, 430-431. 
(19) Abad-Zapatero, C., and Metz, J. T. (2005) Ligand efficiency indices as guideposts for drug discovery., In Drug 
Discov. Today, pp 464-469. 
(20) Cugini, C., Calfee, M. W., Farrow, J. M., Morales, D. K., Pesci, E. C., and Hogan, D. A. (2007) Farnesol, a 
common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Mol. Microbiol. 65, 896-906. 
(21) Fletcher, M. P., Diggle, S. P., Crusz, S. A., Chhabra, S. R., Cámara, M., and Williams, P. (2007) A dual 
biosensor for 2-alkyl-4-quinolone quorum-sensing signal molecules. Environ. Microbiol. 9, 2683-2693. 
(22) Hodgkinson, J., Bowden, S. D., Galloway, W. R. J. D., Spring, D. R., and Welch, M. (2010) Structure-activity 
analysis of the Pseudomonas quinolone signal molecule. J. Bacteriol. 192, 3833-3837. 
(23) Ladbury, J. E., Klebe, G., and Freire, E. (2010) Adding calorimetric data to decision making in lead discovery: a 
hot tip. Nat. Rev. Drug Discov. 9, 23-27. 
3.1 IDENTIFICATION OF SMALL-MOLECULE PQSR ANTAGONISTS 49 
 
 
(24) Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L., and Abell, C. (2006) Probing Hot Spots at Protein−Ligand 
Binding Sites:  A Fragment-Based Approach Using Biophysical Methods. J. Med, Chem. 49, 4992-5000. 
(25) de Bentzmann, S., and Plésiat, P. (2011) The Pseudomonas aeruginosa opportunistic pathogen and human 
infections. Environ. Microbiol. 13, 1655-1665. 
(26) Williams, P. (2011) Book of Abstracts. 1st International HIPS Symposium, Saarbrücken, Germany, June 16. 
(27) Freire, E. (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov. Today 13, 
869-874. 
(28) Ramírez-Gualito, K., Alonso-Ríos, R., Quiroz-García, B., Rojas-Aguilar, A., Díaz, D., Jiménez-Barbero, J., and 
Cuevas, G. (2009) Enthalpic nature of the CH/pi interaction involved in the recognition of carbohydrates by aromatic 
compounds, confirmed by a novel interplay of NMR, calorimetry, and theoretical calculations. J. Am. Chem. Soc. 
131, 18129-18138. 
(29) Nishio, M. (2011) The CH/π hydrogen bond in chemistry. Conformation, supramolecules, optical resolution and 
interactions involving carbohydrates. Phys. Chem. Chem. Phys. 13, 13873-13900. 
(30) Ran, J., and Wong, M. W. (2006) Saturated hydrocarbon-benzene complexes: theoretical study of cooperative 
CH/pi interactions. J. Phys. Chem. A 110, 9702-9709. 
(31) Ma, D., Cook, D. N., Hearst, J. E., and Nikaido, H. (1994) Efflux pumps and drug resistance in gram-negative 
bacteria. Trends Microbiol. 2, 489-493. 
(32) Rich, R. L., and Myszka, D. G. (2010) Grading the commercial optical biosensor literature-Class of 2008: 
&apos;The Mighty Binders&apos;. J. Mol. Recognit. 23, 1-64. 
(33) Giannetti, A. M., Koch, B. D., and Browner, M. F. (2008) Surface plasmon resonance based assay for the 
detection and characterization of promiscuous inhibitors. J. Med. Chem. 51, 574-580. 
(34) Navratilova, I., and Hopkins, A. L. (2010) Fragment screening by surface plasmon resonance. ACS Med. Chem. 
Lett. 1, 44-48. 
(35) Griffith, K. L., and Wolf Jr, R. E. (2002) Measuring β-Galactosidase Activity in Bacteria: Cell Growth, 
Permeabilization, and Enzyme Assays in 96-Well Arrays. Biochem. Biophys. Res. Commun. 290, 397-402. 
(36) Essar, D. W., Eberly, L., Hadero, A., and Crawford, I. P. (1990) Identification and characterization of genes for a 
second anthranilate synthase in Pseudomonas aeruginosa: interchangeability of the two anthranilate synthases and 
evolutionary implications. J. Bacteriol. 172, 884-900. 
(37) Zhang, Y., and Miller, R. M. (1992) Enhanced octadecane dispersion and biodegradation by a Pseudomonas 
rhamnolipid surfactant (biosurfactant). Appl. Environ. Microbiol. 58, 3276-3282. 
(38) Drescher, K., Haupt, A., Unger, L., Turner, S. C., Braje, W., and Grandel (Abbott GmbH & CO KG), R. (2006) 
WO 2006040179. 
(39) Wagner, P. J., and Wang, L. (2006) Electronic Effects of Ring Substituents on Triplet Benzylic Biradicals. Org. 
Lett. 8, 645-647. 
(40) Chill, S. T., and Mebane, R. C. (2010) Facile One-Pot Conversion of Aldehydes into Amides. Synth. Commun. 
40, 2014-2017. 
(41) Willard, M. L., and Maresh, C. (1940) Optical Constants of Benzamide, its Homologs, and Some Aliphatic 
Amides1. J. Am. Chem. Soc. 62, 1253-1257. 
(42) Kliegel, W., and Nanninga, D. (1983) Borchelate von N-substituierten Hydroxamsäuren. Chem. Ber. 116, 2616-
2629. 
(43) Singerman, G. M. (1975) US 3994997. 
(44) Berndt, D. C., Utrapiromsuk, N., and Conran, D. E. (1984) Substituent effects and mechanism in the micellar 
hydrolysis of hydroxamic acids. J. Org. Chem. 49, 106-109. 
 
50 3 RESULTS 
 
 
3.2 A Guidepost for Hit Selection and Optimization Targeting the 
Pseudomonas aeruginosa Transcriptional Regulator PqsR: 
Combination of Thermodynamic Analysis and Site-Directed 
Mutagenesis 
Tobias Klein, Michael Zender, Christina Zimmer, Anke Steinbach, and Rolf W. 
Hartmann 
 
Parts of this manuscript will be submitted to a peer-reviewed journal for publication. 
 
 
Publication II 
 
 
Abstract: The Gram-negative pathogen Pseudomonas aeruginosa coordinates group behaviours 
via a cell density dependent cell-to-cell communication system known as quorum sensing (QS). 
P. aeruginosa employs  a characteristic pqs QS system that functions via the signal molecules 
PQS and its precursor HHQ, which interact with their receptor PqsR thereby controling the 
production of virulence factors and biofilm formation. Therefore, we consider the pqs system a 
novel target to limit P. aeruginosa pathogenicity. Here, we describe the thermodynamic and 
functional characterization of SPR screening hits as guidepost for candidate selection and 
optimization using isothermal titration calorimetry and a heterologous reporter gene assay in E. 
coli, respectively. Given its enthalpy driven binding affinity (KD = 1.3 µM), good ligand 
efficiency (LE = 0.50 kcal/mol), and antagonistic activity (IC50 = 9.6 µM) the oxadiazole 
derivative 2 was the most promising hit. Site-directed mutagenesis together with 
thermodynamic analysis disclosed that 2 and the former reported small-molecule PqsR ligands 
(B, C) bind competitively to PqsR but do not cover exactly the same space in the ligand-binding 
domain of PqsR. Beyond this, first structural modifications of 2 together with calorimetric 
evaluation disclosed the role of the amino- and the trifluoromethyl group of compound 2 for 
ligand binding. Thus, our findings can be used to assist fragment optimization and provide a 
promising starting point for fragment growing or merging strategies that will be applied in 
future experiments. 
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Introduction 
Bacteria are routinely challenged by drastic changes in their extracellular environments1 and the 
ability of bacterial pathogens to sense their immediate environment plays a significant role on 
their capacity to survive and cause diseases.2 Therefore, bacteria have developed systems for 
constantly observing the environment to adapt their lifestyles by modulating the transcription of 
subsets of genes. Beside two-component regulatory systems (TCSs) that allow bacteria to 
couple external stimuli to adaptive response3 they have developed quorum sensing (QS) 
systems4 to monitor the environment for other bacteria and to alter behavior on a population-
wide scale.5 The Gram-negative opportunistic pathogen Pseudomonas aeruginosa exists in 
various environmental habitats and is known to infect a wide range of animal and plant hosts.6 
In humans, it is one of the leading causes for nosocomial infections7 and is responsible for 
chronic lung infections in the majority of cystic fibrosis (CF) patients.8 P. aeruginosa 
coordinates group behaviours employing three QS systems. The las9,10 and the rhl11,12 
communication systems, which use N-acyl homoserine lactones as autoinducers are widespread 
among Gram-negative bacteria. Yet, the third QS system, the pqs system13 is rather unique and 
restricted to particular Pseudomonas and Burkholderia strains.14 It functions via the 4-hydroxy-
alkylquinolone (HAQ) signal molecules PQS (Pseudomonas quinolone signal; 2-heptyl-3-
hydroxy-4(1H)-quinolone) and its precursor HHQ (2-heptyl-4(1H)-quinolone; Figure1).  
 
Figure 1. Structures of the P. aeruginosa QS signal molecules PQS and HHQ.  
Both interact with their receptor PqsR15,16 to control the transcription of virulence genes such as 
pyocyanin,17 rhamnolipids, or hydrogen cyanide18 to name but a few and biofilm formation.19 
PqsR, also known as multiple virulence factor regulator (MvfR), belongs to the family of LysR-
type transcriptional regulators (LTTR). The latter are inactive prior to their binding to small 
molecules, termed as ligands or coinducers. LTTRs comprise approximately 330 amino acids 
and important structural regions remain highly conserved: at the C terminus is a ligand-binding 
domain (LBD) and at the N terminus is a helix–turn–helix (HTH) motif, which provides a 
means of binding to DNA.20 PqsR consists of 332 amino acids and the C-terminal domain 
between amino acids 92–298 contains a predicted LBD.15 
P. aeruginosa has joined the ranks of superbugs;21 bacteria that are resistant to practically all 
antimicrobial drugs available on the market. This is not only due to the high intrinsic resistance 
of P. aeruginosa22 but also to the application of bacteriostatic and bacteriocidic drugs, which 
impose selective pressure. Therefore, the development of antimicrobials that have novel modes 
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of action has come to the fore. In this context we consider PqsR a novel, promising target to 
disrupt PqsR-dependent gene expression thereby limiting P. aeruginosa pathogenicity without 
affecting bacterial viability.15 Recently, we reported on the discovery of two different classes of 
PqsR antagonists: derivatives of the natural effector HHQ (A)23,24 and hydroxamic acid (B)/ 
benzamide (C)-derived fragments with low molecular weight (Figure 2).25 
 
Figure 2. Representative structures of our two classes of PqsR antagonists: derivatives of the 
natural effector HHQ (A), and hydroxamic acid (B)/benzamide (C)-derived fragments.  
Regarding antibacterial discovery, fragment-based design is a promising strategy since it allows 
to address the key issues namely insufficient physicochemical properties and the lack of 
chemical diversity.26,27 For the development of PqsR antagonists, this strategy has been proven 
successful by the hydrophilic hydroxamic-acid derived fragments. In contrast to the HHQ 
derivatives24 they show a comparable potency in E. coli and P. aeruginosa,25 which might be 
due to their ability to penetrate across the low permeable outer membrane of P. aeruginosa.22 In 
order to identify novel hits that increase chemical diversity and facilitate the application of 
fragment optimization strategies28 the CSIRO fragment library has been screened against PqsR 
employing surface plasmon resonance (SPR) biosensor analysis and five promising hits were 
identified (Figure 3).29 
 
 
Figure 3. Chemical structures of the top five hits from the CSIRO fragment library screening. 
Here, we describe the thermodynamic and functional characterization of the top five CSIRO-
screening hits as guidepost for candidate selection and optimization. In combination with site-
directed mutagenesis and first structural modifications the thermodynamic data enabled us to 
study protein-ligand interactions and to estimate the covered space in the LBD. 
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Results and Discussion 
In the SPR screening KD values were used as selection criteria, however, the evaluation of the 
compound affinity alone often does not provide a clear indication of which ligands to select for 
further progression. Therefore, the thermodynamic parameters, which provide a tool for 
understanding biomolecular interactions and an aid for decision making in drug discovery,30,31 
were determined using isothermal titration calorimetry (ITC, Table 1).  
Table 1. Thermodynamic parameters of ligands binding to PqsR. 
Ligand KD (SPR) 
[µM] 
KD (ITC) 
[µM] 
ΔG 
[kcal mol-1] 
ΔH 
[kcal mol-1] 
-TΔS 
[kcal mol-1] 
LE 
[kcal mol-1] 
A  0.6±0 -8.5±0 -9.1±0.1 0.7±0.1 0.38 
B  4.1±0.6 -7.4±0.1 -8.9±0.2 1.5±0.3 0.53 
C  0.9±0 -8.3±0 -9.7±0.3 1.5±0.3 0.63 
1 0.8±0.2 1.8±0.2 -7.9±0.1 -8.6±0.2 0.7±0.2 0.60 
2 0.8±0.3 1.3±0.3 -8.0±0.1 -8.5±0.5 0.4±0.6 0.50 
3 6.8±3.5 7.6±0.7 -7.0±0.1 -6.9±0.1 -0.1±0.1 0.35 
4 6.8±3.8 10.0±1.3 -6.8±0.1 -9.3±0.4 2.5±0.4 0.85 
5 10.7±6.5 8.5±0.7 -6.9±0 -8.6±0 1.6±0.1 0.49 
ITC titrations were performed at 298 K. Data represent mean ± SD from at least two independent experiments. 
The measured data confirmed the top five hits as PqsR binder and showed that the different 
techniques SPR and ITC result in very comparable dissociation constants (KD). Accordingly, 
naphthalene-2-carboxamide (1, KD = 1.8 µM) and the oxadiazole derivative 2 (KD = 1.3 µM) 
displayed the best affinities of the verified hits and bind only slightly weaker than the HHQ 
derivative A (KD = 0.6 µM) and the benzamide C (KD = 0.9 µM). The ratio of free binding 
affinity to molecular size is termed as ligand efficiency (LE), and allows to compare hits of 
widely differing structures and activities.32 LE values > 0.33 kcal/mol are desirable through the 
process of optimization.33 Remarkably, compounds 1-5 showed LEs in the range of 0.35-0.85 
kcal/mol and hence are above this threshold (Table 1). Analysis of the thermodynamic 
signatures revealed that the hits 1-5 are enthalpy driven binders (Table 1) indicating a good non-
covalent bond complementary between the protein and the compounds.31 Given that it is harder 
to improve the ΔH contribution than to improve the ΔS contribution, enthalpy driven binders are 
rather taken on the next optimization level than entropy driven binders. Further, increasing the 
entropic contribution is accompanied by increasing hydrophobicity and therefore the 
improvement is limited by the compounds solubility.31 Taken together, these data emphasize the 
high potential of the previously identified hits. 
In order to evaluate the agonistic and antagonistic activities of the PqsR ligands 1-5 we 
examined the PqsR-mediated transcriptional effect in a reporter gene assay by measuring the β-
galactosidase activity in E. coli harbouring the pEAL08-2 plasmid containing the tacP-pqsR and 
pqsAP-lacZ fusion genes (Table 2).34 E.coli was used as it provides a system to characterize the 
functionality of PqsR ligands independent of the entire pqs system present in P. aeruginosa.35 
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Table 2. Functional activities of PqsR ligands. 
Ligand Agonistic 
activity [%] 
Antagonistic 
activity [%] 
A n.a.a 68±2a☆ 
B n.a. 78±12★ 
C 43±3☆ 48±1☆ 
1 53±14★ 46±9★ 
2 n.a. 107±9☆ 
3 n.a. n.i. 
4 n.a. 22±12 
5 n.a. n.i. 
Agonistic activity was determined by measuring the PqsR stimulation induced by 100 µM of the test compound 
compared to 50 nM PQS (= 100%); n.a. = no agonism (agonistic activity ≤ 20%). Antagonistic activity was determined 
by measuring the inhibition of the PqsR stimulation induced by 50 nM PQS in the presence of 100 µM test compound 
(full inhibition = 100%); n.i. = no inhibition (antagonistic activity ≤ 20%). Mean value of at least two independent 
experiments with n = 4, standard deviation less than 25%. Significance: For the agonist test, induction compared to the 
basal value; for the antagonist test, decrease of the PQS-induced induction. a)Agonistic and antagonistic activity were 
determined in the presence of 5 µM test compound. ☆ p < 0.003; ★ p < 0.05. 
None of the assessed screening hits displayed agonistic activity except for compound 1. 
Interestingly, in addition to its moderate agonistic activity it significantly reduced the 
stimulation of PqsR. Such a mixed functional profile was recently observed for ligand C25 
indicating that this is a common feature of aromatic substituted carboxamides with high affinity 
toward PqsR. While 3-5 showed no or only a weak antagonistic activity the oxadiazole 2 was 
identified as a highly potent PqsR antagonist: 100 µM of 2 led to full inhibition of the PqsR 
stimulation induced by 50 nM PQS. Compared to the HHQ analogue A (IC50 = 1.3 µM) 
compound 2 (IC50 = 9.6 µM) is a less potent PqsR antagonist but it reveals the same potency as 
the hydroxamic acid-derived B (IC50 = 12.5 µM). 
The recently measured thermodynamic data indicated that the tert-butyl substituted 
benzamide C interacts with Glu194 and Phe221 via H-bonds. Identification of further 
fragments, which cover additional or different space in the LBD will facilitate the application of 
optimization strategies such as fragment linking or growing. In this context, combining ITC 
with site-directed mutagenesis provides a valuable tool to analyze the identified fragments. Of 
the identified hits, compounds 1 and 2 looked the most promising with respect to KD, LE, and 
functionality. Therefore, their binding to the Q194A and F221A PqsR mutants was evaluated by 
ITC (Table 3). 
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Table 3. Effect of point mutations on the thermodynamic parameters of PqsR ligands. 
 Q194A F221A 
Ligand ΔΔG 
[kcal mol-1] 
ΔΔH  
[kcal mol-1] 
-TΔΔS 
[kcal mol-1] 
ΔΔG 
[kcal mol-1] 
ΔΔH 
[kcal mol-1] 
-TΔΔS 
[kcal mol-1] 
C -1.3±0☆ -4.4±0.3☆ 3.1±0.3☆ -1.0±0.1☆ -7.6±0.3☆ 6.6±0.4☆ 
1 -1.1±0.1☆ -3.2±0.2☆ 2.1±0.2☆ -0.4±0.1★ -7.1±0.2☆ 6.7±0.2☆ 
2 -0.6±0.1☆ -0.3±0.6 -0.3±0.7 -0.6±0.1☆ -7.1±0.5☆ 6.5±0.6☆ 
ΔΔG, ΔΔH, and –TΔΔS are ΔGWT – ΔGmutant, ΔHWT – ΔHmutant, and –T(ΔSWT – ΔSmutant), respectively. Negative values 
indicate a loss; positive values, a gain compared to wild-type. Errors indicate SD calculated via Gaussian error 
propagation. Significance: effect of the point mutation on the thermodynamic parameters of ligand binding compared to 
the wild-type. ☆ p < 0.003; ★ p < 0.05. 
Due to the structural similarity between naphthalene-2-carboxamide (compound 1) and the 
PqsR ligand C it is not wondrous that Gln194 is also involved in the binding of 1. Comparing 
the thermodynamic signatures of 1 binding to Q194A mutant and wild-type PqsR a loss in ΔH 
of 3.2 kcal/mol was observed. The latter suggests the presence of a weak H-bond between 1 and 
Gln194. Further, the binding of compound 1 to the Q194A mutant showed positive -TΔΔS 
values relative to those of the wild-type. This is in accordance to what was found for compound 
C and might be due to the increased conformational flexibility both of the ligand and the protein 
in the absence of an H-bond. The F221A point mutation affected the binding of 1 and with a 
deficit of 7.1 kcal/mol the enthalpic contribution was significantly reduced compared to the 
wild-type. Probably, F221 might be involved in a π-π interaction with the naphthalene core of 1. 
However, theoretical investigations revealed an interaction energy of -4.2 kcal/mol for the 
benzene-naphthalene complex in the parallel-displaced type.36 The measured data suggest that 1 
adopts the same binding mode as the hydroxamic-acid B and the benzamide C, respectively. 
Thus, compound 1 does not offer structural suggestions for the optimization of the former 
identified ligands. 
Interestingly, for the oxadiazole 2 there was no significant difference in the enthalpic 
contribution observed when binding to Q194A mutant and wild-type PqsR. This revealed that 
Gln194 is not involved in the binding of 2 but competition experiments confirmed that 2 binds 
to the same binding site as C (Figure 4).  
This is in agreement with the fact that the binding of 2 was affected by the F221A mutation. 
Compared to the wild-type the enthalpic contribution was reduced by 7.1 kcal/mol. Possibly, the 
phenyl moiety of 2 makes a π-π interaction with F221 that is favored by the presence of the 
electron withdrawing CF3-substituent.37 Given that 2 and C bind to the same binding site but do 
not interact with the same amino acids there is room for optimization by fragment growing. 
Accordingly, the oxadiazole derivative 2 is the most promising candidate of the identified hits 
not least due to its different molecular scaffold. 
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Figure 4. Competitive binding of ligands to PqsR as measured by ITC. Raw ITC data (top) and 
integrated normalized data (bottom) for titrations of 43 µM H6SUMO-PqsRC87 with 500 µM 2 (■) 
in the absence of C and in the presence of 500 µM compound C (Δ).  
First structural modifications of 2 in combination with thermodynamic analysis were done to 
evaluate the relative contribution of the different functional groups. The CF3 moiety was 
replaced by a methyl group and the thermodynamic signature of the resulting compound 6 was 
compared to that of 2 (Figure 5).  
 
Figure 5. Relative thermodynamic contributions of functional groups to PqsR binding. ΔΔG, 
ΔΔH, and –TΔΔS are ΔG2 – ΔG6/7, ΔH2 – ΔH6/7, and –T(ΔS2 – ΔS6/7), respectively. Negative 
values indicate a loss; positive values, a gain compared to compound 2. Errors indicate SD 
calculated via Gaussian error propagation. Significance: thermodynamic contribution of the 
functional group on the binding of 2 to PqsR. ☆ p < 0.003; ★ p < 0.05. 
Indeed, ligand 6 showed reduced affinity toward PqsR (6, KD = 12.4 µM vs. 2, KD = 1.3 µM), 
which was due to a significant loss in ΔH of 4.4 kcal/mol. Considering the loss in enthalpy, that 
is caused by the F221A mutation (7.1 kcal/mol) and the loss in enthalpy that is due to the 
exchange of the CF3 vs. CH3 (4.4 kcal/mol) the enthalpic contribution of a possible π-π 
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interaction between 6 and Phe221 is 2.7 kcal/mol. Remarkably, this is consistent with the 
binding energy of the gas-phase benzene dimer ranging from 2.0 to 3.0 kcal/mol.38 
The thermodynamic profile of compound 2 binding to the Q194A mutant PqsR revealed that 
the amino group of 2 does not make an H-bond with the only polar residue in the LBD, 
Gln194.39 Yet, to investigate whether the amino group is involved in the formation of a H-bond 
with polar backbone atoms of PqsR it was replaced by hydrogen. The binding affinity of the 
resulting ligand 7 (KD = 6.5 µM) was lower in comparison to 2 (KD = 1.3 µM) but even more 
interesting there was no significant difference in the enthalpic contributions (Figure 5). This 
finding allowed us to exclude that the amino group makes any H-bonds. Further, the PqsR-7 
complex is entropically more unfavorable than the PqsR-2 complex and two possible 
explanations for this finding are (1) compound 7 with its smaller molecular size might release 
less water molecules from the LDB than 2, (2) the binding of 2 might stabilizes PqsR in a more 
disordered conformation compared to the binding of 7.40 
In the benzamide class of PqsR ligands, the tert-butyl substituted C (KD = 0.9 µM) showed a 
significantly increased affinity compared to the CF3 substituted 8 (KD = 7.2 µM) that was due to 
an enthalpic gain (Figure 6). In contrast, the introduction of an electron-donating group such as 
an alkyl moiety is predicted to induce an increasingly unfavorable effect on a π-π interaction 
due to repulsion of the increasingly negative electron densities forming on the aromatic centre.37 
These extremes can be explained by the assumption that the tert-butyl substituent of C directly 
interacts with the receptor and does not impact a probable π-π interaction formed by the phenyl 
ring of C. This hypothesis is further substantiated by the fact that variation of the alkyl chain in 
C affects the enthalpy ΔH.25 
 
 
Figure 6. Effect of replacing a CF3 group by a tBu residue on the binding of benzamide and 
oxadiazole PqsR ligands. ΔΔG, ΔΔH, and –TΔΔS are ΔG8/2 – ΔGC/9, ΔH8/2 – ΔHC/9, and -T(ΔS8/2 
– ΔSC/9), respectively. Negative values indicate a loss; positive values, a gain. Errors indicate 
SD calculated via Gaussian error propagation. Significance: effect of exchanging CF3 by tBu on 
ligands binding to PqsR. ☆ p < 0.003; ★ p < 0.05. 
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The above data provide a structural hint for the optimization of 2 and therefore it was 
investigated whether the introduction of tert-butyl (compound 9) instead of CF3 also increases 
the affinity of the oxadiazole derivative 2. In contrast to what was observed in the benzamide 
class the tert-butyl substituted oxadiazole derivative (9, KD = 3.1 µM) showed a slightly reduced 
affinity compared to the CF3 substituted derivative (2, KD = 1.3 µM) and no significant 
difference in ΔH was observed (Figure 6). Obviously, due to the absence of the H-bond with 
Gln194 the oxadiazole derivatives are able adopt different binding conformations that allow 
compound 2 to interact via the CF3 substitute phenyl ring and compound 9 via the tert-butyl 
group, respectively. 
 
Conclusion 
In summary, thermodynamic and functional data were used for hit characterization and as 
guidepost for candidate selection. The evaluated hits 1-5 showed enthalpy driven binding, 
promising LEs and in addition to this the oxadiazole derivative 2 revealed an antagonistic 
activity comparable to that observed for the hydroxamic acid-derived PqsR antagonist B. Site-
directed mutagenesis together with thermodynamic analysis disclosed that 2 and the former 
reported small-molecule PqsR ligands (B, C) bind competitively to PqsR but do not cover 
exactly the same space in the LBD thereby offering suggestions for optimization using fragment 
growing strategies. First structural modifications of 2 together with calorimetric evaluation were 
done to investigate the relative importance of the functional groups in order to guide fragment 
optimization. Future experiments will aim at merging the best features of the different fragment 
classes to develop druglike molecules that open the door for therapeutic agents with novel 
modes of action for the treatment of P. aeruginosa infections. 
 
Methods 
Protein Expression and Purification. Wild-type, Q194A mutant, and F221A mutant 
H6SUMO-PqsRC87 were expressed in E. coli and purified using a single affinity chromatography 
step. Briefly, E. coli BL21 (DE3) cells containing the pSUMO3_ck4_pqsRC87, the 
pSUMO3_ck4_Q194ApqsRC87 or the the pSUMO3_ck4_F221ApqsRC87 plasmid25 were grown 
in LB medium containing 50 µg ml-1 kanamycin at 37 °C to an OD600 of approximately 0.8 and 
induced with 0.2 mM IPTG for 16 h at 16 °C. The cells were harvested by centrifugation (5000 
rpm, 10 min, 4 °C) and the cell pellet was resuspended in 100 ml binding buffer (50 mM Tris-
HCl, pH 7.8, 150 mM NaCl, 20 mM imidazole, 10% glycerol  (v/v)) and lysed by sonication for 
a total process time of 2.5 min. Cell debris were removed by centrifugation (13000 rpm, 30 min) 
and the supernatant was filtered through a syringe filter (0.2 µm). The clarified lysate was 
immediately applied to a Ni-NTA column (GE Healthcare), washed with 50 mM Tris-HCl, pH 
7.8, 150 mM NaCl, 20 mM imidazole, 10% glycerol (v/v), and eluted with 500 mM imidazole. 
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The protein containing fractions were buffer-exchanged into 20 mM Tris, pH 7.4, 150 mM 
NaCl, 10% glycerol (v/v) for the wild-type and into 20 mM Tris, pH 7.8, 300 mM NaCl, 10% 
glycerol (v/v) for the Q194A and the F221A mutants, using a PD10 column (GE Healthcare) 
and judged pure by SDS-PAGE analysis. The H6SUMO-tagged proteins were stored at -80 °C 
and used for biophysical studies.  
Isothermal titration calorimetry. ITC experiments were carried out using an ITC200 
instrument (Microcal Inc., GE Healthcare). Concentrations of ligand stock solutions in DMSO 
were determined by the weight of the compound.  Final ligand concentrations were achieved by 
diluting 1:20 (v/v) in the experimental buffer resulting in a final DMSO concentration of 5% 
(v/v). Protein concentration was determined by measuring the absorbance at 280 nm using a 
theoretical molarity extinction coefficient of 22,900 M-1cm-1. DMSO concentration in the 
protein solution was adjusted to 5% (v/v). ITC measurements were routinely performed at 25 °C 
in 20 mM Tris, pH 7.4, 150 mM NaCl, 10% glycerol (v/v), 5% DMSO  (v/v) for the wild-type 
PqsRC87and in 20 mM Tris, pH 7.4, 300 mM NaCl, 10% glycerol (v/v), 5% DMSO (v/v) for the 
Q194A and the F221A mutants, respectively. The titrations were performed on 43-190 µM 
H6SUMO-PqsRC87, H6SUMO-Q194APqsRC87 or H6SUMO-F221APqsRC87 in the 200 µl sample 
cell using 2-2.6 µl injections of 0.7-2.0 mM ligand solution every 180 s. The competition 
experiment was performed on 43 µM H6SUMO-PqsRC87, which was incubated with 0.5 mM 
compound C for 30 min at 25 °C. Raw data were collected and the area under each peak was 
integrated. To correct for heats of dilution and mixing the final base line consisting of small 
peaks of the same size at the end of the experiment was subtracted. The experimental data were 
fitted to a theoretical titration curve (one site binding model) using MicroCal Origin 7 software, 
with ΔH (enthalpy change in kcal/mol), KA (association constant in M−1), and N (number of 
binding sites) as adjustable parameters. Thermodynamic parameters were calculated from Eq. 
(3), 
 
ΔG = ΔH - TΔS = RTlnKA = -RTlnKD (3) 
 
where ΔG, ΔH, and ΔS are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R = 1.98 cal/mol/K. The LE for each compound 
was calculated from Eq. (4), 
 
LE = -ΔG/(heavy atom count)  (4) 
 
where ΔG is the change in free energy and heavy atom count is the number of non-hydrogen 
atoms of the compound. For each ligand at least two independent experiments were performed. 
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Representative ITC titrations of 1 and 2 against H6SUMO-PqsRC87, H6SUMO-Q194APqsRC87, 
and H6SUMO-F221APqsRC87 are shown in Figure 7.  
 
Figure 7. Representative ITC titrations. a) ITC titration of 1 (900 µM) against H6SUMO-PqsRC87 
(86 µM). b) ITC titration of 1 (1 mM) against H6SUMO-Q194APqsRC87 (95 µM). c) ITC titration of 
1 (1 mM) against H6SUMO-F221APqsRC87 (124 µM). d) ITC titration of 2 (500 µM) against 
H6SUMO-PqsRC87 (43 µM). e) ITC titration of 2 (500 µM) against H6SUMO-Q194APqsRC87 (50 
µM). f) ITC titration of 2 (500 µM) against H6SUMO-F221APqsRC87 (50 µM). The recorded 
change in heat is shown in units of µcal/sec as a function of time for successive injections of the 
ligand (upper row). Integrated heats (black squares) plotted against the molar ratio of the 
binding reaction. The continuous line represents the results of the non-linear least squares 
fitting of the data to a binding model (lower row). 
Reporter Gene Assay in E. coli. The ability of the compounds to either stimulate or antagonize 
the PqsR-dependent transcription was performed as previously described using a β-
galactosidase reporter gene assay34 in E. coli expressing PqsR with some modifications to 
enable a higher throughput.41 PQS and PqsR ligands were diluted in ethyl acetate, added to the 
wells of a 96 deep well plate and the solvent was evaporated. Overnight cultures of E. coli 
DH5α cells containing the plasmid pEAL08-2 which encodes PqsR under the control of the tac 
promoter and the β-galactosidase reporter gene lacZ controlled by the pqsA promoter, were 
diluted 1:100 in Luria-Bertani medium with ampicillin (50 µg/ml). The culture was incubated at 
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37 °C with shaking until it reached an OD600 of 0.2. For the determination of agonistic activities, 
1 ml aliquots were supplemented with either PQS (50 nM) or the test compound (100 µM). 
Ethyl acetate was used as control. Antagonistic effects of the compounds (100 µM) were 
evaluated in the presence of 50 nM PQS. The β-galactosidase activity was determined after a 
2.5 h incubation period at 37 °C with shaking (150 rpm). OD600, OD420 and OD550 were 
measured and the activity is expressed as ratio of the ethyl acetate control relative to the cultures 
that received either PQS, a test compound or both. For the determination of IC50 value, 
compound 2 was tested at least at least at six different concentrations. The given data represent 
mean of two experiments with n = 4. The log (inhibitor) vs. response model (Prism 5.0) was 
applied for nonlinear regression and determination of IC50-values; the Hill slope was 
constrained equal to 1.0. 
Chemical and Analytical Methods. 1H and 13C NMR spectra were recorded on a Bruker 
DRX-500 instrument. Chemical shifts are given in parts per million (ppm), and 
tetramethylsilane (TMS) was used as internal standard for spectra obtained in CDCl3, MeOH-d4 
and DMSO-d6. Coupling constants (J) are given in hertz. Mass spectrometry (LC/MS) was 
performed on a MSQ® electro spray mass spectrometer (Thermo Fisher). The system was 
operated by the standard software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (125 × 3 mm) 
column (Macherey-Nagel GmbH) was used as stationary phase with water/acetonitrile mixtures 
as eluents. All solvents were HPLC grade. Reagents were used as obtained from commercial 
suppliers without further purification. The reaction progress was determined by thin-layer 
chromatography (TLC) analyzes on silica gel 60, F254 (Merck). Visualization was accomplished 
with UV light.  
General procedure for the synthesis of benzoylthiosemicarbazids. 
Hydrazinecarbothioamide (3 eq.) and THF were filled into a three necked flask. Benzoyl 
chloride (1 eq, 0,2 molar) was added through a dropping funnel while cooling on an ice-bath. 
The mixture was aged at RT under a nitrogen atmosphere for 24 h. The mixture was quenched 
by addition of water and alkalized using NaHCO3 saturated. Afterwards THF was evaporated 
under reduced pressure till a white solid precipitated. The suspension was filtered and the 
resulting cake was washed with water. The white solid was dried in an exsiccator to afford the 
expected benzoylthiosemicarbazids. 
General procedure for the synthesis of Oxadiazole-2-amines. Benzoylthiosemicarbazid 
(1 eq, 0,25 molar) was filled into a three necked flask and IPA was added to give a white 
suspension. A solution of potassium iodid (0,3 eq.) in water (2 ml) and were added. The reaction 
mixture was chilled on an ice-bath and NaOH (1,5 eq) 5 M solution was added to give a yellow 
solution. Dibromodimethylhydantoine (0,75 eq.) dissolved in ACN was added through a 
dropping funnel over 1 h while maintaining the temperature under 10°C. Afterwards the 
reaction was aged for 1 h below 10 °C. The reaction mixture was quenched using NaHSO3 sat. 
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(1 ml) and water was added. The pH was adjusted over 12 using NaHCO3 saturated solution. 
Volatiles were removed under reduced pressure to give a yellow precipitate. The suspension 
was filtered and the cake rinsed with water and IPA to give the respective 5-pheny-[1,3,4]-
oxadiazole-2-amines . 
5-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-amine (2) was prepared according to the 
general procedure and additionally purified by silica gel chromatography using DCM:MeOH 
98:2 to 97:3. 1H-NMR (500 MHz, DMSO-d6): δ 8.08 (d, J = 7.88 Hz, 1H), 8.01 (s, 1H), 7.85 - 
7.90 (m, 1H), 7.75 - 7.81 (m, 1H), 7.39 (s, 2H). 13C NMR (126 MHz, DMSO-d6) d ppm 121.16 
(m, 1 C), 123.70 (d, 1J(C,F)=270.4 Hz, 1 C), 125.35, 126.73 (q, 3J(C,F)=3.7 Hz, 1 C), 128.80, 
129.79 (q, 2J(C,F)=31.2 Hz, 1 C), 130.67, 156.17, 164.19. Rt: 8.30; M+ACN+H: 270.83. 
5-(m-tolyl)-1,3,4-oxadiazol-2-amine (6) was prepared according to the general procedure. 
1H NMR (500 MHz, DMSO-d6) δ ppm 2.37 (s, 3 H) 7.21 (s, 2 H) 7.27 - 7.34 (m, 1 H) 7.41 
(t, J=7.57 Hz, 1 H) 7.56 - 7.60 (m, 1 H) 7.60 - 7.62 (m, 1 H). 13C NMR (126 MHz, DMSO-d6) δ 
ppm 20.87, 122.19, 124.31, 125.39, 129.11, 130.99, 138.54, 157.37, 163.78. Rt: 7,81 
M+ACN+H: 217,00 
2-(3-(trifluoromethyl)phenyl)-1,3,4-oxadiazole (7) A sealed reaction vial was charged 
with 3-(trifluoromethyl)benzohydrazide (400 mg, 1,959 mmol) and triethylorthoformiate (4 ml, 
24,02 mmol). The mixture was heated under an argon atmosphere for 2 h at 160°C. The reaction 
mixture was poured into an saturated Na2CO3 solution on an ice bath while stirring vigoursly. 
The aqueous phase was extracted with EtOAc (2 times) and the combined organic phases were 
washed with brine (2 times). The EtOAc phase was dried with MgSO4 and concentated to 
dryness to yield a yellow oil. The resulting oil was adsorbed to silica gel and purified by flash 
chromatography Hex:EtOAc 95:5 to 80:20 to give a colourless oil. The oil crystallized in the 
fridge as the expected pure product. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.86 (t, J=8.75 Hz, 
1 H) 8.02 (d, J=7.82 Hz, 1 H) 8.25 (s, 1 H) 8.32 (d, J=7.64 Hz, 1 H) 9.43 (s, 1 H). 13C NMR 
(126 MHz, DMSO-d6) δ ppm 123.6 (q, 1J (C,F)=272.2 Hz, 1 C), 123.0 (q, 3J(C,F)=3.7 Hz, 1 C), 
124.3, 128.5 (q, 3J(C,F)=3.7 Hz, 1 C) 130.1 (q, 2J(C,F)=32.1 Hz, 1 C), 130.7, 130.9, 155.0, 
162.6. Rt: 10.03 [M+ACN+H] 255.91. 
5-(3-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-amine (9) was prepared starting from (3-(tert-
butyl)benzoyl)thiosemiamidecarbazide and following the general procedure for the preparation 
of oxadiazole-2-amines. 1H NMR (500 MHz, DMSO-d6) d ppm 1.31 (s, 9 H), 7.23 (s, 2 H), 
7.45 (t, J=7.7 Hz, 1 H), 7.55 (d, J=7.9 Hz, 1 H), 7.61 (d, J=7.6 Hz, 1 H), 7.79 (s, 1 H). 13C NMR 
(126 MHz, DMSO-d6) d ppm 30.90 (3 C), 34.48, 121.49, 122.36, 124.15, 127.48, 129.04, 
151.60, 157.59, 163.80. LC-MS: Rt: 9,65 [M+H] 218,12 [M+ACN+H] 259,09 
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Abstract: 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the reduction of 
estrone to estradiol, which is the most potent estrogen in humans. Inhibition of 17β-HSD1 and 
thereby reducing the intracellular estradiol concentration is thus a promising approach for the 
treatment of estrogen dependent diseases. In the past, several steroidal and non-steroidal 
inhibitors of 17β-HSD1 have been described but so far there is no cocrystal structure of the 
latter in complex with 17β-HSD1. However, a distinct knowledge of active site topologies and 
protein-ligand interactions is a prerequisite for structure-based drug design and optimization. An 
elegant strategy to enhance this knowledge is to compare inhibition values obtained for one 
compound toward ortholog proteins from various species, which are highly conserved in 
sequence and differ only in few residues. In this study the inhibitory potencies of selected 
members of different non-steroidal inhibitor classes toward marmoset 17β-HSD1 were 
determined and the data were compared with the values obtained for the human enzyme. A 
species specific inhibition profile was observed in the class of the (hydroxyphenyl)naphthols. 
Using a combination of computational methods, including homology modelling, molecular 
docking, MD simulation, and binding energy calculation, a reasonable model of the three-
dimensional structure of marmoset 17β-HSD1 was developed and inhibition data were 
rationalized on the structural basis. In marmoset 17β-HSD1, residues 190 to 196 form a small α-
helix, which induces conformational changes compared to the human enzyme. The docking 
poses suggest these conformational changes as determinants for species specificity and energy 
decomposition analysis highlighted the outstanding role of Asn152 as interaction partner for 
inhibitor binding. In summary, this strategy of comparing the biological activities of inhibitors 
toward highly conserved ortholog proteins might be an alternative to laborious x-ray or site-
directed mutagenesis experiments in certain cases. Additionally, it facilitates inhibitor design 
and optimization by offering new information on protein-ligand interactions. 
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Introduction 
Human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the NAD(P)H 
dependent reduction of the weak estrogen estrone (E1) to the biologically most active estrogen 
estradiol (E2; Fig. 1) [1].  
 
Figure 1. Interconversion of estrone (E1) and estradiol (E2). 
This reaction, which represents the last step in E2 biosynthesis, takes place in target cells where 
the estrogens exert their effects via the estrogen receptors α and β. Besides their physiological 
effects, estrogens are involved in the development and the progression of estrogen dependent 
diseases (EDDs) like breast cancer, endometriosis and endometrial hyperplasia [2-4]. In the past 
few years, aromatase inhibitors have been intensively investigated for the treatment of EDDs [5-
7] but they lead to unwanted side effects due to their strong reduction of estrogen levels in the 
whole body. Therefore reducing local E2 levels by inhibition of 17β-HSD1 is a promising 
therapeutic approach for the treatment of EDDs. An analogous intracrine concept has already 
been proved successful for the treatment of androgen dependent diseases such as benign 
prostatic hyperplasia and alopecia by using 5α-reductase inhibitors [8-11]. 17β-HSD2 catalyzes 
the reverse reaction (oxidation of E2 to E1; Fig. 1) and inhibition of this enzyme must be 
avoided for the therapeutic concept to work. However, specific inhibition of 17β-HSD2 in bone 
cells may provide a novel approach to prevent osteoporosis [12]. 
17β-HSD1 is a cytosolic enzyme that belongs to the superfamiliy of short-chain 
dehydrogenases/reductases (SDRs) [13]. It consists of 327 amino acid residues (34.9 kDa) and 
the active form exists as homodimer [14]. 17β-HSD1 comprises a Rossmann fold, associated 
with cofactor binding, and a steroid-binding cleft [15]. The latter is described as a hydrophobic 
tunnel with polar residues at each end: His221/Glu282 on the C-terminal side, and 
Ser142/Tyr155, belonging to the catalytic tetrad, which is present in the majority of 
characterized SDRs [16], on the other side [17]. To date 22 crystal structures of 17β-HSD1 are 
available as apoform, binary or ternary complexes [18-20]. All crystal structures show an 
overall identical tertiary structure, while major differences have been identified only for the 
highly flexible βFαG’-loop. It is not resolved in ten crystal structures, while the remaining 
twelve showed high b-factor values for this area, which is an additional hint for the flexibility of 
the βFαG’-loop. In some crystal structures a short α-helix was observed in the loop region but 
its occurrence seems not to be dependent on the presence of steroidal ligands, cofactor or 
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inhibitor. However, the position and length of the α-helix changes: in the apoform (PDB entry 
1bhs) the helix is limited to the beginning of the loop while in presence of steroidal ligands 
and/or cofactor it is shifted to the end (PDB entries 1dht, 1equ, and 1iol). Further, dependent on 
the presence of cofactor and ligands, the βFαG’-loop can occupy three possible orientations: an 
opened, semi-opened, and closed enzyme conformation [21]. 
Several steroidal and non-steroidal inhibitors of 17β-HSD1 have been described [18,22-37], 
but only for the former cocrystal structures exist. While several computational studies have been 
performed in order to elucidate the interactions of non-steroidal inhibitors with 17β-HSD1 
[26,27,33,37,38], structural data confirming the results are still missing.  
However, a distinct knowledge of active site topologies and protein-ligand interactions is a 
prerequisite for structure-based drug design and optimization. To further increase this 
knowledge, inhibition values obtained for one compound toward proteins, differing only in few 
residues might be advantageous. For this purpose, wild type proteins and their mutants carrying 
a set of point mutations can be used. As alternative, proteins from various species, which are 
highly conserved in sequence and differ only in few residues, might be considered.  
This latter approach was applied in the present study employing human and marmoset 
monkey (callithrix jacchus) 17β-HSD1. Selected human 17β-HSD1 inhibitors, representative of 
our structurally diverse inhibitor classes, were tested toward the marmoset 17β-HSD1. The 
resulting inhibitory potencies were compared with those obtained for the human enzyme and 
remarkable differences were only observed in the class of the (hydroxyphenyl)naphthols. In 
order to rationalize the species-specific inhibition profiles at the structural basis, a homology 
model of the marmoset enzyme was built using a human 17β-HSD1 x-ray structure as template. 
Further, the docking poses of selected compounds into both the human crystal structure and the 
modelled marmoset 17β-HSD1 were considered. Notably, the marmoset homology model and 
the docking poses of the inhibitors presented herein were validated by their ability to explain 
inhibition data. Subsequently, the complexes of two representative inhibitors, docked into the 
marmoset model and the human crystal structure, respectively, were subjected to MD 
simulations to investigate their conformational equilibrium. In addition, binding energy 
calculations as well as energy decomposition analysis were performed, with the aim to 
investigate the influence of the marmoset amino acid variations on the inhibitory potencies. The 
current work provides new insights into the marmoset 17β-HSD1 active site topology, reveals 
probable inhibitor binding modes in human and marmoset 17β-HSD1, and identifies amino 
acids responsible for species specificity in 17β-HSD1 inhibition. 
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Results  
Comparison of 17β-HSD type 1 and type 2 sequences. To identify regions that are conserved 
through several species, the sequences of rodent, cynomolgus, marmoset and human 17β-HSDs 
1 were aligned (Fig. 2A). The N-terminal region (residues 1-190), which constitutes the 
common Rossmann fold as well as the catalytic tetrad, is highly conserved for the analyzed 
species. Remarkable differences were observed in the F/G segment (residues 191-230), which is 
lining the steroid-binding site, and the C-terminal region (residues 231-285). Sequence 
alignment of human and marmoset 17β-HSD1 revealed that they share 80 % sequence identity 
and 85 % similarity (Fig. 2A). Focusing on the steroid-binding site (residues 94 to 196 and 214 
to 284), the identity increases to 87 %, with five major amino acid variations observed in the 
marmoset enzyme: A191P, E194Q, S222N, V225I and E282N. In contrast, comparing 
cynomolgus and human 17β-HSD1, which show even 91% identity, only one of the 
aforementioned amino acid variations can be found (E282H; Fig. 2A). With the exception of 
marmoset 17β-HSD1, Ala191 and Glu194 are conserved through the analyzed species (Fig. 2A) 
indicating the significance of the observed variations between human and marmoset. 17β-HSDs 
1 of mouse and rat are 83 % similar to the human enzyme in the first 287 amino acids. In both 
analyzed rodent enzymes His221, which is involved in steroid binding [17], is mutated into a 
glycine (H221G). Moreover, several other amino acids of the substrate-binding site are replaced 
by more bulky residues (L96F, N152H, M193Y/H, S222Y). Interestingly, rat and mouse 17β-
HSDs 1 are significantly less sensitive to inhibition by steroidal inhibitors compared to the 
human ortholog [39] and different classes of non-steroidal potent human 17β-HSD1 inhibitors 
turned out to be only weak inhibitors of E2 formation in rat liver preparations [40]. This might 
be partially explained by the absence of His221 as interaction partner as well as by the reduced 
volume of the active site (M193Y/H, S222Y). Sequence identities between human 17β-HSD2 
and 17β-HSD2 of the selected species range from 61 % (mouse) to 93 % (cynomolgus) while 
the F/G segment and the C-terminal region show the most pronounced variability (Fig. 2B). The 
comparison of 17β-HSD1 with the correspondent type 2 enzymes of the analyzed species 
revealed, that the type 2 enzymes have about 80 additional N-terminal residues relative to the 
type 1 enzymes. Sequence comparison showed that they share a very low overall sequence 
identity (≤ 25 %) with major differences in the F/G segment and the C-terminal domain, which 
constitute the active site. However, some amino acid motifs, characteristic for SDR enzymes 
[18], are highly conserved: the T-G-xxx-G-x-G motif, the Y-xxx-K sequence and the N-A-G 
motif (Fig. 2B). For marmoset 17β-HSD2 only a fragment of the primary sequence is available, 
which is 143 amino acids in length and  constitutes the Rossman fold whereas the F/G segment 
and the C-terminal region are missing (Fig. 2B). This segment is 29 % identical to marmoset 
17β-HSD1. 
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Figure 2. Multiple sequence alignment of 17β-HSD type 1 and type 2 from selected species. 
Species and subtype are indicated on the left, followed by residue numbering. Residues are 
colored by percentage identity and red arrows indicate major amino acid variations in marmoset 
compared to the other species. A) Multiple sequence alignment of 17β-HSD1 from selected 
species. B) Multiple sequence alignment of human 17β-HSD1 with 17β-HSD2 from selected 
species. 
As human and marmoset 17β-HSD1 differ in few residues of the activesite, comparison of the 
inhibitory potencies of selected inhibitors, observed toward both enzymes, is suitable to further 
increase the knowledge of active site topologies and protein-ligand interactions. In particular, 
the amino acid variations in the flexible βFαG’-loop, which is suggested to play a crucial role in 
ligand binding, will be used to elucidate the function of the loop in more detail. 
 
Inhibition of marmoset 17β-HSD1 and 17β-HSD2. Marmoset placental tissue was used as 
enzyme source and the proteins were partially purified following a described procedure [41]. 
Tritiated E1 was incubated with 17β-HSD1, cofactor and inhibitor. The separation of substrate 
and product was performed by HPLC. In an assay similar to the 17β-HSD1 test, marmoset 
placental microsomes containing 17β-HSD2 were incubated with tritiated E2 in the presence of 
NAD+ and inhibitor. Labelled product was quantified after HPLC separation. 
The inhibition values of compounds 1-20 (Fig. 3) are shown in Table 1. The 
bis(hydroxyphenyl) substituted arenes 1-11 showed comparable or even higher inhibitory 
potencies toward marmoset 17β-HSD1 compared to the human enzyme. For example, 
compound 8, which is a potent inhibitor of human 17β-HSD1 (IC50 = 151 nM), showed a 
stronger inhibitory potency toward marmoset 17β-HSD1 (IC50 = 4 nM).  
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Figure 3. Chemical structures of selected human 17β-HSD1 inhibitors. Representative 
structures of our three inhibitor classes: the bis(hydroxyphenyl) substituted arenes (1-11), the 
bicyclic substituted hydroxyphenylmethanones (12, 13) and the (hydroxyphenyl)naphthols (14-
20). 
Table 1. Inhibition of human and marmoset 17β-HSD1 and 17β-HSD2 by compounds 1-20. 
 Human IC50 [nM] Marmoset IC50 [nM]c 
compd X R1 R2 R3 17β-HSD1a 17β-HSD2b 17β-HSD1d 17β-HSD2e 
1 CH F H  8 940 < 5f > 50 
2 N H H  50 4004 102 > 50 
3 CH H H  69 1953 31 > 50 
4 CH CH3 H  46 1971 < 50 > 50 
5 N CH3 H  143 2023 < 50 > 50 
6 CH H F  42 463 < 5f 85 
7 CH F F  17 218 < 5f 43 
8  4-OH OH H 151 1690 4f > 50 
9  3-OH H OH 77 1271 2f > 50 
10  3-OH CH3 OH 64 869 3f > 50 
11  3-OH F OH 64 510 < 50 72 
12  H OH  33 478 < 50 43 
13  OC2H5   78 502 < 50 59 
14     116 5641 > 50 > 50 
15 C OH   36 959 32 > 50 
16 N    26 1157 > 50 > 50 
17 C H   20 540 52 > 50 
18 
19 
C NH2   53 1757 n.i. > 50 
19 
 
C NHSO2CH3   15 403 > 50 > 50 
20 C NHCOCH3   83 1239 > 50 n.i. 
aHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500µM; bHuman placental, microsomal 
fraction, substrate E2, 500 nM, cofactor NAD+, 1500µM; cLogit transformed values calculated from % inhibition at 50 nM 
inhibitor concentration, for inhibition values < 30% or > 70%, a trend is given; dMarmoset monkey placental, cytosolic 
fraction, substrate E1, 500 nM, cofactor NADH, 500µM; eMarmoset monkey placental, microsomal fraction, substrate 
E2, 500 nM, cofactor NAD+, 1500µM; fInhibitor concentration: 5nM; n.i.: no inhibition; Human IC50 values were retrieved 
from literature (corresponding references are indicated with the structural formulas in Fig. 3). 
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Comparable inhibition data for human and marmoset 17β-HSD1 were also measured for the 
bicyclic substituted hydroxyphenylmethanones 12 and 13. This indicates that the binding of the 
two aforementioned inhibitor classes is reinforced or at least not affected by the amino acid 
variations in marmoset 17β-HSD1. In the class of the (hydroxyphenyl)naphthols, the human 
17β-HSD1 inhibitor 14 (IC50 = 116 nM) showed also a good inhibitory potency toward 
marmoset 17β-HSD1 (IC50 > 50 nM). The introduction of space filling substituents in position 1 
of the naphthol core of 14 is beneficial for the inhibition of the human enzyme (16, IC50 = 26 
nM), but for marmoset 17β-HSD1 no increase in inhibitory potency was observed (16, IC50 > 50 
nM) compared to the unsubstituted 14. Interestingly, further enlargement of the substituents in 
1-position of 14 led to highly active human 17β-HSD1 inhibitors (19, IC50 = 15 nM) while a 
reduced potency toward marmoset 17β-HSD1 (19, IC50 > 50 nM) was found.  
The inhibitory potencies of compounds 1-20 toward marmoset 17β-HSD2 were also 
determined to prove whether marmoset monkey is a suitable species for in vivo evaluation of 
17β-HSD1 inhibitors (Table 1). Remarkably, lower selectivity of compounds toward non-target 
marmoset 17β-HSD2 was observed, when comparing to human 17β-HSD2. 
 
Homology modelling and MD simulations of marmoset 17β-HSD1. In order to obtain a more 
precise picture of the three-dimensional structure of the marmoset 17β-HSD1, a homology 
model was generated. A set of 100 models was built with MODELLER 9v7 [42] using the 
ternary complex E1-NADPH-human 17β-HSD1 as template. This complex was obtained by 
docking E1 into human 17β-HSD1 employing the Protein Data Bank (PDB) entry 1fdt with 
conformation B for residues 187-200 (in the following determined as 1fdtB). This 3D structure 
was chosen as it represents a ternary complex with NADP+ and E2 in the closed enzyme 
conformation, as the βFαG’-loop is resolved, and as this protein structure was already 
successfully used in previous docking studies with the investigated compound classes [30,36]. 
The best model was chosen according to internal DOPE-score [43] and PROCHECK [44] tests. 
Notably, it presents a short α-helix (residues 190-196) in the region between the βF-sheet 
(residues 178-186) and the αG’-helix (residues 209-227), with Pro191 in the first turn of the 
helix (N1 position; Fig. 4), thus differing from the secondary structure of the template.  
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Figure 4. Three-dimensional structure superimposition of marmoset and human 17β-HSD1. 
Low energy structure of marmoset 17β-HSD1 (green) in complex with E1 and NADPH (orange) 
from MD simulation superimposed onto the x-ray structure of human 17β-HSD1 (grey, PDB 
code: 1fdtB). When two residues are indicated, the first corresponds to marmoset 17β-HSD1 
and the second to human 17β-HSD1. 
The selected model was further refined both as holoenzyme with NADPH and as ternary 
complex with NADPH and E1 by MD simulations. The trajectories of the two MD simulations 
were stable with a α-carbon root-mean-square deviation (RMSD) to the starting structure below 
3.0 Å (Fig. 5). No major structural differences were observed when comparing the simulated 
holoenzyme and the ternary complex. Therefore, the following results, based on analysis of the 
ternary complex, also apply to the holoform. 
 
Figure 5. RMSD analysis of the MD simulations of the marmoset 17β-HSD1 model. Time-
dependent Cα-RMSD for all residues of the secondary (orange) and ternary (green) complex.  
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After an initial inward rotation in the MD simulation, the short α-helix (residues 190-196) 
remained stable for the last 5 ns of the MD simulation, with an average backbone RMSD to the 
final conformation of 1.03 Å. Remarkably, a similar behaviour cannot be expected for the 
region between the βF-sheet and the αG’-helix in the human enzyme. The differences in the 
crystal structures suggest a high flexibility for the βFαG’-loop: it is not resolved in ten crystal 
structures and the remaining twelve show high b-factor values for this area. Some crystal 
structures present a short α-helix in the loop region whose position and length varies dependent 
on the presence of steroidal ligands, cofactor or inhibitor. In the apoform (PDB entry 1bhs) the 
helix is limited to the beginning of the loop, whereas in presence of steroidal ligands and/or 
cofactor it is shifted to the end (PDB entries 1dht, 1equ, and 1iol). Further, in the human 
enzyme, the βFαG’-loop axis occupies different orientations dependent on the presence of 
cofactor and ligands. In the marmoset however, both the holoform and the ternary complex 
show a helix starting already at the beginning of the βFαG’-loop with its axis in only one 
conformation.  
The presence of the newly formed α-helix (residues 190-196) induced a different orientation 
of the side chain of Met193. Compared to the template structure, Met193 protrudes deeper into 
the substrate-binding site and stabilizes E1 by hydrophobic interactions (Fig. 4). Furthermore, 
during MD simulation a kink in the loop between the βD-sheet and the αE-helix was observed. 
Thereby the side chain of Leu96 was brought closer to E1 allowing Van der Waals contacts 
(Fig. 4). Summarizing, in the final part of the MD simulation E1 was stabilized by both 
lipophilic interactions and hydrogen bonds: Leu96, Leu149, Met193, and Phe259 constrained 
the steroidal scaffold while Ser142/Tyr155 and His221/Asn282 interacted with the carbonyl 
oxygen in 17-position and the 3 OH-group, respectively. The latter residue took over the H-
bond acceptor abilities of Glu282, which is involved in forming an H-bond with the 3 OH-group 
of E1 in the human enzyme.  
Employing CASTp [45], the active site volumes of human and marmoset 17β-HSD1 were 
calculated. The above-described conformational changes of Leu96 and Met193 as well as the 
S222N and V225I mutations resulted in a reduced volume of the marmoset 17β-HSD1 active 
site (478 Å3) compared to that of the human ortholog (627 Å3). 
The stereochemical quality of the holoenzyme and the ternary complex models obtained 
from MD simulations was checked with PROCHECK [44]. The majority of the residues of the 
investigated structures were found to occupy the most favoured regions of the Ramachandran 
plots, while the other residues occupied the additional allowed regions. In detail, in the ternary 
complex 78.1 % of the residues were placed in the most favoured region, 20.2 % in the 
additional allowed region, 1.2 % in the generously allowed region, and only 0.4 % in the 
disallowed region (for the holoform: 81.8 %, 17.4 %, 0.8 % and 0 %).  
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Molecular docking. As the potent inhibitors of human 17β-HSD1 12 and 19 are structurally 
diverse and exhibit different potencies toward marmoset 17β-HSD1 they were chosen as 
representatives to rationalize the observed species-specific inhibition profiles. Employing 
AutoDock 4 [46], both compounds were docked into the active sites of marmoset and human 
17β-HSD1 using the equilibrated, ternary complex after 5537 ps and the x-ray structure 1fdtB 
(see experimental part), respectively. The inhibitor poses used for further investigation were 
selected considering binding energy and statistical representativity (cluster population; Table 
S1) and are shown in Figure 6.  
Table S1. Cluster analysis of molecular docking results.  
Comp No of clusters Cluster No of conformations Best binding energy (∆Gbind) 
Human x-ray structure (1fdtB)  
12 3 1 2 
 
 
-4.77 
  2 45 -4.65 
  3 3 -4.58 
19 5 1 24 -5.94 
  2 1 -5.44 
  3 19 -4.98 
  4 1 -4.92 
  5 5 -4.87 
Marmoset monkey homology model  
12 3 1 21 -5.60 
  2 27 -5.41 
  3 1 -5.0 
  4 1 -4.59 
19 5 1 7 -5.79 
  2 33 -5.74 
  3 3 -5.11 
  4 5 -4.41 
  5 2 -4.10 
All energies are expressed in kcal mol-1. The lowest energy conformation of each cluster, which is marked in bold was 
used for further investigation. 
In the human enzyme both inhibitors are placed in the substrate-binding site and they occupy an 
apolar subpocket consisting of the following amino acids: Gly94, Leu95, Leu96, Asn152, 
Tyr155, and Phe192 (Fig. 6A). While the carbonyl group of compound 12 mimics the D-ring 
keto function of E1, forming H-bonds with Ser142 and Tyr155, its para-OH group resembles the 
3-OH of E1, which interacts with His221 via an H-bond. The meta-hydroxyphenyl moiety is 
projecting into the subpocket, where it forms an additional H-bond with Asn152 and is 
stabilized by π-π-interactions with Tyr155 and Phe192.  
The (hydroxyphenyl)naphthol-core of compound 19 occupies the substrate-binding site and 
is stabilized by three H-bonds: the 2-OH group interacts with Ser142 as well as with Tyr155 and 
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the OH group in meta position of the phenyl ring in 6-position interacts with His221. In this 
case, the sulfonamide substituted phenyl ring in 1-position of the naphthol core protrudes into 
the subpocket, where it is stabilized by H-bonds with Asn152 and with the -NH- of the 
backbone of Leu95 (Fig. 6A). 
 
Figure 6. Hypothetical binding modes of compounds 12 and 19. A) Superimposition of lowest 
energy structures of 12 (orange) and 19 (cyan) obtained by docking into the x-ray structure of 
human 17β-HSD1 (magenta, PDB code: 1fdtB). B) Superimposition of lowest energy structures 
of 12 (light green) and 19 (yellow) obtained by docking into the marmoset 17β-HSD1 homology 
model (green). C) Superimposition of lowest energy structures of 12 (light green) docked into 
the marmoset 17β-HSD1 model (green) and of 12 (orange) docked into the x-ray structure of 
human 17β-HSD1 (magenta, PDB code: 1fdtB). D) Superimposition of lowest energy structures 
of 19 (yellow) docked into the marmoset 17β-HSD1 model (green) and of 19 (cyan) docked into 
the x-ray structure of human 17β-HSD1 (magenta, PDB code: 1fdtB).  
Also in the marmoset enzyme both compounds occupy the substrate-binding site, but only 12 
protrudes into the apolar subpocket (Fig. 6B). Due to the altered side chain conformation of 
Leu96 in the marmoset enzyme, compound 12 is slightly displaced toward the C-terminus (Fig. 
6C). Regarding the interaction pattern, only minor changes were observed: the carbonyl group 
forms only an H-bond with Ser142 but for the para-OH group a second H-bond with Asn282 
was observed (Fig. 6C). 
Interestingly, compound 19 resulted in a completely different binding mode when docked 
into the homology model of marmoset 17β-HSD1 with respect to its position in the human 
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crystal structure 1fdtB (Fig. 6D). The OH-group in meta position of the phenyl ring makes an 
H-bond with the backbone carbonyl oxygen of Cys185 and the 2-OH function forms H-bonds 
with His221 and Asn282 in a bifurcated fashion. The sulfonamide substituted phenyl ring is 
located in the C-terminal gate and might be stabilized by π-π-interactions with Phe259 and an 
H-bond with the backbone -NH- of Leu262.  
 
Validation of the docking complexes by means of MD simulations and free energy 
calculations (MM/PBSA). With the aim to validate the docking results and to unravel possible 
induced-fit mechanisms, different MD simulations were run in explicit aqueous solution. 
Distance restraints were applied to inhibitors only in the first ns of the MD simulations with the 
aim of maintaining their proper orientation. For the rest of the MD simulation no restraints were 
used and the whole complexes were left free to move. This was done in order to avoid trapping 
the inhibitor in an unstable conformation, which could bias the results. The RMSD values of the 
heavy atoms of the inhibitors and of the Cα-atoms of the enzymes were analyzed as a function 
of time to assess the degree of conformational drift, as shown in Figure 7.  
 
 
Figure 7. Time dependent RMSD analysis of Cα of 17β-HSD1 and of the heavy atoms in the 
ligands. A) Cα-RMSD of human 17β-HSD1 is colored in magenta and the heavy atoms RMSD 
of compound 12 in light green. B) Cα-RMSD of human 17β-HSD1 is colored in magenta and the 
heavy atoms RMSD of compound 19 in yellow. C) Cα-RMSD of marmoset 17β-HSD1 is colored 
in green and the heavy atoms RMSD of compound 12 in light green. D) Cα-RMSD of marmoset 
17β-HSD1 is colored green and the heavy atoms RMSD of compound 19 in yellow. 
In the simulation of 12 bound to human 17β-HSD1 the Cα-RMSD of the protein as well as the 
RMSD of the heavy atoms of 12 showed a stable plateau (~ 2.2 Å) from 1.0 to 2.5 ns (Fig. 7A). 
After 2.5 ns the Cα-RMSD of the protein increased and a minor fluctuation of the heavy atom 
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RMSD of 12 was observed. The latter finding could be related to a slight shift of the inhibitor 
toward the C-terminal end of the enzyme. Notably, the hydrogen bonds between 12 and 17β-
HSD1, which were observed in the initial structure, were conserved during the 4 ns simulation 
suggesting that both protein and 12 fluctuations do not impact the inhibitor binding. 
Both human 17β-HSD1 and compound 19 were stable in the simulation of their complex 
(Fig 7B). During the simulation (after 1.5 ns) the hydrogen bond of the meta-OH group with 
His221 is replaced by an H-bond with Glu282. However, after 2.1 ns, this hydrogen bond is 
interrupted for 0.2 ns allowing the hydroxyphenyl ring to rotate freely around the axis of the 
bond to the naphthol core thereby inducing a minor fluctuation of the heavy atom RMSD of 19. 
After this short interruption the H-bond interaction with Glu282 is re-established. On the other 
side, the hydrogen bonds between the 2-OH group and Ser142/Tyr155 as well as between the 
sulfonamide moiety and Asn152/Leu95 endured constant.  
During the MD simulation of 12 in complex with marmoset 17β-HSD1, the meta-
hydroxyphenyl moiety of 12 moved further out of the subpocket. This was reflected by the 
minor fluctuation of the RMSD of the heavy atoms of 12 after 1.4 ns (Fig. 7C). While this 
motion caused the break of the H-bond with Asn152, it also placed the meta-OH group in an 
appropriate distance to Asn222, thus allowing a new H-bond formation.  
The analysis of the MD simulation of the marmoset 17β-HSD1-19 complex revealed an 
overall stable Cα-RMSD of the protein. However, after 1.8 ns, a ~ 0.5 Å fluctuation of the 
heavy atom RMSD of 19 was observed (Fig. 7D) corresponding to the rotation around the axis 
of the bond between the hydroxyphenyl ring and the naphthol core. Thereby the H-bond with 
the backbone amino group of Leu262 was lost. 
Furthermore, for each of the four MD trajectories absolute free energy (∆G) and relative 
binding affinity (∆Gbind) were calculated applying MM/PBSA methods and NMODE analysis 
(Table 2).  
Table 2. Free energy calculations for the MD simulations of the four docking complexes. 
comp ELEC VDW GAS PBSOL PBTOT (∆Gbind) TSTOT ∆G 
 mean mean mean mean (±SE) mean (±SE) mean (±SE) 
Human x-ray structure (1fdtB) 
12 -15.4 -40.4 -55.7 35.1 -20.6±3.8 -15.9±6.6 -4.7±7.6 
19 -36.7 -50.1 -86.8 64.2 -22.6±5.0 -15.3±6.8 -7.3±8.4 
Marmoset monkey homology model 
12 -24.5 -38.1 -61.3 40.0 -21.3±4.9 -15.4±5.3 -5.8±7.2 
19 -42.2 -34.4 -76.5 50.3 -26.3±4.4 -23.1±4.3 -3.2±6.1 
∆G and ∆Gbind values correspond to the longest stable plateau for each MD. (∆G) free binding energy; (PBTOT) 
(∆Gbind) relative binding energy; (ELEC) electrostatic contribution in gas phase; (VDW) Van der Waals contribution in 
gas phase; (GAS) free energy in vacuum; (PBSOL) solvation energy; (TSTOT) (T∆S) entropic contribution; (mean) 
mean value; (SE) standard error of the mean; all energies expressed in kcal mol-1. 
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This was done for the following stable sectors: 1000 to 2500 ps for 12 in complex with human 
17β-HSD1 (Fig. 7A), 2300 to 4160 ps for 19 in complex with human 17β-HSD1 (Fig. 7B), 
1500 to 4160 ps for 12 in complex with marmoset 17β-HSD1 (Fig. 7C) and 1800 to 4160 ps for 
19 in complex with marmoset 17β-HSD1 (Fig 7D). All four complexes showed favorable ∆G 
values, ranging from -7.3 kcal mol-1 to -3.2 kcal mol-1. The free energies observed for 
compound 12 in complex with human (∆G = -4.7 kcal mol-1) and marmoset 17β-HSD1 (∆G = -
5.8 kcal mol-1) are in the same range. This is in accordance with the inhibitory activities of 12, 
which are comparable for both species (see Table 1). Regarding compound 19, the complex 
with human 17β-HSD1 shows a more favorable free energy (∆G = -7.3 kcal mol-1) than the one 
with marmoset 17β-HSD1 (∆G = -3.2 kcal mol-1). This is mainly due to poor entropic 
contributions in the latter case. Remarkably, this finding is in concert with the experimentally 
determined inhibition data: compound 19 is a highly potent human 17β-HSD1 inhibitor (IC50 = 
15nM) with reduced activity toward the marmoset enzyme (IC50 > 50 nM). 
 
Analysis of the binding interactions using MM/GBSA methods. Focusing on the specific 
interactions, which mediate the binding of 12 and 19 to human and marmoset 17β-HSD1, we 
have analyzed the interaction energies of both inhibitors with the residues of the binding sites, 
employing a pairwise per-residue energy decomposition analysis.  
Table 3. Interaction energies between the inhibitors 12 and 19 and the proximal (4.0 Å) binding 
site residues of human 17β-HSD1. 
comp Gly94 Leu95 Leu96 Ser142 Leu149 Asn152 Tyr155 Cys185 Gly186 Pro187 
12 -1.8 -0.3 -1.2 -1.3 -2.2 -4.1 -1.5 -0.2 -0.4 -1.3 
19 -0.7 -0.7 -1.7 -1.3 -2.0 -5.7 -2.6 -0.3 -0.8 -2.0 
comp Phe192 Met193 Tyr218 His221 Ser222 Val225 Arg258 Phe259 Leu262 Glu282 
12 -1.2 -1.0 -0.7 -1.8 -0.8 -1.7 -0.1 -1.2 -0.4 -0.1 
19 -1.8 -1.9 -0.1 -0.2 -0.4 -1.9 -0.5 -0.9 -0.3 -4.3 
All energies are expressed in kcal mol-1. 
Inspection of the interaction energies with human 17β-HSD1 (Table 3) showed that the 
hydrogen bonds of 12 (-4.1 kcal mol-1) and 19 (-5.7 kcal mol-1) with Asn152 contributed most to 
the interaction energies. Besides Asn152, further residues of the subpocket (Gly94, Leu95, 
Leu96) interact with both inhibitors revealing energies from -0.3 kcal mol-1 to -1.8 kcal mol-1. 
The energies of the hydrogen bonds between 12 and the catalytic residues Ser142 as well as 
Tyr155 are -1.3 kcal mol-1 and -1.5 kcal mol-1, respectively. In case of compound 19 the 
interaction energies are -1.3 kcal mol-1 for the H-bond with Ser142 and -1.3 kcal mol-1 for the 
H-bond with Tyr155. Further binding site residues, which significantly contribute to the binding 
of compounds 12 and 19 (Leu149, Pro187, Phe192, Met193, Val225, and Phe259) show 
interaction energies from -0.9 kcal mol-1 to -2.2 kcal mol-1. Regarding the polar amino acids at 
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the C-terminal end of the binding site, His221 takes primarily part in the binding of 12 (-1.8 
kcal mol-1 for 12 vs. -0.2 kcal mol-1 for 19) while Glu282 is mainly involved in binding 
compound 19 (-0.1 kcal mol-1 for 12 vs. -4.3 kcal mol-1 for 19). 
The interaction energies of 12 and 19 with marmoset 17β-HSD1 are listed in Table 4. 
Remarkably, for inhibitor 12, the energy contribution of the H-bond with the marmoset Asn152 
(-1.6 kcal mol-1) is 2.6 fold reduced compared to the human enzyme, while for compound 19 it 
is almost lost (-0.2 kcal mol-1). Both for 12 and 19 reduced energies were also observed for 
interactions with Gly94, Leu95, and Leu96. Interestingly, inhibitor 12 showed an interaction 
with Asn222 in the marmoset enzyme (-3.3 kcal mol-1), which was not observed for Ser222 in 
human 17β-HSD1 (-0.8 kcal mol-1). This is not the case for 19, as the interaction with Asn222 (-
0.3 kcal mol-1) does not contribute significantly to the interaction energy. In addition to Leu149, 
Pro187, Met193, Ile225, and Phe259, which interact with both compounds in the human 
enzyme, Gly186, His221, and Asn282 significantly contribute to the binding of 12 and 19 to 
marmoset 17β-HSD1 with interaction energies in the range from -0.4 kcal mol-1 to -3.6 kcal 
mol-1. Interestingly, in marmoset 17β-HSD1 the interaction energy between 12 and Asn282 (-
3.2 kcal mol-1) is 32 fold increased compared to that with Glu282 in the human enzyme (-0.1 
kcal mol-1). In marmoset 17β-HSD1 an increased energy is also observed for the interaction of 
compound 19 with His221 (-2.6 kcal mol-1) compared to the human enzyme (-0.2 kcal mol-1). 
Table 4. Interaction energies between the inhibitors 12 and 19 and the proximal (4.0 Å) binding 
site residues of marmoset monkey 17β-HSD1. 
comp Gly94 Leu95 Leu96 Ser142 Leu149 Asn152 Tyr155 Cys185 Gly186 Pro187 
12 -0.0 -0.1 -0.8 -2.1 -2.0 -1.6 -0.8 -0.3 -0.7 -2.0 
19 -0.0 -0.1 -0.2 -0.9 -1.1 -0.2 -0.3 -3.5 -2.0 -2.0 
comp Phe192 Met193 Tyr218 His221 Asn222 Ile225 Arg258 Phe259 Leu262 Asn282 
12 -0.4 -1.3 -1.4 -0.8 -3.3 -1.9 -0.1 -1.3 -0.9 -3.2 
19 -0.0 -0.4 -0.0 -2.6 -0.3 -2.6 -3.7 -1.9 -1.0 -3.6 
All energies are expressed in kcal mol-1. 
Discussion  
When the three-dimensional structures of marmoset and human 17β-HSD1 are compared, one 
of the most striking features is the small α-helix including the residues 190 to 196. It is formed 
in the segment between the βF-sheet and the αG’-helix starting from the interface residue 
Thr190, which is half in and half out of the helix (N-cap position). In contrast to the human 
enzyme, where this region is highly flexible, as suggested by the different crystal structures, the 
α-helix stayed stable during the MD simulation in both the holoform and the ternary complex. 
The observed conformational stability might be explained by the presence of a proline in 
position 191 instead of an alanine. Proline is a favorable candidate for N1 position because of its 
own conformational properties: with only one rotatable angle it loses less entropy than other 
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amino acids in forming an α-helix and thereby it should have some stabilizing influence [47]. 
Furthermore, in an analysis of sequence-structural characteristics in protein crystal structures, 
proline was found to be a favoured residue at N1 position. Especially the residue pair involving 
threonine at N-cap and proline at N1 position, which is observed for marmoset 17β-HSD1, has a 
high prevalence [48].  
In order to analyze the influence of the conformational changes in marmoset 17β-HSD1 on 
ligand binding, docking studies with subsequent MD simulations, free energy calculations, and 
energy decomposition analyzes were carried out. While the conformational differences between 
the marmoset and the human enzyme did not affect the binding mode of 12 remarkably, the 
suggested binding mode of 19 differed strongly in 17β-HSD1 of both species. One possible 
explanation for that might be the lower sterical demand of 12 compared to 19. However, the 
energy contribution of the interaction between 12 and the marmoset Asn152 is reduced, whereas 
it was outstanding in complex with the human enzyme. Due to the minimal shift of 12 in the 
marmoset binding pocket, the geometric parameters for the H-bond with Asn152 are no longer 
optimal. Interestingly, in the marmoset enzyme an additional interaction of 12 with Asn222 is 
observed, which seems to compensate the deficit in interaction energy due to the absent 
interaction with Asn152 resulting in comparable binding energies for 12 in complex with human 
and marmoset 17β-HSD1. The latter finding is in accordance with the inhibition data observed 
for compound 12 and validates the marmoset 17β-HSD1 model.  
Considering compound 19, no particular interactions with the subpocket residues of the 
marmoset enzyme exist. Although weak interactions between 19 and the C-terminal region of 
marmoset 17β-HSD1 are observed, the binding free energy is less favorable compared to that 
calculated for the human 17β-HSD1-19 complex. As the C-terminal part of the enzyme has 
already been discussed as a potential product exit gate of the enzyme [21], inhibitor 19 might be 
solvent exposed. This is consistent with the unfavorable entropy term of this complex resulting 
in the least favorable free energy. 
Obviously, the presence of a proline in the flexible loop region and the thereby induced 
conformational changes in marmoset 17β-HSD1 are decisive for the species specific inhibition 
of 19. On one hand interactions with subpocket residues like Asn152, recently discussed as 
relevant interaction partner [49], are prevented and on the other hand the inhibitor is forced in 
an unfavorable solvent exposed conformation.  
The bis(hydroxyphenyl) substituted arenes (compounds 1-11) show similar or increased 
inhibitory potencies toward marmoset 17β-HSD1 when comparing to human 17β-HSD1. 
Recently performed docking experiments proposed a steroidal binding mode when the human 
crystal structure 1fdtB was used [33]. The high inhibitory potencies toward marmoset 17β-
HSD1 are in concert with the modelled structure of marmoset 17β-HSD1 as steroid-like binding 
is not affected by the proposed conformational changes. Obviously, they even stabilize the 
3.3 STRUCTURAL BASIS FOR 17β-HSD1 SPECIES SPECIFICITY 81 
 
 
bis(hydroxyphenyl) substituted arenes in the marmoset 17β-HSD1 binding pocket as indicated 
by the observed inhibitory potencies.  
Differing inhibitory potencies toward human 17β-HSD1 and 17β-HSD2 may arise from 
sequence variations in the regions 94-196 and 214-284 (numbering according to 17β-HSD1), 
which might lead to differences in the active sites of the two human subtypes. A lower 
selectivity of compounds toward non-target marmoset 17β-HSD2 was observed, when 
comparing to human 17β-HSD2. Obviously, the differences in the active sites of marmoset 17β-
HSD1 and 17β-HSD2 are less pronounced compared to the human orthologs. However, as the 
available marmoset 17β-HSD2 sequence is missing the F/G segment and the C-terminal part 
this hypothesis cannot be proved.  
The validity of the presented homology model is further substantiated by its ability to 
explain the reduced inhibitory potency of C-15 substituted estrone derivatives toward marmoset 
17β-HSD1 [39]. The substituents in 15-position of the steroid were designed to occupy the hole 
between the flexible βFαG’-loop and the αG’-helix in the human enzyme [50]. Together with 
the helix formation and the conformational changes in the βD/αE-segment, the S222N mutation 
limits the size of the hole in marmoset 17β-HSD1 and thereby might reduce the inhibitory 
potency toward the marmoset enzyme.  
 
Conclusion  
An elegant strategy to gain more knowledge of active site topologies and, in particular, of 
protein-ligand interactions is to compare inhibition values obtained for one compound toward 
ortholog proteins from various species, which are highly conserved in sequence and differ only 
in few residues. Thereby, such an approach can be a valid alternative to site-directed 
mutagenesis. As human and marmoset 17β-HSD1 enzymes meet these criteria, selected human 
17β-HSD1 inhibitors were assessed for their inhibitory potencies toward marmoset 17β-HSD1. 
While a species specific inhibition profile was observed in the class of the 
(hydroxyphenyl)naphthols, representatives of the other evaluated compound classes showed 
similar or even higher inhibition compared to those observed for the human enzyme. Using a 
combination of computational methods, including homology modeling, molecular docking, MD 
simulation, and binding energy calculation, a reasonable model of the three-dimensional 
structure of marmoset 17β-HSD1 was developed and inhibition data were rationalized on the 
structural basis. In the marmoset 17β-HSD1, residues 190 to 196 form a small α-helix, which is 
obviously stabilized by the presence of a proline in N-cap position (residue 191) and induces 
conformational changes that affect ligand binding. Furthermore energy decomposition analysis 
highlighted the important role of Asn152 as interaction partner for inhibitor binding.  
This work could not only offer a better understanding of the active site topologies and of the 
protein-ligand interactions, but also provides novel structural clues that will help to design and 
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optimize potent human 17β-HSD1 inhibitors with improved inhibitory potency toward 
marmoset 17β-HSD1. This is an important step to turn compounds, which show a promising 
pharmaceutical profile, into candidates for in vivo evaluation. Thus, our combined 
computational approach could also be considered as a valuable tool to achieve this goal. 
 
Methods 
Sequence Alignment and Model Building. The amino acid sequences of rat (accession number 
P51657), mouse (P51656) cynomolgus (Q4JK77) and marmoset 17β-HSD1 (Q9GME2) as well 
as human (P37059), cynomolgus (Q4JK76), marmoset (Q9GME5), mouse (P51658) and rat 
(Q62730) 17β-HSD2 were obtained from the uniprot webpage. These sequences were pairwise 
aligned with human 17β-HSD1 (PDB code: 1fdt) using MAFFT version 5 [51]. Using this 
alignment, a set of 100 comparative models of marmoset 17β-HSD1 was built employing 
Modeller9v7 [42], with the ternary complex E1-NADPH-human 17β-HSD1 as template. This 
complex resulted from docking of E1 to human 17β-HSD1 (PDB code: 1fdtB) (see below). The 
best homology model was then selected according to the Modeller energy score, DOPE score 
[43] and PROCHECK [44] tests. The reliability of the built homology models was checked by 
Prosa2003 [52] (Fig. S1), ERRAT [53], and Verify3D [54] (Fig. S2). 
 
Figure S1. Energy profile drawn for the marmoset 17β-HSD1 model using PROSA. Energy 
profiles of marmoset 17β-HSD1 in complex with NADPH (orange) and of marmoset 17β-HSD1 
in complex with NADPH and E1 (green). 
 
Figure S2. Verify3D results for the marmoset 17β-HSD1 model.. Verify-3D results are shown for 
the secondary complex of marmoset 17β-HSD1 (orange) with NADPH and for ternary complex 
(green) with NADPH and E1; residues with positive score are reasonably folded. 
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MD Simulations. MD simulations were performed using the AMBER 9.0 suite program [55]. 
The partial atomic charges for E1 and the inhibitors were derived from the molecular 
electrostatic potential (MEP) previously calculated using GAMESS [56], according to the RESP 
methodology [57]. For the protein, partial atomic charges were read from the AMBER 9.0 
libraries. The AMBER99SB force field [58] was employed to define atom types and potentials 
for the protein, while the general AMBER force field (gaff) [59] was used to define all needed 
atom types and parameters for E1 and the inhibitors. For NADPH (charge -4), the parameters 
previously reported by Ulf Ryde were applied (). 
The input files for the MD simulation were prepared with the xLEaP module of AMBER. 
Each system was solvated with an octahedral box of TIP3P water molecules of 10Å radius and 
neutralized by the addition of Na+ ions. Finally, for each complex the topology and the 
coordinate files were written and used in the MD simulations. 
Before starting the production-run phase, the following equilibration protocol was applied to 
all systems. At the beginning the system was energy-minimized in two stages: firstly, the 
solvent was relaxed while all the solute atoms were harmonically restrained to their original 
positions with a force constant of 100 kcal mol-1 Å-2 for 1000 steps; and secondly, the whole 
molecular system was minimized for 2500 steps by conjugate gradient. Subsequently, the 
system was heated during 60 ps from 0 to 300 K at constant volume conditions (NTV, PBC 
conditions), and then equilibrated keeping both temperature and pressure constant (NTP, PBC 
conditions, 300 K, 1 atm) during 100 ps. Electrostatic interactions were computed using the 
Particle Mesh Ewald method [60], and the SHAKE [61] algorithm was employed to keep all 
bonds involving hydrogen atoms rigid. NADPH, E1 and the inhibitors were constrained during 
the equilibration with a force constant of 20 kcal mol-1 Å-2. After equilibration, a MD production 
stage (NTP, PBC conditions, 300 K, 1 atm) was performed. The total simulation length differed 
for the various complexes ranging from 4 to 6 ns. Distance restraints were applied to 
substrate/inhibitor with the aim of maintaining their proper orientation at the beginning (first ns) 
of production stage. 
For the ternary complex of marmoset 17β-HSD1 with E1 and NADPH, two additional 
distance restraints were used: between the keto-oxygen of E1 and the side chain oxygen of 
Ser142 (d=2.40-3.00 Å; force constant: 10 kcal mol-1 Å-2) and between the oxygen of the OH-
group in 17-position of E1 and the NE2 nitrogen of the His221 side chain (d=2.70-3.40 Å; force 
constant: 10 kcal mol-1 Å-2).  
For the ternary complex of human 17β-HSD1 with 12 and NADPH, three additional 
distance restraints were used: between the keto-oxygen of 12 and the side chain oxygen of 
Tyr155 (d=2.80-3.40 Å; force constant: 10 kcal mol-1 Å-2), between the oxygen of the OH-group 
in meta-position of 12 and the OD1 oxygen of the Asn152 side chain (d=2.70-3.30 Å; force 
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constant: 10 kcal mol-1 Å-2), and between the oxygen of the para OH-group of 12 and the NE2 
nitrogen of the His221 side chain (d=2.70-3.30 Å; force constant: 10 kcal mol-1 Å-2). 
For the ternary complex of marmoset 17β-HSD1 with 12 and NADPH three additional 
distance restraints were used: between the keto-oxygen of 12 and the side chain oxygen of 
Ser142 (d=2.50-3.10 Å; force constant: 10 kcal mol-1 Å-2), between the oxygen of the OH-group 
in meta-position of 1 and the OD1 oxygen of the Asn152 side chain (d=2.40-3.00 Å; force 
constant: 10 kcal mol-1 Å-2), and between the oxygen of the para OH-group of 12 and the OD1 
oxygen of the Asn282 side chain (d=2.50-3.10 Å; force constant: 10 kcal mol-1 Å-2). 
For the ternary complex of human 17β-HSD1 with 19 and NADPH three additional distance 
restraints were used: between the oxygen of the OH-group in 2-position of the naphthol core 
and the side chain oxygen of Tyr155 (d=2.80-3.40 Å; force constant: 10 kcal mol-1 Å-2), 
between the oxygen of the OH-group in meta-position of the phenyl ring and the NE2 nitrogen 
of the His221 side chain (d=3.00-4.20 Å; force constant: 10 kcal mol-1 Å-2), and between the 
nitrogen of the sulfonamide moiety of 19 and the OD1 oxygen of the Asn152 side chain 
(d=2.70-3.40 Å; force constant: 10 kcal mol-1 Å-2). 
For the ternary complex of marmoset 17β-HSD1 with 19 and NADPH two additional 
distance restraints were used: between the oxygen of the OH-group in 2-position of the naphthol 
core and the NE2 nitrogen of the His221 side chain (d=2.70-3.40 Å; force constant: 10 kcal mol-
1 Å-2) and between the oxygen of the OH-group in meta-position of the phenyl ring of 19 and 
the backbone carbonyl oxygen of Cys185 (d=2.40-3.00 Å; force constant: 10 kcal mol-1 Å-2). 
Trajectories were analyzed using the AMBER ptraj module, the MMTSB toolset [62] and 
the molecular visualization program VMD (Visual Molecular Dynamics) [63]. The resulting 
low energy structures were extracted for the homology model (apoform and ternary complex) 
and subjected to a subsequent minimization of 1000 steps (500 steps of steepest descent 
followed by 500 steps of conjugate gradient), using the sander module of AMBER. The 
modified generalized Born solvation model (IGB=2) [64] was used. Active site volumes of low 
energy structures were calculated using the CASTp [45]. 
Molecular docking. The three-dimensional structures used for docking studies were either 
retrieved from the PDB (1fdt, conformation B for residues 187-200) or from the homology 
modelling with subsequent MD simulation (equilibrated ternary complex after 5537 ps). The 
cocrystallized E2 and water molecules were removed from the PDB file. Hydrogen atoms and 
neutral end groups were added, NADP+ was turned into NADPH and correct atom types were 
set. Ionization states and hydrogen positions were assigned using the Protonate 3D utility of 
MOE2009.10 (Chemical Computing Group Inc., Montreal, Canada). Ligand structures were 
built in MOE and RESP charges were assigned as described above. The 17β-HSD1 three-
dimensional structures and ligand structures were prepared for docking studies through the 
graphical user interface AutoDockTools4 [46]. For the ligands, non-polar hydrogen atoms were 
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deleted, rotatable bonds were defined and RESP charges were kept. For the protein, non-polar 
hydrogen atoms were deleted and charges were added to the structure. Autodock4.2 [46] was 
used to dock the ligands in the steroidal binding site of the processed protein structures. A box, 
centered on the steroid-binding site, was set to define the docking area. Grid points of 90 x 90 x 
90 with 0.250 Å spacing were calculated around the docking area for all the ligand atom types 
using AutoGrid4.2. For each inhibitor, 50 separate docking calculations were performed. Each 
docking calculation consisted of 25x105 energy evaluations using the Lamarckian genetic 
algorithm local search (GALS) method. Each docking run was performed with a population size 
of 250. A mutation rate of 0.02 and a crossover rate of 0.8 were used to generate new docking 
trials for subsequent generations. The docking results from each of the 50 calculations were 
clustered on the basis of root-mean-square deviation (RMSD = 2.0 Å) between the Cartesian 
coordinates of the ligand atoms and were ranked on the basis of the free binding energy. 
Free energy calculations using the MM/PBSA method. The calculation of binding free 
energy was evaluated using the MM/PBSA (Molecular Mechanics/ Poisson Boltzmann Surface 
Area) method as implemented in AMBER11 [65]. The electronic and Van der Waals energies 
were calculated using the sander module in AMBER11. The solvation free energy contributions 
may be further decomposed into an electrostatic and hydrophobic contribution. The electrostatic 
portion is calculated using the linearized PB equation. The hydrophobic contribution is 
approximated by the LCPO method [66] implemented within sander. The changes in entropy 
upon ligand association ∆S are estimated by normal mode analysis. For stable plateaus of the 
MD trajectories, snapshots were collected every 20th frame (every 20 ps) and used to calculate 
relative binding affinity (∆Gbind) and absolute free energy (∆G).  
Energy decomposition using the MM/GBSA method. A free energy decomposition of the 
protein ligand complexes was performed on a pairwise per-residue basis using the MM/GBSA 
(Molecular Mechanics/ Generalized Born Surface Area) method as implemented in AMBER11. 
The GBSA implicit-solvent solvation model was used in order to avoid the retarding effect of 
the PBSA method.  
Inhibition assay. [2, 4, 6, 7-3H]-E1 and [2, 4, 6, 7-3H]-E2 were bought from Perkin Elmer, 
Boston. Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 
Marmoset 17β-HSD1 and 17β-HSD2 were obtained from marmoset placenta according to 
previously described procedures [41]. Fresh marmoset placenta was homogenized and cytosolic 
and microsomal fractions were separated by centrifugation. For the partial purification of 17β-
HSD1, the cytosolic fraction was precipitated with ammonium sulfate. 17β-HSD2 was obtained 
from the microsomal fraction. 
Inhibition of 17β-HSD1: Inhibitory activities were evaluated by an established method 
with minor modifications [41]. Briefly, the enzyme preparation was incubated with NADH [500 
µM] in the presence of potential inhibitors at 37 °C in a phosphate buffer (50 mM) 
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supplemented with 20 % of glycerol and EDTA (1 mM). Inhibitor stock solutions were prepared 
in DMSO. The final concentration of DMSO was adjusted to 1 % in all samples. The enzymatic 
reaction was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]-E1 (final 
concentration: 500 nM, 0.15 µCi). After 10 min, the reaction was stopped by the addition of 
HgCl2 (10 mM) and the mixture was extracted with diethylether. After evaporation, the steroids 
were dissolved in acetonitrile. E1 and E2 were separated using acetonitrile/water (45:55) as 
mobile phase in a C18 reverse phase chromatography column (Nucleodur C18 Gravity, 3 µm, 
Macherey-Nagel, Düren) connected to an HPLC-system (Agilent 1200 Series, Agilent 
Technologies, Waldbronn). Detection and quantification of the steroids were performed using a 
radioflow detector (Agilent 1200 Series, Agilent Technologies, Waldbronn). The conversion 
rate was calculated after analysis of the resulting chromatograms according to the following 
equation: . Each value was calculated from at least three independent 
experiments.  
Inhibition of 17β-HSD2: The 17β-HSD2 inhibition assay was performed similarly to the 
17β-HSD1 procedure. The microsomal fraction was incubated with NAD+ [1500 µM], test 
compound and a mixture of unlabelled- and [2, 4, 6, 7-3H]-E2 (final concentration: 500 nM, 
0.11 µCi) for 20 min at 37 °C. Further treatment of the samples and HPLC separation was 
carried out as mentioned above. The conversion rate was calculated after analysis of the 
resulting chromatograms according to the following equation: . 
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Abstract: An attractive target, that has still to be explored for the treatment of estrogen-
dependent diseases, such as breast cancer and endometriosis, is the enzyme responsible for the 
last step in the biosynthesis of estradiol (E2): 17β-hydroxysteroid dehydrogenase type 1 (17β-
HSD1). It catalyzes the reduction of the weakly active estrone (E1) into E2, which is the most 
potent estrogen in humans. Inhibition of 17β-HSD1 lowers intracellular E2 concentrations and 
thus presents a therapy option for estrogen-dependent pathologies. Recently, we have reported 
on a new class of highly active and selective 17β-HSD1 inhibitors: bicyclic substituted 
hydroxyphenylmethanones. Here, further structural variations on the bicyclic moiety were 
performed, especially focusing on the exchange of its OH-function. Twenty-nine novel 
inhibitors were synthesized and evaluated for 17β-HSD1 inhibition in a cell-free and cellular 
assay, for selectivity toward 17β-HSD2 and estrogen receptors (ER) α and β as well as for 
metabolic stability. Compound 23 turned out to be the best compound of this study with 
excellent IC50-values of 12 nM in the cell-free assay and 78 nM in the cellular assay, a high 
selectivity, and a reasonable stability. A molecular docking study provided insight into the 
protein-ligand interactions of 23. 
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Introduction 
17β-Hydroxysteroid dehydrogenases (17β-HSDs) are responsible for the oxido-reduction 
reactions of steroid hormones at the 17 position, especially for estrogens and androgens, and use 
subtype-specifically NADPH (in case of 17β-HSD1) or NAD+ (17β-HSD2) as cofactors. 
Although these are reversible reactions, under in vivo conditions the catalysis is unidirectional 
due to the fact that NADP+ is abundant in its reduced form, whereas NAD+ is mainly present in 
its oxidized form.[1] 17β-HSDs catalyze the conversion of hormones with high receptor affinity 
to the corresponding low affinity forms and vice versa. They are expressed in the gonads and 
show characteristic expression patterns in peripheral tissues.[2] Therefore 17β-HSDs play a 
pivotal role in the local regulation of hormone levels.[2] In addition to their individual tissue and 
subcellular distributions, they also differ in their substrate specificities.[3, 4]  
17β-HSD1 is the most extensively characterized 17β-HSD subtype. It catalyzes the last step 
in the biosynthesis of the highly active estrogen 17β-estradiol (E2): the reduction of the weakly 
active estrone (E1; Figure 1). 
 
Figure 1. Intervention of AIs and 17β-HSD1 inhibitors in the estrogen synthesis. 
It is well known that E2, the natural ligand of the estrogen receptors α and β (ER α and ERβ), 
has a high impact on the de- velopment and progression of estrogen-dependent diseases, such as 
breast cancer, endometriosis, and endometrial hyper- plasia.[5–7] Reduction of estrogen levels by 
interference with E2 biosynthesis has been used as a treatment of ER-positive post- menopausal 
breast cancer for almost thirty years. Up to now, aromatase inhibitors (AIs) are the first-line 
therapeutics for these patients.[8,9] In the past few years, AIs have been intensively 
investigated.[10–15] However, inhibition of E2 synthesis by AIs does not affect the last but only 
the penultimate step. It results in a strong reduction of estrogen levels in the whole body leading 
to unwanted side effects. Therefore, intracellular regulation of estrogen levels in the diseased 
tissues by 17β-HSD1 is a promising therapeutic approach for the treatment of estrogen-
dependent diseases. An analogous concept has already been proved successful for the treatment 
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of androgen-dependent diseases, such as benign prostatic hyperplasia and alopecia, by using 5α-
reductase inhibitors.[16–19] Proof-of-concept for the treatment of breast cancer was performed in 
dif- ferent mouse models.[20–22] However, no 17β-HSD1 inhibitor has reached clinical trials so 
far. Furthermore, inhibition of 17β-HSD1 could have an additional antitumor effect, because it 
is also involved in the metabolism of retinoic acid,[23,24] a natural compound known to have 
tumor inhibiting activity.[25] As the therapeutic efficacy of 17β-HSD1 inhibitors should not be 
counteracted, selectivity towards 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) is 
required. This enzyme catalyzes the reverse reaction - oxidation of E2 into E1. Additionally, for 
reducing the risk of intrinsic estrogenic effects, affinity of the inhibitors to the ERs should be 
avoided. 
In recent years, the structural architecture of 17β-HSD1 has been investigated and numerous 
crystallographic data have been determined[24] and assigned to the different steps of the catalytic 
cycle.[26] Several, mostly steroidal, compounds have already been published as 17β-HSD1 
inhibitors,[24,27–30] using this information. With regards to nonsteroidal inhibitors, there are three 
compound classes with IC50 values in the low nanomolar range described: 
thiophenepyrimidinones,[31,32] hydroxyphenyl-naphthols,[33–36] and 
bis(hydroxyphenyl)heterocycles.[37–41] Recently, we reported bicyclic substituted 
hydroxyphenylmetha-nones as a new class of 17β-HSD1 inhibitors (Figure 2A).[42] 
 
Figure 2. Bicyclic substituted hydroxyphenylmethanones as inhibitors of 17β-HSD1 
These inhibitors also show a very promising biological profile. As the hydroxy function on the 
benzoyl part is more important for inhibitory activity (Figure 2B), replacement of the phenyl 
OH group was regarded as an appropriate modification to gain further interactions and to avoid 
possible phase II metabolism in this position.[43] 
Herein, we report the replacement of the hydroxy group of the phenyl ring adjacent to the 
thiophene in bicyclic substituted hydroxyphenyl methanones. In order to evaluate whether it is 
possible to achieve additional interactions in the C-terminal region of the target enzyme, various 
substituents were introduced. Synthesis, biological evaluation and structure–activity 
relationships (SAR) of new highly potent and selective 17β-HSD1 inhibitors are described. 
Furthermore, the probable binding mode of the most potent compound was investigated by 
molecular docking studies to explain the SAR obtained. 
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Design 
Binding mode investigations of three potent compounds of this class (B1–B3) revealed a 
steroid-like binding mode with the benzoyl moiety occupying an apolar subpocket, previously 
described to have an impact on ligand binding.[44,45] The phenyl ring adjacent to the thiophene 
was found to mimic the steroidal A ring binding in the C-terminal region of the protein. It is 
known that there is space for additional substituents in this region since several highly active 
steroidal inhibitors have extensions in position 2.[46] The most potent inhibitors of these 
derivatives bear an additional phenyl ring connected by a C2 linker.[46] Thus, the expected 
steroid-like binding mode of B1–B3 prompted us to further investigate this C-terminal region by 
exchanging the phenyl hydroxy group. 
 
Results 
Chemistry. The synthesis of compounds 1-29 is depicted in Scheme 1. The methoxylated 
intermediate 1b was synthesized via Friedel-Crafts-acylation of 2-bromothiophene with 3-
methoxybenzoyl chloride using aluminium chloride. The methoxy function was cleaved 
according to method B (BBr3, CH2Cl2, -78 °C to rt, 18 h)[47] to yield compound 1a in 
quantitative yields.  
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Scheme 1. Synthesis of compounds 1-29. Reagents and conditions: a) AlCl3, anhydrous 
CH2Cl2, 0 °C, 0.5 h followed by rt, 1 h for compound 1b; b) Cs2CO3, Pd(PPh3)4, 
DME/EtOH/water (1:1:1), microwave conditions (150 W, 15 bar, 150 °C, 15 min) for compound 
2a; c): Cs2CO3, Pd(PPh3)4, DME/water (1:1) reflux, 4 h for compounds 20a-22a and 29 (Method 
A2) and 2 h for compounds 1, 3-19 and 23-28 (Method A1); d) Method B: BBr3, CH2Cl2, -78 °C, 
18 h for compounds 1a, 2 and 20-22. 
Starting from these brominated key intermediates 1a and 1b and the appropriate commercially 
available boronic acids, Suzuki cross coupling reactions[48] were carried out using two different 
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methods. Compound 2a was prepared in a one-pot synthesis by means of microwave assisted 
Suzuki reaction (Cs2CO3, DME/EtOH/water (1:1:1), Pd(PPh3)4, MW (150 W, 150 °C, 15 bar 15 
min)).[38] All other compounds were prepared following method A. Using DME/water (1:1) as 
solvent, caesium carbonate and Pd(PPh3)4 as catalyst, the reaction mixtures were stirred under 
reflux either for 2 h (method A1; 1, 3-19 and 23-28) or for 4 h (method A2; 20a-22a and 29). 
Demethylation of 2a, sulfonamide derivatives 21 and 22 and nitrile 20 was performed using 
method B (BBr3, CH2Cl2, -78 °C to rt, 18 h). 
 
Activity: Inhibition of human 17β-HSD1. Human placenta was used as enzyme source and 
partially purified following a described procedure.[49]  Tritiated E1 was incubated with 17β-
HSD1, cofactor and inhibitor. The separation of substrate and product was performed by HPLC. 
The inhibition values of compounds 1-29 are shown in Table 1.  
Compound 1, lacking the OH-function on the phenyl ring, showed an inhibitory activity, 
which is slightly weaker than the activities of the hydroxylated compounds B1-B3. As 
compound 2 (ortho-methoxy) and 3 (meta-methoxy) revealed remarkable IC50 values around 90 
nM, it became apparent that a hydrogen-bond donor is beneficial (B1-B3)[42] but not necessarily 
needed in this region for inhibitory potency. The ortho- and meta-ethoxy-compounds 9 and 10, 
respectively, exhibited similar 17β-HSD1 inhibition as their corresponding methoxy-derivatives 
2 and 3 indicating that there is some space for further substituents. The good inhibitory activity 
of 12 (IC50 = 62 nM) indicates the presence of additional space, which was further investigated 
by the introduction of substituents on each position of the benzyloxy-moiety (13-19). 
While the introduction of a carbonitrile in the meta position adjacent to the thiophene (20, 
IC50 = 225 nM) or methanesulfonamide group (21, IC50 = 150 nM; 22, IC50 = 125 nM) did not 
induce significant changes in enzyme inhibition compared to the unsubstituted compound 1 
(IC50 = 155 nM), the methylbenzenesulfonamide 23 was clearly more potent and exhibited the 
highest 17β-HSD1 inhibitory activity (IC50 = 12 nM) in this study similar to those obtained in 
the previous study B1-B3.[42] 
Compared to compound 1 (IC50 = 155 nM), the naphthalene-substituted derivative 24 
showed a slight drop of activity (IC50 = 300 nM). Introduction of a dihydrobenzofuran moiety 
(25), which represents a rigidification of the ethoxy-substituent of compound 11 (IC50 = 498 
nM), led to increased inhibition values (IC50 = 55 nM). Obviously, rigidified systems are more 
appropriate for inhibitory activity in this position of the molecule indicating a sterical hindrance 
for larger substituents in para-position. This observation was confirmed by comparing 
compounds 6 and 26; by replacing the two methoxy-functions (6) with an acetale (26), the weak 
inhibition (44 % at 1 µM) could be increased to an IC50-value of 66 nM. 
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Table 1. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds 1-29 
 
Compd. X 
IC50 [nM][a] 
selectivity factor[d] 
17β-HSD1[b] 17β-HSD2[c] 
B1 2-hydroxy 95 18 0.2 
B2 3-hydroxy 22 109 5 
B3 4-hydroxy 33 478 14 
1 H 155 128 0.8 
2 2-methoxy 86 196 2 
3 3-methoxy 95 342 4 
4 4-methoxy 220 507 2 
5  510 1036 2 
6 3,4-dimethoxy 44 %[e] 44 %[e]  
7 3,4,5-trimethoxy 54 %[e] 26 %[e]  
8 2,3,4-trimethoxy 515 915 2 
9 2-ethoxy 94 195 2 
10 3-ethoxy 78 502 6 
11 4-ethoxy 498 586 1 
12 H 62 797 13 
13 2-methoxy 35 1065 30 
14 3-methoxy 47 768 16 
15 4-methoxy 60 702 12 
16 3,5-dimethoxy 31 789 26 
17 2-chloro 54 1197 22 
18 3-chloro 40 1034 26 
19 4-chloro 36 1003 28 
20 3-nitrile 225 354 2 
21 3-methanesulfonamide 150 563 4 
22 N-methylmethanesulfonamide 125 559 4 
23 3-(4-methylbenzenesulfonamide) 12 169 14 
24 2-naphthalene 300 253 0.8 
25 5-(2,3-dihydrobenzofurane) 55 319 6 
26 5-(1,3-benzodioxol) 66 299 5 
27 5-indole 151 173 1 
28 6-indole 192 283 2 
29 6-indazole 107 410 4 
[a] Mean value of three determinations, standard deviation less then 26 %; [b] Human placenta, cytosolic fraction, 
substrate E1, 500 nM, cofactor NADH, 500µM; [c] Human placenta, microsomal fraction, substrate E2, 500 nM, cofactor 
NAD+, 1500µM; [d] IC50 (17β-HSD2) / IC50 (17β-HSD1); [e] inhibition at 1 µM (inhibitor concentration). 
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Selectivity: Inhibition of human 17β-HSD2 and affinities for ERα and ERβ. 17β-HSD2 acts 
as a biological counterpart of the type 1 enzyme by catalyzing the reverse reaction. Therefore, 
inhibition of this enzyme must be avoided. In an assay similar to the 17β-HSD1 test, human 
placental microsomes were incubated with tritiated E2 in the presence of NAD+ and inhibitor to 
evaluate inhibition of 17β-HSD2. Labeled product was quantified after HPLC separation. 
Inhibition values of all compounds are depicted in Table 1. In vitro selectivity toward 17β-
HSD2 is expressed as selectivity factor (SF), describing the ratio of the concentrations required 
to inhibit the isoenzymes by 50 % (IC50 17β-HSD2/IC50 17β-HSD1). 
SFs of methoxy- and ethoxy-compounds 1-2, 4-9 and 11 do not exceed 2. Higher SFs were 
observed for compounds bearing substituents in meta position. However, SFs up to 50, as 
achieved in the previous study,[42] were not obtained.  
Interestingly, enlargement of the ether resulted in a slight increase of selectivity: compound 
3 (SF = 4) versus 10 (SF = 6). Remarkably, the benzyloxy-derivative 12 showed a 13-fold 
higher inhibition of 17β-HSD1 compared to the type 2 enzyme indicating that the space within 
this area of the latter enzyme might be more restricted than in 17β-HSD1. Accordingly, 
introduction of substituents into the benzyloxy moiety might lead to further enhancement of 
selectivity. While this hypothesis was confirmed by the meta-methoxy- (13), dimethoxy- (16) 
and the chloro-derivatives (17-19), the monomethoxy-compounds (14-15) showed different 
results. Compounds 14 (meta-methoxy, SF = 16) and 15 (para-methoxy, SF = 12) revealed 
similar selectivity toward 17β-HSD2 as the nonsubstituted benzyloxy compound 12 (SF = 13).  
Considering the sulfonamides 21-23, it is striking that the introduction of a phenyl ring also 
increases selectivity (for 21 and 22, SF = 4 versus 23 SF = 14). These results attract increasing 
notice to a phenyl ring within this area of the protein with regard to its influence on activity and 
selectivity. 
As estrogens function via activation of ERs, the affinity of 17β-HSD1 inhibitors toward 
ERα and ERβ should be as low as possible in order to avoid stimulatory effects. Since E1 shows 
tenfold lower affinity toward ERα[50] and 50-fold lower affinity toward ERβ[50]  compared with 
E2 (relative binding affinity (RBA) = 100 % for E2), inhibitors having an RBA below 0.1 % 
were considered to possess too little affinity to exert estrogenic effects. As E1 is the only active 
estrogen present during 17β-HSD1 inhibition, inhibitors with much lower receptor affinity than 
E1 are negligible for receptor activation. All compounds having a SF value higher than 10 were 
evaluated in this competition assay. None of them showed higher RBA values than 0.1 % (data 
not shown) confirming our design concept focusing on nonsteroidal inhibitors. 
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Further biological evaluations. Using T47D cells expressing both 17β-HSD1 and 17β-HSD2, 
the intracellular potencies of selected compounds were evaluated (Table 2).  
Table 2. Inhibition of 17β-HSD1 in cell-free and cellular assay by selected compounds. 
 
Compd. R 
IC50 [nM][a] 
cell-free assay[b] cellular assay[c] 
10  78 154 
12  62 53 %[d] 
13  35 441 
14  47 565 
15  60 526 
16  31 40 %[d] 
17  54 34 %[d] 
18  40 49 %[d] 
19  36 47 %[d] 
23  12 78 
25  55 357 
a] Mean value of three determinations, standard deviation less then 24 %; [b] Human placenta, cytosolic fraction, 
substrate E1, 500 nM, cofactor NADH, 500µM; [c] T47D cells, substrate E1, 50 nM; [d] inhibition at 1 µM (inhibitor 
concentration) 
Regarding the benzyloxy-substituted compounds 12-19, only the monomethoxy-substituted 
benzyloxy-derivatives 13-15 showed moderate inhibition of E2 formation (IC50 = 526, 441 and 
565 nM, respectively). However, the dimethoxy (16) and chloro substituents (17-19) have a 
negative impact on cellular activity, which might be explained by insufficient cell penetration or 
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increased intracellular metabolism. Interestingly, the ethoxy derivative 10, without bearing an 
additional phenyl ring, exhibited a three- to fourfold higher intracellular inhibitory activity (IC50 
= 154 nM) than compounds 13-15.  
Methylbenzenesulfonamide 23 turned out to be the most potent 17β-HSD1 inhibitor of this 
study both in the cell-free (IC50 = 12 nM) and in the cellular assay (IC50 = 78 nM). 
In order to find an appropriate species for demonstrating in vivo efficacy in a disease-
oriented animal model, compounds 1, 13 and 23 were tested in a cell-free assay using the 
cytosolic fraction of mouse liver preparation and under conditions similar to our standard cell-
free assay. However, no mentionable inhibition of 17β-HSD1 or 17β-HSD2 could be detected 
(data not shown). Therefore, the search for an optimal species pertaining to in vivo proof-of-
concept for this class of compounds is ongoing.  
Furthermore, metabolic stability of the most active compound 23 (IC50 = 12 nM) and the 
most selective compound 13 (SF = 30) of this study were evaluated using human liver 
microsomes (Table 3). The data of both compounds and the references dextrometorphan and 
verapamil are given in Table 3. Compounds 13 and 23 showed intrinsic clearances (CLint) of 
81.2 and 109 µL min-1 mg-1 protein, respectively, and therefore can be considered to be in the 
high clearance category. Regarding the reference drugs, dexreomethorphan and verapamil, the 
commonly used calcium channel blocker verapamil revealed a very similar CLint of 105 µL 
min-1 mg-1 protein defining a high but not too high liability to metabolic degradation. 
Table 3. Metabolic stability of compounds 13, 23 and control compounds using human liver 
microsomes 
Compd. 
CLint[a]  
[µL/min/mg protein] 
t1/2 
[min] 
dextrometorphan 10.7 129 
verapamil 105 13.2 
13 81.2 17.1 
23 109 12.8 
[a] Intrinsic metabolic clearance (CLint); test concentration = 3 µM. 
Molecular Modeling. A docking study was performed in order to gain deeper insight into the 
molecular interactions between the most potent inhibitor 23 and 17β-HSD1 and to understand 
the SAR. In Figure 3, the binding mode of compound 23 is shown, indicating hydrogen-bonding 
interactions between the OH functionality and Asn152, as well as between the keto oxygen 
atom and Tyr155. The second hydrogen bond of the ketone with Ser142, which was proposed 
for B1-B3, was not predicted by modeling studies to be present for 23. The 
methylbenzenesulfonamide substituent is predicted to interact with two amino acids, which are 
located in the C-terminal region. His221 is suggested to form a hydrogen bond with one 
sulfonamide-oxygen atom, while Phe259 might be involved in π-π-interactions with the benzene 
moiety. 
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Figure 3. Hypothetical binding mode of compound 23 (cyan) obtained by docking into 17β-
HSD1 (PDB-ID: 1FDT-B). Cofactor NADPH (orange), interacting residues (green) and cartoon 
rendered tertiary structure (grey) of the active site are shown. Hydrogen bonds are drawn in 
black dashed lines. Figure generated with MOE (Chemical Computing Group Inc., Montreal, 
Canada). 
Discussion and Conclusions 
From our previous work in this class of compounds,[42] it was demonstrated that variation of the 
OH position on the phenyl ring do not result in marked differences in the inhibitory activity of 
evaluated compounds B1-B3. In this paper, we have reported on the replacement of the hydroxy 
group on the phenyl ring in the class of the bicyclic substituted hydroxyphenyl methanones. 
Various substituents were introduced in order to evaluate whether additional interactions in the 
C-terminal region are beneficial for inhibitory activity. The biological data show that 17β-HSD1 
inhibition can also be achieved without the OH functionality on the phenyl ring. Considering the 
design concept of the previous study, this hydroxyl group was expected to form hydrogen bonds 
with His221 and Glu282 in the C-terminal region of the steroid binding pocket. Obviously, the 
hydrogen-bond donor property is not necessary for strong inhibitory activity with regard to the 
methoxy derivatives. Glu282, which is expected to accept a hydrogen bond from this OH group, 
does not seem to be involved in inhibitor binding at all. In general, its relevance for ligand 
binding is discussed controversially. While site-directed mutagenesis studies indicated no 
significant interaction between Glu282 and the 3-OH group of the substrate,[51] hydrogen 
bonding between both was found in several independent crystal structures.[52,53] The hydrogen-
bond acceptor property of the phenol might play a more important role since compound 1, 
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without hydroxyl functionality on the phenyl ring, showed a slightly reduced 17β-HSD1 
inhibition. However, the potential hydrogen-bond donor His221 is already known as an 
important factor for substrate interaction.[54] Although this amino acid is described to be 
implicated in enzyme stabilisation[44] by interacting with Glu282, it appears to be also involved 
in the binding of our inhibitors.  
Regarding the mono-methoxy- and ethoxy derivatives (2-5 and 9-11, respectively), it 
becomes apparent that the para-position seems to be less favorable than meta and ortho. 
Moreover, di- and trimethoxy-derivatives (6-8) showed a strong decrease in activity as well, 
indicating that the space around this phenyl ring is sterically restricted. This finding is in 
accordance with our docking results. According to the orientation of the phenyl ring, the 
disubstitution of 6 compels the methoxy groups to adopt a conformation leading to steric clashes 
with either Tyr218 or Phe259. Indeed, taking into account that the 1,3-benzodioxol compound 
26 showed a much higher affinity than the corresponding dimethoxy compound 6, it can be 
concluded that the binding pocket is very restricted.  
Concerning flexible substituents, 17β-HSD1 inhibitory activity as well as selectivity toward 
the type 2 enzyme revealed the meta position to be the most favorable. Starting with compound 
3, it is striking that an enlargement of the meta substituents resulted in increased selectivity (SF 
of 3 <10 <12 < 13/16-19). Interestingly, the IC50 values for 17β-HSD1 inhibition of all 
benzyloxy-derivatives are in the same range and similar to that of the ethoxy compound 10. 
Therefore, although influencing the selectivity toward 17β-HSD2, the phenyl ring of the 
benzyloxy substituent does not seem to specifically interact with 17β-HSD1. Further 
investigation is still warranted as to whether the phenyl ring is pointing out of the 17β-HSD1 
active site.  
Sulfonamide 23 turned out to be the most potent inhibitor of this study. Compared to its 
methanesulfonamide analog 21, the introduction of the phenyl led to 12-fold higher 17β-HSD1 
inhibition. The docking study revealed the benzene ring of 23 to be implicated in a π-π 
interaction with Phe259. Comparing B2 (meta-OH) and 23, both compounds interact with 
Asn152. The relevance of this amino acid for ligand binding was already confirmed by a co-
crystal structure of a highly potent, steroidal 17β-HSD1 inhibitor.[44] B2 and 23 showed similar 
IC50 values although the hydrogen-bonding interaction of 23 with Ser142 was not present in the 
observed binding mode. The π-π interactions found for compound 23 might be able to 
compensate the loss of the hydrogen bond between the ketone and Ser142. 
In summary, we have reported on further developments in the class of bicyclic substituted 
hydroxyphenylmethanones. The high inhibitory activities of inhibitors bearing large substituents 
like benzylsulfonamide or benzyloxy revealed that these groups take advantage of the additional 
space in the C-terminal region. Although comparable inhibitory potencies were achieved, they 
have to be considered critically in terms of ligand efficiency. However, further bioisosteric 
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replacements of the phenolic hydroxyl group might lead to compounds combining high potency 
with good selectivity and intracellular activity. The most promising compound of this study, 
methylbenzenesulfonamide 23, shows strong inhibitory activity in both cellular and cell-free 
assays as well as no affinity toward estrogen receptors α and β. It might be a candidate for 
further lead optimization, especially regarding its selecticity and cellular activity. 
 
Experimental Section 
Chemistry. Chemical names follow IUPAC nomenclature. Starting materials were purchased 
from Aldrich, Acros, Lancaster, Combi Blocks, Merck or Fluka and were used without 
purification. Column chromatography (CC) was performed on silica gel (70-200 mm). 
Preparative thin layer chromatography (TLC) was performed on 1 mm SIL G-100 UV254 glass 
plates (Macherey-Nagel). Reactions were monitored using Alugram SIL G UV254 TLC plates 
(Macherey-Nagel). All microwave irradiation experiments were carried out in a CEM-Discover 
monomode microwave apparatus.  
1H-NMR and 13C-NMR spectra were measured on a Bruker AM 500 spectrometer (500 
MHz) at 300 K. Chemical shifts (δ) are reported in parts per million (ppm), with the residual 
solvent as the internal standard (CDCl3: d = 7.24 ppm (1H-NMR) and d = 77 ppm (13C-NMR) 
and CD3COCD3: d = 2.05 ppm (1H-NMR) and d = 30.8 ppm (13C-NMR)). Signals are described 
as singlet (s), doublet (d), triplet (t), doublet of doublets (dd), doublet of doublets of doublets 
(ddd), multiplet (m), douplet of triplets (dt), triplet of doublets (td), and quadruplet (q). All 
coupling constants (J) are given in hertz (Hz). Mass spectra were recorded on a TSQ Quantum 
(Thermo Finnigan) instrument using electrospray ionization (ESI). 
Tested compounds possessed >98% chemical purity as measured by HPLC. The methods 
for HPLC analysis and a table of data for all tested compounds are provided in the Supporting 
Information. 
General procedure for Suzuki coupling (Method A): A mixture of 2-bromothiophene 
derivative (1 eq), boronic acid derivative (1.2 eq), caesium carbonate (4 eq) and 
tetrakis(triphenylphosphine) palladium (0.01 eq) in an oxygen free DME/water (1:1) solution 
was refluxed under nitrogen atmosphere for 2 h (method A1) or 4 h (method A2), respectively. 
The reaction mixture was cooled to rt. The aqueous layer was extracted with ethyl acetate. The 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
concentrated to dryness. The product was purified by column chromatography (CC), CC 
followed by preparative TLC or CC followed by preparative HPLC, respectively. 
 
General procedure for ether cleavage (Method B): To a solution of methoxybenzene 
derivative (1 eq) in dry dichloromethane at -78 °C (dry ice/acetone bath), boron tribromide in 
dichloromethane (1 M, 3 eq per methoxy function) was added dropwise. The reaction mixture 
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was stirred for 20 h at rt under nitrogen atmosphere. Water was added to quench the reaction, 
and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The product 
was purified by CC, CC followed by preparative HPLC or recrystallization, respectively. 
General procedure for purification using preparative HPLC: Compounds were purified 
via an Agilent Technologies Series 1200–preparative HPLC using a RP C18 Nucleodur 100-5 
column (30 x 100 mm / 50 µM from Macherey Nagel GmbH) as the stationary phase with a 
linear gradient (solvents: acetonitrile, water) starting from 20 % acetonitrile up to 100 % over 36 
min. 
(5-Bromo-2-thienyl)(3-methoxyphenyl)methanone (1b). A mixture of 2-bromothiophene 
(145 mg, 0.89 mmol), 3-methoxybenzoyl chloride (152 mg, 0.89 mmol) and aluminium chloride 
(119 mg, 0.89 mmol) in anhydrous dichloromethane was stirred at 0 °C for 0.5 h. The reaction 
mixture was warmed to rt and stirred for 1 h. HCl 1M was used to quench the reaction. The 
aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with 
brine, dried over magnesium sulfate, filtered and concentrated to dryness. The product was 
purified by CC (hexane/ethyl acetate 97:3); yield: 77 % (204 mg, white powder). 1H NMR 
(CD3COCD3): 7.55 (d, J = 4.1 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.42 (td, J = 1.5 Hz and J = 7.9 
Hz, 1H), 7.35-7.34 (m, 1H), 7.33 (d, J = 4.1 Hz, 1H), 7.22 (ddd, J = 0.9 Hz and J = 2.5 Hz and J 
= 8.2 Hz, 1H), 3.88 (s, 3H); 13C NMR (CD3COCD3): 187.90, 161.75, 140.45, 137.40, 133.85, 
131.60, 123.95, 123.05, 120.45, 115.45, 56.85. 
(5-Bromo-2-thienyl)(3-hydroxyphenyl)methanone (1a). The title compound was prepared 
by reaction of 1b (650 mg, 2.19 mmol) and boron tribromide (6.57 mmol) according to method 
B. The product was used in the next step without further purification; quantitative yield (620 
mg, white powder). 1H NMR (CD3COCD3): 8.76 (s, 1H), 7.54 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 
7.8 Hz, 1H), 7.34-7.32 (m, 2H), 7.30 (t, J = 2.1 Hz, 1H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz 
and J = 8.2 Hz, 1H); 13C NMR (CD3COCD3): 187.90, 159.45, 147.25, 140.45, 137.25, 133.80, 
131.70, 123.80, 122.10, 121.60, 117.25. 
(3-Hydroxyphenyl)(5-phenyl-2-thienyl)methanone (1). The title compound was prepared 
by reaction of 1a (150 mg, 0.53 mmol), benzene boronic acid (78 mg, 0.64 mmol), caesium 
carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) 
according to method A1. The product was purified by CC (hexane/ethyl acetate 8:2); yield: 
28 % (42 mg, beige powder); 1H NMR (CD3COCD3): 8.81 (s, 1H), 7.81-7.80 (m, 2H), 7.72 (d, J 
= 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 1H), 7.49 (t, J = 7.9 Hz, 2H), 7.44-7.39 (m, 2H), 7.37 (dt, J = 
1.5 Hz and J = 7.6 Hz, 1H), 7.34-7.33 (m, 1H), 7.13 (ddd, J = 1.5 Hz and J = 2.5 Hz and J = 7.9 
Hz, 1H); 13C NMR (CD3COCD3): 188.75, 159.40, 154.30, 144.20, 141.30, 137.85, 135.15, 
131.55, 131.15, 131.05, 128.05, 126.30, 122.05, 121.25, 117.30; MS (ESI): 281 (M+H)+. 
104 3 RESULTS 
 
 
(3-Methoxyphenyl)[5-(2-methoxyphenyl)-2-thienyl]methanone (2a). A mixture of 1b 
(200 mg, 0.67 mmol), 2-methoxybenzene boronic acid (122 mg, 0.80 mmol), caesium carbonate 
(873 mg, 2.68 mmol) and tetrakis(triphenylphosphine) palladium (8 mg, 7 mmol) was 
suspended in an oxygen free DME/EtOH/water (1:1:1) solution. The reaction mixture was 
exposed to microwave irradiation (15 min, 150 W, 150 °C, 15 bar). After reaching rt, water was 
added and the aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered and concentrated to dryness. 
The product was purified by CC (hexane/ethyl acetate 9:1); yield: 67 % (145 mg, yellow 
powder). 1H NMR (CD3COCD3): 7.85 (dd, J = 1.9 Hz and J = 7.9 Hz, 2H), 7.69 (d, J = 1.3 Hz, 
1H), 7.49-7.44 (m, 2H), 7.42-7.38 (m, 2H), 7.21-7.18 (m, 2H), 7.07 (dt, J = 0.9 Hz and J = 7.9 
Hz, 1H), 4.01 (s, 3H), 3.89 (s, 3H); 13C NMR (CD3COCD3): 189.10, 161.70, 158.10, 149.85, 
144.05, 141.70, 136.50, 132.15, 131.45, 130.15, 127.80, 123.75, 123.10, 122.95, 119.90, 
115.50, 114.05, 57.10, 56.80. 
(3-Hydroxyphenyl)[5-(2-methoxyphenyl)-2-thienyl]methanone (2). The title compound 
was obtained by reaction of 2a (145 mg, 0.45 mmol) and boron tribromide (2.70 mmol) 
according to method B. The product was purified by CC (hexane/ethyl acetate 8:2) followed by 
preparative HPLC; yield: 55 % (76 mg, yellow oil); 1H NMR (CD3COCD3): 7.83 (dd, J = 1.6 
Hz and J = 7.9 Hz, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.67 (d, J = 4.1 Hz, 1H), 7.41-7.35 (m, 4H), 
7.18 (d, J = 7.9 Hz, 1H), 7.14-7.12 (m, 1H), 7.07-7.04 (m, 1H), 4.00 (s, 3H); 13C NMR 
(CD3COCD3): 189.20, 159.30, 158.05, 149.70, 144.10, 141.70, 136.40, 132.10, 131.45, 130.10, 
127.70, 123.75, 122.90, 122.05, 120.95, 117.25, 114.00, 57.10; MS (ESI): 311 (M+H)+. 
(3-Hydroxyphenyl)[5-(3-methoxyphenyl)-2-thienyl]methanone (3). The title compound 
was prepared by reaction of (5-bromo-2-thienyl)(3-hydroxyphenyl)methanone (1a) (150 mg, 
0.53 mmol), 3-methoxybenzene boronic acid (97 mg, 0.64 mmol), caesium carbonate (691 mg, 
2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method 
A1. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 94 % (154 mg, beige 
powder); 1H NMR (CD3COCD3): 7.71 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 1H), 7.42-7.35 
(m, 4H), 7.34 (t, J = 1.9 Hz, 1H), 7.32 (t, J = 1.9 Hz, 1H), 7.13 (ddd, J = 1.3 Hz and J = 2.2 Hz 
and J = 7.6 Hz, 1H), 7.00 (ddd, J = 1.3 Hz and J = 2.2 Hz and J = 7.6 Hz, 1H), 3.89 (s, 3H); 13C 
NMR (CD3COCD3): 188.75, 162.35, 159.45, 154.20, 144.25, 141.30, 137.75, 136.45, 132.25, 
131.60, 126.55, 122.10, 121.25, 120.45, 117.30, 116.75, 113.35, 56.80; MS (ESI): 311 (M+H)+. 
(3-Hydroxyphenyl)[5-(4-methoxyphenyl)-2-thienyl]methanone (4). The title compound 
was prepared by reaction of 1a (150 mg, 0.53 mmol), 4-methoxybenzene boronic acid (97 mg, 
0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) 
palladium (6 mg, 5 mmol) according to method A1. The product was purified by CC 
(hexane/ethyl acetate 8:2) followed by preparative TLC (hexane/ethyl acetate 7:3); yield: 96 % 
(158 mg, yellow powder); 1H NMR (CD3COCD3): 8.72 (s, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.66 
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(d, J = 4.1 Hz, 1H), 7.45 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.35 (dt, J = 1.3 Hz and J 
= 7.8 Hz, 1H), 7.34 (t, J = 2.1 Hz, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 
1H), 7.02 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H); 13C NMR (CD3COCD3): 188.60, 162.65, 159.35, 
154.65, 143.15, 141.45, 138.00, 131.50, 129.45, 127.75, 125.05, 122.05, 121.05, 117.25, 
116.50, 56.80; MS (ESI): 311 (M+H)+. 
(3-Hydroxyphenyl)[5-(6-methoxypyridin-3-yl)-2-thienyl]methanone (5). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 6-methoxypyridine-3-boronic 
acid (98 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 85:15); yield: 63 % (104 mg, beige powder); 1H NMR 
(CD3COCD3): 8.86 (s, 1H), 8.60 (dd, J = 0.6 Hz and J = 2.4 Hz, 1H), 8.06 (dd, J = 2.5 Hz and J 
= 8.5 Hz, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.55 (d, J = 4.1 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.36 
(dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.33-7.32 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and 
J = 7.8 Hz, 1H), 6.88 (dd, J = 0.6 Hz and J = 8.5 Hz, 1H), 3.94 (s, 3H); 13C NMR (CD3COCD3): 
188.65, 166.40, 159.45, 150.95, 146.40, 141.25, 138.55, 137.90, 131.55, 126.10, 122.05, 
121.25, 117.25, 113.05, 54.95; MS (ESI): 312 (M+H)+. 
[5-(3,4-Dimethoxyphenyl)-2-thienyl](3-hydroxyphenyl)methanone (6). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3,4-dimethoxybenzene boronic 
acid (117 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 8:2); yield: 73 % (132 mg, yellow powder); 1H NMR 
(CD3COCD3): 8.78 (s, 1H), 7.68 (d, J = 4.1 Hz, 1H), 7.51 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 7.8 
Hz, 1H), 7.38-7.34 (m, 3H), 7.32-7.31 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 
Hz, 1H), 7.06-7.04 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H); 13C NMR (CD3COCD3): 189.65, 159.40, 
152.60, 151.80, 141.50, 137.95, 131.55, 128.05, 125.35, 122.00, 121.10, 120.95, 117.25, 
114.05, 111.70, 57.25, 57.20; MS (ESI): 341 (M+H)+. 
(3-Hydroxyphenyl)[5-(3,4,5-trimethoxyphenyl)-2-thienyl]methanone (7). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3,4,5-trimethoxybenzene 
boronic acid (136 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 8:2); yield: 71 % (140 mg, yellow powder); 1H NMR 
(CD3COCD3): 8.76 (s, 1H), 7.68 (d, J = 4.1 Hz, 1H), 7.56 (d, J = 4.1 Hz, 1H), 7.40 (t, J = 7.8 
Hz, 1H), 7.35 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.33-7.32 (m, 1H), 7.12 (ddd, J = 1.3 Hz and 
J = 2.5 Hz and J = 7.9 Hz, 1H), 7.07 (s, 2H), 3.93 (s, 6H), 3.78 (s, 3H); 13C NMR (CD3COCD3): 
188.70, 159.40, 155.95, 154.75, 143.80, 141.35, 137.75, 131.55, 130.70, 126.20, 122.05, 
121.15, 117.25, 105.85, 61.70, 57.65; MS (ESI): 371 (M+H)+. 
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(3-Hydroxyphenyl)[5-(2,3,4-trimethoxyphenyl)-2-thienyl]methanone (8). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 2,3,4-trimethoxybenzene 
boronic acid (136 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 8:2); yield: 62 % (122 mg, yellow powder); 1H NMR 
(CD3COCD3): 8.80 (s, 1H), 7.66 (d, J = 4.1 Hz, 1H), 7.59-7.56 (m, 2H) 7.39 (t, J = 7.8 Hz, 1H), 
7.35 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.33-7.32 (m, 1H), 7.11 (ddd, J = 1.3 Hz and J = 2.5 
Hz and J = 7.9 Hz, 1H), 6.92 (d, J = 9.1 Hz, 1H), 3.95 (s, 3H), 3.91 (s, 3H), 3.87 (s, 3H); 13C 
NMR (CD3COCD3): 189.10, 159.40, 156.60, 152.85, 149.65, 143.70, 141.80, 136.60, 131.45, 
126.65, 124.40, 122.00, 121.65, 121.00, 117.25, 110.35, 62.05, 62.00, 57.50; MS (ESI): 371 
(M+H)+. 
5-(2-Ethoxyphenyl)-2-thienyl](3-hydroxyphenyl)methanone (9). The title compound was 
prepared by reaction of 1a (150 mg, 0.53 mmol), 2-ethoxybenzene boronic acid (106 mg, 0.64 
mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 
mg, 5 mmol) according to method A1. The product was purified by CC (hexane/ethyl acetate 
85:15); yield: 88 % (151 mg, yellow oil); 1H NMR (CD3COCD3): 7.87 (dd, J = 1.5 Hz and J = 
7.9 Hz, 1H), 7.74 (d, J = 4.1 Hz, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.41-7.35 (m, 3H), 7.34 (t, J = 
2.1 Hz, 1H), 7.18-7.16 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H), 7.06 
(td, J = 1.3 Hz and J = 7.6 Hz, 1H), 4.28 (q, J = 6.9 Hz, 2H), 1.55 (t, J = 6.9 Hz, 3H); 13C NMR 
(CD3COCD3): 189.15, 157.30, 144.00, 141.75, 138.40, 136.30, 132.05, 131.45, 130.05, 127.55, 
123.80, 122.80, 122.10, 121.00, 117.30, 114.75, 113.00, 66.35, 16.10; MS (ESI): 325 (M+H)+. 
[5-(3-Ethoxyphenyl)-2-thienyl](3-hydroxyphenyl)methanone (10). The title compound 
was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-ethoxybenzene boronic acid (106 mg, 
0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) 
palladium (6 mg, 5 mmol) according to method A1. The product was purified by CC 
(hexane/ethyl acetate 8:2) followed by preparative TLC (hexane/ethyl acetate 7:3); yield: 91 % 
(157 mg, beige powder); 1H NMR (CD3COCD3): 8.80 (s, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.56 (d, 
J = 4.1 Hz, 1H), 7.41-7.34 (m, 4H), 7.32 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.28 (t, J = 2.1 Hz, 
1H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H), 6.96 (ddd, J = 1.3 Hz and J = 2.5 
Hz and J = 7.9 Hz, 1H), 4.11 (q, J = 6.9 Hz, 2H), 1.38 (t, J = 6.9 Hz, 3H); 13C NMR 
(CD3COCD3): 188.70, 161.55, 159.35, 154.20, 144.10, 141.25, 137.70, 136.35, 132.20, 131.55, 
126.40, 122.05, 121.20, 120.25, 117.25, 117.15, 113.90, 65.25, 16.05; MS (ESI): 325 (M+H)+. 
[5-(4-Ethoxyphenyl)-2-thienyl](3-hydroxyphenyl)methanone (11). The title compound 
was prepared by reaction of 1a (150 mg, 0.53 mmol), 4-ethoxybenzene boronic acid (106 mg, 
0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) 
palladium (6 mg, 5 mmol) according to method A1. The product was purified by CC 
(hexane/ethyl acetate 8:2); yield: 71 % (122 mg, beige powder); 1H NMR (CD3COCD3): 8.76 (s, 
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1H), 7.72 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 4.1 Hz, 1H), 7.45 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 7.8 
Hz, 1H), 7.35 (dt, J = 1.3 Hz and J = 7.8 Hz, 1H), 7.33-7.32 (m, 1H), 7.11 (ddd, J = 0.9 Hz and 
J = 2.5 Hz and J = 7.8 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 4.11 (q, J = 6.9 Hz, 2H), 1.38 (t, J = 
6.9 Hz, 3H); 13C NMR (CD3COCD3): 188.60, 162.00, 159.40, 154.75, 143.10, 141.45, 138.05, 
131.50, 129.45, 127.60, 125.00, 122.00, 121.05, 117.25, 117.00, 65.30, 16.00; MS (ESI): 325 
(M+H)+. 
{5-[3-(Benzyloxy)phenyl]-2-thienyl}(3-hydroxyphenyl)methanone (12). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-(benzyloxy)benzene boronic 
acid (146 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 8:2); yield: 71 % (146 mg, beige powder); 1H NMR 
(CD3COCD3): 8.76 (s, 1H), 7.70 (d, J = 4.1 Hz, 1H), 7.58 (d, J = 4.1 Hz, 1H), 7.52-7.51 (m, 
2H), 7.43-7.32 (m, 9H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H), 7.08 (ddd, J 
= 1.3 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H), 5.22 (s, 2H); 13C NMR (CD3COCD3): 188.70, 
161.40, 159.40, 154.10, 144.20, 141.25, 139.10, 137.75, 136.45, 132.30, 131.55, 130.30, 
129.70, 129.50, 126.50, 122.10, 121.25, 120.65, 117.65, 117.30, 114.35, 71.65; MS (ESI): 387 
(M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(2-methoxybenzyl)oxy]phenyl}-2-thienyl)methanone (13). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(2-
methoxybenzyl)oxy]benzene boronic acid (165 mg, 0.64 mmol), caesium carbonate (691 mg, 
2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method 
A1. The product was purified by CC (hexane/ethyl acetate 7:3); yield: 64 % (142 mg, beige 
powder); 1H NMR (CD3COCD3): 8.74 (s, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 
1H), 7.48 (m, 1H), 7.42-7.36 (m, 5H), 7.34-7.31 (m, 2H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz 
and J = 7.9 Hz, 1H), 7.08-7.04 (m, 2H), 6.97 (td, J = 1.3 Hz and J = 7.6 Hz, 1H), 5.21 (s, 2H), 
3.90 (s, 3H); 13C NMR (CD3COCD3): 188.75, 161.55, 159.40, 159.15, 154.20, 144.20, 141.30, 
137.75, 136.45, 132.30, 131.60, 131.15, 130.85, 126.95, 126.50, 122.30, 122.10, 121.25, 
120.55, 117.60, 117.30, 114.25, 112.55, 66.70, 56.95; MS (ESI): 417 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(3-methoxybenzyl)oxy]phenyl}-2-thienyl)methanone (14). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(3-
methoxybenzyl)oxy]benzene boronic acid (165 mg, 0.64 mmol), caesium carbonate (691 mg, 
2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method 
A1. The product was purified by CC (hexane/ethyl acetate 8:2); yield: 74 % (163 mg, beige 
powder); 1H NMR (CD3COCD3): 8.75 (s, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 
1H), 7.44-7.36 (m, 5H), 7.34-7.30 (m, 2H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 
1H), 7.10-7.08 (m, 3H), 6.91-6.89 (m, 1H), 5.21 (s, 2H), 3.81 (s, 3H); 13C NMR (CD3COCD3): 
188.75, 161.95, 161.40, 159.45, 154.10, 141.30, 140.70, 137.75, 136.50, 132.30, 131.60, 
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131.40, 126.55, 122.10, 121.55, 121.25, 120.70, 117.70, 117.30, 115.15, 115.00, 114.40, 71.55, 
56.55; MS (ESI): 417 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(4-methoxybenzyl)oxy]phenyl}-2-thienyl)methanone (15). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(4-
methoxybenzyl)oxy]benzene boronic acid (165 mg, 0.64 mmol), caesium carbonate (691 mg, 
2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method 
A1. The product was purified by CC (hexane/ethyl acetate 8:2); yield: 59 % (131 mg, beige 
powder); 1H NMR (CD3COCD3): 8.83 (s, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 
1H), 7.44 (d, J = 8.5 Hz, 2H), 7.41-7.36 (m, 5H), 7.34-7.33 (m, 1H), 7.13 (ddd, J = 1.3 Hz and J 
= 2.5 Hz and J = 7.9 Hz, 1H), 7.07 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 1H), 6.96 (d, 
J = 8.5 Hz, 2H), 5.14 (s, 2H), 3.80 (s, 3H); 13C NMR (CD3COCD3): 186.90, 181.65, 161.60, 
161.50, 159.40, 144.25, 141.30, 137.75, 136.45, 132.30, 131.60, 131.30, 131.00, 126.50, 
122.10, 121.25, 120.55, 117.75, 117.30, 115.75, 114.35, 71.50, 56.55; MS (ESI): 417 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(3,5-dimethoxybenzyl)oxy]phenyl}-2-thienyl)methanone (16). 
The title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(3,5-
dimethoxybenzyl)oxy]benzene boronic acid (184 mg, 0.64 mmol), caesium carbonate (691 mg, 
2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method 
A1. The product was purified by CC (hexane/ethyl acetate 8:2) followed by preparative HPLC; 
yield: 47 % (112 mg, beige powder); 1H NMR (CD3COCD3): 7.71 (d, J = 4.1 Hz, 1H), 7.59 (d, J 
= 4.1 Hz, 1H), 7.42-7.35 (m, 5H), 7.33-7.32 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J 
= 7.9 Hz, 1H), 7.09-7.06 (m, 1H), 6.68 (d, J = 2.2 Hz, 2H), 6.44 (t, J = 2.2 Hz, 1H), 5.17 (s, 
2H), 3.79 (s, 6H); 13C NMR (CD3COCD3): 188.80, 163.10, 161.35, 159.50, 154.10, 144.25, 
141.50, 141.25, 137.75, 136.45, 132.30, 131.55, 126.55, 122.00, 121.25, 120.65, 117.70, 
117.30, 114.40, 107.20, 101.35, 71.55, 56.65; MS (ESI): 447 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(2-chlorobenzyl)oxy]phenyl}-2-thienyl)methanone (17). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(2-
chlorobenzyl)oxy]benzene boronic acid (168 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 
mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. 
The product was purified by CC (hexane/ethyl acetate 8:2); yield: 51 % (113 mg, beige 
powder); 1H NMR (CD3COCD3): 8.78 (s, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.68-7.66 (m, 1H), 7.61 
(d, J = 4.1 Hz, 1H), 7.50-7.48 (m, 1H), 7.46-7.45 (m, 1H), 7.43-7.36 (m, 6H), 7.34-7.33 (m, 
1H), 7.14-7.10 (m, 2H), 5.31 (s, 2H); 13C NMR (CD3COCD3): 188.75, 161.20, 159.40, 153.95, 
144.30, 141.25, 137.75, 136.60, 136.55, 134.80, 132.40, 131.70, 131.55, 131.50, 131.30, 
129.15, 126.65, 122.10, 121.25, 121.00, 117.55, 117.30, 114.40, 69.10; MS (ESI): 421 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(3-chlorobenzyl)oxy]phenyl}-2-thienyl)methanone (18). The title 
compound was prepared by reaction of (5-bromo-2-thienyl)(3-hydroxyphenyl)methanone (1a) 
(150 mg, 0.53 mmol), 3-[(3-chlorobenzyl)oxy]benzene boronic acid (168 mg, 0.64 mmol), 
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caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 
mmol) according to method A1. The product was purified by CC (hexane/ethyl acetate 8:2); 
yield: 55 % (122 mg, beige powder); 1H NMR (CD3COCD3): 8.80 (s, 1H), 7.70 (d, J = 4.1 Hz, 
1H), 7.58 (d, J = 4.1 Hz, 1H), 7.57-7.56 (m, 1H), 7.48-7.46 (m, 1H), 7.43-7.34 (m, 8H), 7.13 
(ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 1H), 7.10-7.08 (m, 1H), 5.24 (s, 2H); 13C NMR 
(CD3COCD3): 188.75, 161.10, 159.40, 153.95, 144.25, 141.65, 141.25, 137.70, 136.50, 135.75, 
132.35, 132.05, 131.55, 129.70, 129.25, 127.75, 126.55, 122.05, 121.25, 120.85, 117.60, 
117.30, 114.35, 70.70; MS (ESI): 421 (M+H)+. 
(3-Hydroxyphenyl)(5-{3-[(4-chlorobenzyl)oxy]phenyl}-2-thienyl)methanone (19). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-[(4-
chlorobenzyl)oxy]benzene boronic acid (168 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 
mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. 
The product was purified by CC (hexane/ethyl acetate 8:2); yield: 63 % (141 mg, beige 
powder); 1H NMR (CD3COCD3): 8.76 (s, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.60 (d, J = 4.1 Hz, 
1H), 7.54 (d, J = 8.8 Hz, 2H), 7.45-7.38 (m, 6H), 7.37 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.34-
7.33 (m, 1H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 1H), 7.09-7.08 (m, 1H), 5.24 
(s, 2H); 13C NMR (CD3COCD3): 188.75, 161.20, 159.40, 154.00, 144.30, 141.25, 138.15, 
137.75, 136.50, 135.05, 132.35, 131.55, 131.20, 130.40, 126.55, 122.10, 121.25, 120.85, 
117.65, 117.30, 114.35, 70.85; MS (ESI): 421 (M+H)+. 
3-[5-(3-Methoxybenzoyl)-2-thienyl]benzonitrile (20a). The title compound was prepared 
by reaction of 1b (300 mg, 1.01 mmol), 3-cyanobenzene boronic acid (178 mg, 1.21 mmol), 
caesium carbonate (1.32 g, 4.04 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 
mmol) according to method A2. The product was purified by CC (hexane/ethyl acetate 9:1); 
yield: 88 % (282 mg, beige powder); 1H NMR (CDCl3): 7.95 (t, J = 1.6 Hz, 1H), 7.90-7.88 (m, 
1H), 7.67-7.64 (m, 2H), 7.55 (t, J = 7.9 Hz, 1H), 7.47 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.42 
(t, J = 7.9 Hz, 1H), 7.40-7.39 (m, 2H), 7.15 (ddd, J = 1.3 Hz and J = 2.8 Hz and J = 8.2 Hz, 1H), 
3.88 (s, 3H); 13C NMR (CDCl3): 187.50, 159.70, 149.70, 138.95, 135.65, 134.70, 132.05, 
130.45, 130.10, 129.55, 129.50, 125.00, 121.65, 118.80, 118.15, 113.80, 113.60, 55.50. 
3-[5-(3-Hydroxybenzoyl)-2-thienyl]benzonitrile (20). The title compound was prepared 
by reaction of 20a (282 mg, 0.88 mmol) and boron tribromide (2.64 mmol) according to method 
B. The product was purified by recrystallization (EtOH/acetonitrile); yield: 66 % (176 mg, beige 
powder); 1H NMR (CD3COCD3): 8.78 (s, 1H), 8.23 (t, J = 1.6 Hz, 1H), 8.12 (ddd, J = 0.9 Hz 
and J = 1.9 Hz and J = 7.9 Hz, 1H), 7.83-7.81 (m, 1H), 7.78-7.76 (m, 2H), 7.72 (td, J = 0.7 Hz 
and J = 7.9 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.40-7.38 (m, 1H), 7.36-7.35 (m, 1H), 7.14 (ddd, J 
= 1.6 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H); 13C NMR (CD3COCD3): 188.75, 151.25, 145.50, 
141.00, 140.70, 137.75, 136.45, 134.15, 132.40, 131.65, 131.30, 127.85, 122.15, 121.45, 
117.30, 115.35, 110.30; MS (ESI): 306 (M+H)+. 
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N-{3-[5-(3-Methoxybenzoyl)-2-thienyl]phenyl}methanesulfonamide (21a). The title 
compound was prepared by reaction of 1b (300 mg, 1.01 mmol), 3-
[(methylsulfonyl)amino]benzene boronic acid (178 mg, 1.21 mmol), caesium carbonate (1.32 g, 
4.04 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 mmol) according to method 
A2. The product was used in the next step without further purification; yield: 96 % (376 mg, 
beige powder); 1H NMR (CD3COCD3): 7.76 (t, J = 1.9 Hz, 1H), 7.70 (d, J = 4.1 Hz, 1H), 7.55-
7.52 (m, 2H), 7.48-7.43 (m, 3H), 7.41 (ddd, J = 0.9 Hz and J = 1.9 Hz and J = 7.9 Hz, 1H), 
7.38-7.37 (m, 1H), 7.21-7.19 (m, 1H), 3.87 (s, 3H), 3.07 (s, 3H); 13C NMR (CD3COCD3): 
188.60, 161.60, 153.60, 144.30, 141.40, 141.05, 137.90, 136.15, 131.45, 126.70, 123.70, 
123.05, 122.35, 120.05, 119.30, 115.50, 59.70, 40.65. 
N-{3-[5-(3-Hydroxybenzoyl)-2-thienyl]phenyl}methanesulfonamide (21). The title 
compound was prepared by reaction of 21a (200 mg, 0.52 mmol) and boron tribromide (1.56 
mmol) according to method B. The crude mixture was washed with MeOH. The resulted 
suspension was filtered and the precipitated product was evaporated to dryness; yield: 87 % 
(168 mg, beige powder); 1H NMR (CD3COCD3): 8.79 (s, 1H), 8.76 (s, 1H), 7.76 (t, J = 1.9 Hz, 
1H), 7.73 (d, J = 4.1 Hz, 1H), 7.60-7.57 (m, 2H), 7.48 (t, J = 7.9 Hz, 1H), 7.42-7.36 (m, 3H), 
7.34 (t, J = 1.9 Hz, 1H), 7.13 (ddd, J = 1.2 Hz and J = 2.5 Hz and J = 7.6 Hz, 1H), 3.07 (s, 3H); 
13C NMR (CD3COCD3): 188.75, 159.45, 153.50, 144.50, 141.45, 137.80, 132.30, 131.65, 
126.70, 122.35, 122.10, 121.30, 119.30, 117.30, 40.65; MS (ESI): 374 (M+H)+. 
N-{3-[5-(3-Methoxyphenyl)-2-thienyl]benzyl}methanesulfonamide (22a). The title 
compound was prepared by reaction of 1b (200 mg, 0.67 mmol), 3-
{[(methylsulfonyl)amino]methyl}benzene boronic acid (183 mg, 0.80 mmol), caesium 
carbonate (1.32 g, 4.04 mmol) and tetrakis(triphenylphosphine) palladium (12 mg, 10 mmol) 
according to method A2. The product was purified by CC (hexane/ethyl acetate 9:1); yield: 
94 % (253 mg, beige powder); 1H NMR (CD3COCD3): 7.87-7.86 (m, 1H), 7.75-7.72 (m, 1H), 
7.61 (d, J = 4.1 Hz, 1H), 7.51-7.45 (m, 4H), 7.39-7.38 (m, 1H), 7.22 (ddd, J = 1.6 Hz and J = 
2.5 Hz and J = 7.6 Hz, 1H), 7.42 (s, 1H), 7.41 (s, 1H), 3.90 (s, 3H), 2.92 (s, 3H); 13C NMR 
(CD3COCD3): 188.70, 161.75, 154.15, 144.20, 141.65, 138.00, 135.35, 131.55, 131.40, 130.55, 
127.45, 127.05, 126.55, 123.05, 120.10, 115.50, 56.85, 48.30, 41.60. 
N-{3-[5-(3-Hydroxybenzoyl)-2-thienyl]benzyl}methanesulfonamide (22). The title 
compound was prepared by reaction of 22a (253 mg, 0.63 mmol) and boron tribromide (1.89 
mmol) according to method B. The crude mixture was washed with MeOH. The resulted 
suspension was filtered and the precipitated product was evaporated to dryness; yield: 81 % 
(197 mg, beige powder); 1H NMR (CD3COCD3): 8.76 (s, 1H), 7.86 (s, 1H), 7.75-7.72 (m, 2H), 
7.62 (d, J = 4.0 Hz, 4H), 7.50-7.48 (m, 2H), 7.41 (t, J = 7.8 Hz, 1H), 7.37 (dt, J = 1.4 Hz and J 
= 7.6 Hz, 1H), 7.34-7.33 (m, 1H), 7.13 (ddd, J = 1.2 Hz and J = 2.4 Hz and J = 7.6 Hz, 1H), 
6.61 (s, 1H), 4.41 (s, 1H), 4.40 (s, 1H), 2.92 (s, 3H); 13C NMR (CD3COCD3): 188.75, 159.45, 
3.4 INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 111 
 
 
154.00, 144.30, 141.65, 141.25, 137.85, 135.35, 131.60, 131.40, 130.50, 127.45, 127.05, 
126.50, 122.10, 121.25, 117.25, 48.30, 41.55; MS (ESI): 388 (M+H)+. 
N-{3-[5-(3-Hydroxybenzoyl)-2-thienyl]phenyl}-4-methylbenzenesulfonamide (23). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 3-{[(4-
methylphenyl)sulfonyl]amino}benzene boronic acid (239 mg, 0.64 mmol), caesium carbonate 
(691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to 
method A1. The crude mixture was washed with MeOH. The resulted suspension was filtered 
and the precipitated product was evaporated to dryness.; yield: 53 % (126 mg, beige powder); 
1H NMR (CD3COCD3): 7.75 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 4.1 Hz, 1H), 7.62 (t, J = 1.8 Hz, 
1H), 7.50-7.48 (m, 2H), 7.40 (t, J = 7.6 Hz, 1H), 7.38-7.32 (m, 5H), 7.27 (ddd, J = 0.9 Hz and J 
= 2.2 Hz and J = 8.2 Hz, 1H), 7.13 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 1H), 2.35 (s, 
3H); 13C NMR (CD3COCD3): 188.70, 159.45, 153.40, 145.75, 144.45, 141.20, 140.95, 138.85, 
137.80, 136.05, 132.10, 131.60, 131.55, 129.05, 126.60, 123.80, 122.70, 122.05, 121.30, 
119.55, 117.30, 22.35; MS (ESI): 450 (M+H)+. 
(3-Hydroxyphenyl)[5-(2-naphthyl)-2-thienyl]methanone (24). The title compound was 
prepared by reaction of 1a (150 mg, 0.53 mmol), 2-naphthaleneboronic acid (110 mg, 0.64 
mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 
mg, 5 mmol) according to method A1. The product was purified by CC (hexane/ethyl acetate 
8:2); yield: 57 % (100 mg, yellow powder); 1H NMR (CD3COCD3): 8.86 (s, 1H), 8.36 (s, 1H), 
8.03-8.00 (m, 2H), 7.95-7.91 (m, 2H), 7.76 (d, J = 4.1 Hz, 1H), 7.74 (d, J = 4.1 Hz, 1H), 7.59-
7.54 (m, 2H), 7.42 (t, J = 7.6 Hz, 1H), 7.39 (dt, J = 1.5 Hz and J = 7.6 Hz, 1H), 7.37-7.36 (m, 
1H), 7.15-7.13 (m, 1H); 13C NMR (CD3COCD3): 188.75, 159.45, 154.30, 144.35, 141.30, 
137.95, 135.55, 131.60, 130.90, 130.30, 129.65, 128.85, 128.80, 127.05, 126.70, 125.80, 
122.05, 121.25, 117.30; MS (ESI): 331 (M+H)+. 
[5-(2,3-Dihydro-1-benzofuran-5-yl)-2-thienyl](3-hydroxyphenyl)methanone (25). The 
title compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 2,3-dihydro-1-benzofuran-
5-boronic acid (105 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 7:3); yield: 65 % (111 mg, yellow powder); 1H NMR 
(CD3COCD3): 7.67-7.66 (m, 2H), 7.57-7.55 (m, 1H), 7.44 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 7.8 
Hz, 1H), 7.35 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.32-7.31 (m, 1H), 7.11 (ddd, J = 1.3 Hz and 
J = 2.5 Hz and J = 7.9 Hz, 1H), 6.82 (d, J = 8.5 Hz, 1H), 4.63 (t, J = 8.8 Hz, 2H), 3.29 (t, J = 8.8 
Hz, 2H); 13C NMR (CD3COCD3): 188.55, 159.35, 141.55, 138.05, 131.50, 130.85, 128.40, 
127.80, 125.05, 124.80, 122.00, 121.00, 117.20, 111.45, 73.55, 73.50; MS (ESI): 323 (M+H)+. 
[5-(1,3-Benzodioxol-5-yl)-2-thienyl](3-hydroxyphenyl)methanone (26). The title 
compound was prepared by reaction of 1a (150 mg, 0.53 mmol), 1,3-benzodioxole-5-boronic 
acid (106 mg, 0.64 mmol), caesium carbonate (691 mg, 2.12 mmol) and 
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tetrakis(triphenylphosphine) palladium (6 mg, 5 mmol) according to method A1. The product 
was purified by CC (hexane/ethyl acetate 8:2); yield: 70 % (120 mg, yellow powder); 1H NMR 
(CD3COCD3): 8.76 (s, 1H), 7.66 (d, J = 4.1 Hz, 1H), 7.46 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 7.8 
Hz, 1H), 7.35 (dt, J = 1.3 Hz and J = 7.6 Hz, 1H), 7.33-7.32 (m, 1H), 7.30 (ddd, J = 0.6 Hz and 
J = 1.9 Hz and J = 8.2 Hz, 1H), 7.28-7.27 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 
7.9 Hz, 1H), 6.93 (d, J = 7.9 Hz, 1H), 6.08 (s, 2H); 13C NMR (CD3COCD3): 188.60, 159.40, 
154.40, 150.55, 143.35, 141.35, 137.90, 131.55, 129.35, 125.60, 122.35, 122.05, 121.15, 
117.25, 110.65, 108.15, 103.70; MS (ESI): 325 (M+H)+. 
(3-Hydroxyphenyl)[5-(1H-indol-5-yl)-2-thienyl]methanone (27). The title compound was 
prepared by reaction of 1a (150 mg, 0.53 mmol), indol-5-boronic acid (103 mg, 0.64 mmol), 
caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 
mmol) according to method A1. The product was purified by CC (hexane/ethyl acetate 7:3); 
yield: 47 % (80 mg, yellow powder); 1H NMR (CD3COCD3): 10.46 (s, 1H), 8.70 (s, 1H), 7.90-
7.89 (m, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 4.1 Hz, 1H), 7.49 
(dd, J = 1.5 Hz and J = 8.2 Hz, 1H), 7.46-7.45 (m, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.36 (dt, J = 1.5 
Hz and J = 7.6 Hz, 1H), 7.34-7.33 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 Hz and J = 7.9 Hz, 
1H), 6.54-6.53 (m, 1H); 13C NMR (CD3COCD3): 186.40, 159.40, 138.10, 137.50, 131.50, 
128.95, 125.05, 122.85, 122.00, 121.00, 119.80, 117.25, 111.10, 103.85; MS (ESI): 320 
(M+H)+. 
(3-Hydroxyphenyl)[5-(1H-indol-6-yl)-2-thienyl]methanone (28). The title compound was 
prepared by reaction of 1a (150 mg, 0.53 mmol), indol-6-boronic acid (103 mg, 0.64 mmol), 
caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 mg, 5 
mmol) according to method A1. The product was purified by CC (hexane/ethyl acetate 7:3); 
yield: 49 % (83 mg, yellow powder); 1H NMR (CD3COCD3): 10.48 (s, 1H), 8.77 (s, 1H), 7.90-
7.89 (m, 1H), 7.69 (d, J = 4.1 Hz, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 4.1 Hz, 1H), 7.49 
(dd, J = 1.5 Hz and J = 8.2 Hz, 1H), 7.45-7.44 (m, 1H), 7.40 (td, J = 0.6 Hz and J = 7.6 Hz, 1H), 
7.36 (dt, J = 1.5 Hz and J = 7.6 Hz, 1H), 7.34-7.33 (m, 1H), 7.12 (ddd, J = 1.3 Hz and J = 2.5 
Hz and J = 7.9 Hz, 1H), 6.54-6.53 (m, 1H); 13C NMR (CD3COCD3): 188.60, 159.40, 156.90, 
142.85, 141.60, 138.50, 138.10, 131.50, 131.15, 128.95, 128.45, 125.05, 122.85, 122.00, 
121.00, 119.80, 117.25, 111.10, 103.80; MS (ESI): 320 (M+H)+. 
(3-Hydroxyphenyl)[5-(2H-indazol-5-yl)-2-thienyl]methanone (29). The title compound 
was prepared by reaction of 1a (150 mg, 0.53 mmol), 2H-indazole-5-boronic acid (104 mg, 0.64 
mmol), caesium carbonate (691 mg, 2.12 mmol) and tetrakis(triphenylphosphine) palladium (6 
mg, 5 mmol) according to method A2 refluxing the mixture for 14 h instead of 4 h. The product 
was purified by CC (hexane/ethyl acetate 6:4); yield: 75 % (127 mg, yellow powder); 1H NMR 
(CD3SOCD3): 13.27 (s, 1H), 9.87 (s, 1H), 8.24 (s, 1H), 8.17 (s, 1H), 7.79 (dd, J = 1.5 Hz and J 
= 8.5 Hz, 1H), 7.71 (d, J = 4.1 Hz, 1H), 7.66-7.63 (m, 2H), 7.38 (t, J = 7.9 Hz, 1H), 7.28 (dt, J = 
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1.3 Hz and J = 7.9 Hz, 1H), 7.22-7.21 (m, 1H), 7.06 (ddd, J = 0.9 Hz and J = 2.5 Hz and J = 7.9 
Hz, 1H); 13C NMR (CD3SOCD3): 186.60, 179.45, 157.35, 153.20, 140.45, 139.85, 138.65, 
136.65, 134.35, 129.70, 125.10, 124.65, 124.15, 123.25, 119.50, 118.35, 115.05, 111.05; MS 
(ESI): 321 (M+H)+. 
 
Biology. [2, 4, 6, 7-3H]-E2 and [2, 4, 6, 7-3H]-E1 were bought from Perkin Elmer (Boston, 
USA). Quickszint Flow 302 scintillator fluid was bought from Zinsser Analytic (Frankfurt, 
Germany).17β-HSD1 and 17β-HSD2 were obtained from human placenta according to 
previously described procedures.[49] Fresh human placenta was homogenized and cytosolic 
fraction and microsomes were separated by centrifugation. For the partial purification of 17β-
HSD1, the cytosolic fraction was precipitated with ammonium sulfate. 17β-HSD2 was obtained 
from the microsomal fraction. For the use of human placenta, informed consent was obtained 
from the parturient. 
Inhibition of 17β-HSD1: Inhibitory activities were evaluated by an established method 
with minor modifications. Briefly, the enzyme preparation was incubated with NADH [500 µM] 
in the presence of potential inhibitors at 37 °C in a phosphate buffer (50 mM) supplemented 
with 20 % of glycerol and EDTA (1mM). Inhibitor stock solutions were prepared in DMSO. 
The final concentration of DMSO was adjusted to 1 % in all samples. The enzymatic reaction 
was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]-E1 (final concentration: 
500 nM, 0.15 mCi). After 10 min, the incubation was stopped with HgCl2 and the mixture was 
extracted with diethylether. After evaporation, the steroids were dissolved in acetonitrile. E1 
and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 reverse phase 
chromatography column (Nucleodur C18 Gravity, 3 µm, Macherey-Nagel, Düren, Germany) 
connected to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn, 
Germany). Detection and quantification of the steroids were performed using a radioflow 
detector (Berthold Technologies, Bad Wildbad, Germany). The conversion rate was calculated 
after analysis of the resulting chromatograms according to the following equation: 
100
1%2%
2%% ×
+
=
EE
Econversion
. Each value was calculated from at least three independent 
experiments.  
Inhibition of 17β-HSD2: The 17β-HSD2 inhibition assay was performed similarly to the 
17β-HSD1 procedure. The microsomal fraction was incubated with NAD+ [1500 µM], test 
compound and a mixture of unlabelled- and [2, 4, 6, 7-3H]-E2 (final concentration: 500 nM, 
0.11 mCi) for 20 min at 37 °C. Further treatment of the samples and HPLC separation was 
carried out as mentioned above. The conversion rate was calculated after analysis of the 
resulting chromatograms according to the following equation: 1002%1%
1%% ×
+
=
EE
Econversion . 
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ER-affinity: The binding affinity of selected compounds to the ERα and ERβ was 
determined according to Zimmermann et al. Briefly, 0.25 pmol of ERα or ERβ, respectively, 
were incubated with [2, 4, 6, 7-3H]-E2 (10 nM) and test compound for 1 h at room temperature. 
The potential inhibitors were dissolved in DMSO (5 % final concentration). Evaluation of non-
specific-binding was performed with diethylstilbestrol (10 µM). After incubation, ligand-
receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL TE-buffer). The 
complex formed was separated, washed and resuspended in ethanol. For radiodetection, 
scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt, Germany) was added and 
samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku, 
Finland). For determination of the relative binding affinity (RBA), inhibitor and E2 
concentrations required to displace 50 % of the receptor bound labeled E2 were determined. 
RBA values were calculated according to the following equation:
100
)(
)2([%]
50
50 ×=
compoundIC
EICRBA
. 
The RBA value for E2 was set at 100 %. 
Inhibition of 17β-HSD1 in T47D cells: A stock culture of T47D cells was grown in RPMI 
1640 medium supplemented with 10 % FCS, L-glutamine (2 mM), penicillin (100 IU/mL), 
streptomycin (100 µg/mL), insulin-zinc-salt (10 µg/mL) and sodium pyruvate (1 mM) at 37 °C 
under 5 % CO2 humidified atmosphere. The cells were seeded into a 24-well plate at 1x106 
cells/well in DMEM medium with FCS, L-glutamine and the antibiotics added in the same 
concentrations as mentioned above. After 24 h the medium was changed for fresh serum free 
DMEM and a solution of test compound in DMSO was added. Final concentration of DMSO 
was adjusted to 1 % in all samples. After a pre-incubation of 30 min at 37 °C with 5 % CO2, the 
incubation was started by addition of a mixture of unlabelled- and [2, 4, 6, 7-3H]- E1 (final 
concentration : 50 nM, 0.15 mCi). After 0.5 h incubation, the enzymatic reaction was stopped 
by removing of the supernatant medium. The steroids were extracted with diethylether. Further 
treatment of the samples was carried out as mentioned for the 17β-HSD1 assay. 
Metabolic stability: Human liver microsomes (final protein concentration 0.5 mg/mL), 0.1 
M phosphate buffer pH 7.4 and test compound (final substrate concentration = 3 µM; final 
DMSO concentration = 0.25 %) were preincubated at 37 °C prior to the addition of NADPH 
(final concentration = 1 mM) to initiate the reaction. Dextrometorphan and verapamil were used 
as references. All incubations were performed singularly for each test compound. Each 
compound was incubated for 0, 5, 15, 30 and 45 min (control: 45 min). The reactions were 
stopped by the addition of 50 µL methanol containing internal standard at the appropriate time 
points. The incubation plates were centrifuged at 2,000 rpm for 20 min at 4 °C to precipitate the 
protein. The sample supernatants were combined in cassettes of up to 4 compounds and 
analyzed using LC-MS/MS. 
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Molecular Modeling: Docking studies were performed using the AutoDock4.2[56] program. 
Atomic coordinates of 17β-HSD1 were derived from the structure of the ternary complex 17β-
HSD1, NADP+ and E2 (PDB-ID: 1FDT (conformation B for residues 187-200)). The crystal 
structure was energy minimized with MOE2009.10 (Chemical Computing Group Inc., 
Montreal, Canada) applying the AMBER99 force field and generalized Born model, keeping the 
coordinates of backbone atoms fixed. Ligand structures were built, assigned AM1-BCC charges, 
and minimized in MOE with the MMFF94x force field. The 17β-HSD1 x-ray structure and 
ligand structures were prepared for docking studies through the graphical user interface 
AutoDockTools1.5.4.[56] For the ligands, nonpolar hydrogen atoms were deleted, rotatable 
bonds were defined and AM1-BCC charges kept. For the protein, non-polar hydrogen atoms 
were deleted and charges were added to the structure. The docking area has been defined by a 
box, centered on the steroid binding site. Grid points of 90 x 90 x 90 with 0.250 Å spacing were 
calculated around the docking area for all the ligand atom types using AutoGrid4.2. For each 
inhibitor, 50 separate docking calculations were performed. Each docking calculation consisted 
of 25x105 energy evaluations using the Lamarckian genetic algorithm local search (GALS) 
method. Each docking run was performed with a population size of 250. A mutation rate of 0.02 
and a crossover rate of 0.8 were used to generate new docking trials for subsequent generations. 
The docking results from each of the 50 calculations were clustered on the basis of root-mean-
square deviation (RMSD = 2.0 Å) between the Cartesian coordinates of the ligand atoms and 
were ranked on the basis of the free binding energy. 
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4 Final Discussion 
Exploiting all the available information on the system under study is characteristic for a rational 
drug design approach that is able to organize drug discovery more successful. Thus, the aim of 
the present study was to increase the body of knowledge of protein-ligand interactions and 
active site topologies to advance drug discovery at different stages: (1) hit identification, 
characterization and optimization in case of PqsR and (2) lead optimization in case of 17β-
HSD1. 
One major goal of this work was to discover low molecular weight compounds targeting the 
P. aeruginosa transcriptional regulator PqsR. In doing so, we followed a rational design 
strategy, which was based on the κ-opioid receptor agonist I/1† and is described in chapter 3.1. 
The latter was subjected to fragmentation into smaller pieces and analogs and the resulting 
library was screened for affinity toward PqsR in a SPR biosensor assay to map out different 
pharmacophoric elements required for high-affinity binding. Fragment-based drug discovery is 
considered as a promising strategy to address antibacterial discovery issues that are namely: (1) 
the lack of chemical diversity compatible with novel anti-bacterial targets (Mochalkin et al., 
2009) and (2) the fact that the physicochemical properties, which are required to penetrate into 
the bacterial cytoplasm are considerably different from those needed for eukaryotic drug 
discovery (O'Shea and Moser, 2008). These are also two possible explanations why the high 
expectations of discovering novel antibacterial drugs employing high-throughput screening 
strategies with very large synthetic or natural product compound libraries have not met with 
success (Mochalkin et al., 2009). Some antibiotic natural products may have been naturally 
selected to possess desirable antibacterial properties, however, the absence of desirable drug-
like properties and the low tractability for medicinal chemistry lead optimization efforts makes 
it difficult to use them as drugs. Another advantage of fragment-based design compared to 
conventional screening attempts is the number of screened compounds. In a fragment screening 
typically several thousand compounds are evaluated while a conventional screening assesses a 
million or more compounds (Hajduk and Greer, 2007). Besides the mentioned pros of screening 
small molecules an important issue is the usually low binding affinity (Waldrop, 2009). But LE, 
which is the ratio of free binding affinity to the number of heavy atoms, normalizes affinity and 
molecular size of a compound and therefore it is a valuable tool for effective hit selection. In the 
present study, it was successfully applied and led among other candidates to the identification of 
the most promising hit I/4 (LE=0.63 kcal/mol). The latter also showed antagonistic activity in a 
heterologous reporter gene assay in E. coli highlighting its potential for further optimization. 
                                                            
†  For the sake of clarity, all compounds that are referred to in chapter 4 are characterized by a Roman numeral I–IV to identify the 
paper in which they are published, and an Arabic numeral that is identical with the corresponding compound number of the 
particular publication (e.g., I/1 is compound 1 from paper I) 
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Using E. coli for initial investigation of functionality allows to evaluate agonistic and 
antagonistic activities independent of the entire pqs system present in P. aeruginosa (Fletcher et 
al., 2007). Further, P. aeruginosa is characterized by a synergy between drug efflux pumps with 
broad substrate specificity and low outer membrane permeability (Ma et al., 1994) that would 
impede the analysis of structure-functional activity relationships for compounds, which have 
insufficient physicochemical properties to penetrate into the P. aeruginosa cytoplasm. However, 
especially due to the higher bar for getting small molecules into P. aeruginosa it is crucial to 
investigate, at least for the most active compounds, whether they also work in a P. aeruginosa 
background. 
During the optimization of compound I/4, it has been observed that the introduction of an 
alkyl chain in the para-position of the benzamide core and its stepwise enlargement led to a 
gradual increase in affinity (compounds I/6-I/9). Interestingly, the rising affinity in this series is 
due to incremental more favorable enthalpic contributions. This finding is an indication that the 
alkyl chain contributes to ligand binding via specific non-covalent interactions and that the 
enlarged affinity is not just because of hydrophobic effects. Otherwise, increasing entropic 
contributions would have reflected it. As shown in Table 1, the latter is clearly not the case and 
the entropic contribution becomes rather more unfavorable in the course of expanding the alkyl 
residue.  
Table 1. Thermodynamic parameters of ligands I/6-I/9 binding to PqsR. 
 
 
Ligand R KD 
[µM] 
ΔG 
[kcal mol-1] 
ΔH 
[kcal mol-1] 
-TΔS 
[kcal mol-1] 
6 Me 31.2±3.4 -6.1±0.1 -2.2±0.1 -3.9±0.1 
7 Et 7.3±0.6 -7.0±0.1 -4.6±0.3 -2.4±0.3 
8 iPr 3.0±0.4 -7.5±0.1 -6.3±0.3 -1.3±0.4 
9 tBu 0.9±0 -8.3±0 -9.7±0.3 1.5±0.3 
ITC titrations were performed at 298 K. Data represent mean ± SD from at least three independent experiments. 
Negatively correlated ΔH and -TΔS changes are often observed in protein ligand interactions. 
This ubiquitous phenomenon is termed as enthalpy-entropy compensation and it arises from the 
structuring of protein regions by newly formed hydrogen bonds or other polar interactions, 
resulting in a loss in conformational entropy (Ladbury et al., 2010). This trend becomes 
particularly evident when plotting the ΔH valus versus the -TΔS values (Figure 15) revealing a 
reasonable linear correlation (r2 = 0.9573, n = 9). In this context, ITC is a powerful method that 
allows improving our understanding of the enthalpic and entropic contributions to binding. 
NH2
O
R
I/6-I/9
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Figure 15. Plot of enthalpy (ΔH) vs entropy (-TΔS) for the investigated compounds I/1, I/4, and 
I/6-I/12.  
To understand these interesting results on the molecular basis, site-directed mutagenesis was 
employed in combination with ITC. Compared to the wild-type, I/9 binds to F221A mutant 
PqsR with a significant loss in ΔH (7.6 kcal/mol; Figure 16a) demonstrating that this amino acid 
is involved in a specific interaction, such as a CH/π hydrogen bond. The latter has its origin in 
dispersion forces, which have an impact on the enthalpic term of free energy (Ramírez-Gualito 
et al., 2009). A salient feature of the CH/π hydrogen bond is that it works cooperatively and for 
cases involving aliphatic CH groups as the hydrogen donor, the energy of a CH/π hydrogen 
bond is between -1.5 and -2.5 kcal/mol (Nishio, 2011). This indicates that Phe221 might form 
three CH/π bonds with the tBu-moiety of I/9 (Figure 16b) as described for the interaction of 
benzene with isobutane (Ran and Wong, 2006). 
 
Figure 16. a) Thermodynamic profiles determined by ITC for the binding of ligand I/9 to wild-
type and F221A mutant PqsR. b) Proposed interactions between I/9 and PqsR.                         
c) Thermodynamic profiles determined by ITC for the binding of ligand I/9 to wild-type and 
Q194A mutant PqsR. Hydrogen bonds are represented in red dashed lines.  
Interestingly, for the interaction of I/9 with the Q194A mutant also a loss in ΔH (4.4 kcal/mol; 
Figure 16c) was observed. Considering that a well-placed H-bond can make a favorable 
enthalpic contribution in the order of -4 to -5 kcal/mol (Freire, 2008), the results suggest that 
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Gln194 forms a H-bond with the amide function of I/9 as shown in Figure 16b. Hence, 
thermodynamic analysis particularly in combination with site-directed mutagenesis provides a 
valuable tool to investigate protein-ligand interactions. 
A further interesting observation made during this study was that the replacement of the 
amide in I/9 and I/7, which showed agonistic and antagonistic activity, by a hydroxamic acid 
(compounds I/11 and I/12) led to pure antagonists. Probably, the introduced OH group makes 
additional interactions that favour antagonism or it leads to a slight shift of the hydroxamic acid-
derived ligands in the effector binding site. The latter could result in the formation of new 
interactions that promote antagonistic activity or in the loss of interactions that are essential for 
agonistic activity. However, the presence of a H-bond between the hydroxamic acid I/11 and 
Gln194 is substantiated by the thermodynamic data. This finding led us to the conclusion that 
Gln194 is no key player in determining between agonistic and antagonistic activity. 
Despite the higher bar for getting small molecules into P. aeruginosa the antagonistic 
activity of I/11 could be confirmed (IC50 in E. coli = 12.5 µM vs. IC50 in P. aeruginosa = 23.6 
µM). Additionally, I/11 was able to reduce the production of the virulence factor pyocyanin in 
P. aeruginosa (IC50 = 87.2 µM). These encouraging findings confirmed that fragment-based 
design is a proper strategy to handle physicochemical property issues. Probably, the penetration 
of the small hydrophilic hydroxamic acid I/11 (MW=193.11 g/mol; logP = 2.1) across the outer 
membrane exceeds its efflux or the antagonist I/11 is no substrate of the efflux pumps.  
In summary, through application of rational design and biophysical methods, we developed 
to the best of our knowledge the first small-molecule PqsR ligands. LEs and functional 
properties were used to guide the elaboration process that resulted in the potent hydroxamic 
acid-derived PqsR antagonist I/11. Compared to the recently described HHQ analogues (Lu et 
al., 2012) compound I/11 is a less potent antagonist but, as a consequence of its low molecular 
weight and its activity in P. aeruginosa, it has a high potential for further optimization. 
However, due to its ability to chelate metal ions the hydroxamic acids could impede bacterial 
iron utilization causing bacteriostasis. As this would counterwork the concept of quorum 
sensing inhibition, hit to lead optimization should address the replacement of this functional 
group. Site-directed mutagenesis together with thermodynamic analysis disclosed that Gln194 
and Phe221 are involved in ligand binding, probably by making hydrogen bonds and CH/π 
interactions, respectively. Though, the molecular basis of agonism and antagonism is still not 
understood and future experiments should tackle these questions. 
Structural information and thermodynamic parameters or their accordant efficiency indices 
can be used to guide fragment progressing that includes three main strategies: linking, growing, 
and merging (Schulz and Hubbard, 2009). Besides the thermodynamic and functional 
characterization of the screening hits II/1-II/5 towards PqsR chapter 3.2 describes the 
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application of site-directed mutagenesis, structure modifications, and calorimetric analysis to 
study PqsR-ligand interactions and to estimate the covered space in the binding pocket.  
The efficiency index that includes affinity is LE. The latter plays an important role in 
selecting candidates that will undergo hit-to-lead optimization but it can also be used as a 
quantitative measure of effective fragment elaboration. LE values > 0.33 kcal/mol are desirable 
(Hopkins et al., 2004) and it is important to begin with a fragment above this threshold, 
regardless of absolute potency or molecular weight. Because efficiency remains constant 
throughout lead optimization, beginning with a suboptimal fragment lead can frustrate 
subsequent optimization efforts, especially when trying to balance multiple properties such as 
solubility, permeability, and stability. A drop in LE of more than 10% during fragment 
elaboration is likely an indication that either the site or the nature of the modification is not 
ideal, even if modest gains in potency are achieved (Hajduk, 2006). The enthalpic contribution 
is also often used for decision-making in hit selection and enthalpy driven binders are rather 
taken on the next optimization level than entropy driven binders for three major reasons: (1) it is 
harder to improve the ΔH contribution than to improve the ΔS contribution; (2) enthalpy steered 
interactions such as hydrogen bonds are more specific than entropy driven hydrophobic 
contacts, thus the optimization of enthalpic binders will reduce the risk of unspecific binding to 
off-target proteins, which is often associated with unwanted side-effects; (3) increasing the 
entropic contribution is accompanied by increasing hydrophobicity and therefore the 
improvement is limited by the compounds solubility (Ladbury et al., 2010). Based on these 
criteria the screening hits II/1-II/5 are appropriate candidates for optimization: LEs range from 
0.35 to 0.85 kcal/mol and all compounds show enthalpy driven binding. 
Table 2. Effect of point mutations on the thermodynamic parameters of ligands II/C, II/1, II/2. 
 
 
 
 Q194A F221A 
Ligand ΔΔG 
[kcal mol-1] 
ΔΔH  
[kcal mol-1] 
-TΔΔS 
[kcal mol-1] 
ΔΔG 
[kcal mol-1] 
ΔΔH 
[kcal mol-1] 
-TΔΔS 
[kcal mol-1] 
II/C -1.3±0☆ -4.4±0.3☆ 3.1±0.3☆ -1.0±0.1☆ -7.6±0.3☆ 6.6±0.4☆ 
II/1 -1.1±0.1☆ -3.2±0.2☆ 2.1±0.2☆ -0.4±0.1★ -7.1±0.2☆ 6.7±0.2☆ 
II/2 -0.6±0.1☆ -0.3±0.6 -0.3±0.7 -0.6±0.1☆ -7.1±0.5☆ 6.5±0.6☆ 
ΔΔG, ΔΔH, and –TΔΔS are ΔGWT – ΔGmutant, ΔHWT – ΔHmutant, and –T(ΔSWT – ΔSmutant), respectively. Negative values 
indicate a loss; positive values, a gain compared to wild-type. Errors indicate SD calculated via Gaussian error 
propagation. Significance: effect of the point mutation on the thermodynamic parameters of ligand binding compared to 
the wild-type. ☆ p < 0.003; ★ p < 0.05. 
O
NH2
II/C
NN
O NH2
F3C
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II/1 II/2
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Structural information has successfully been applied in numerous fragment-based lead 
discovery campaigns to guide optimization (Schulz and Hubbard, 2009). In this subproject, site-
directed mutagenesis in combination with thermodynamic analysis was applied to investigate 
the space in the binding pocket that is covered by the ligands II/1 and II/2 (Table 2). Of the 
identified hits, the latter looked the most promising with respect to the above descibed criteria as 
well as functionality that is a further key feature in decision-making. Just like observed for 
compound II/C, Phe221 and Gln194 are also involved in the binding of II/1. Due to the 
structural similarity between these two compounds this finding is not wondrous and it can be 
assumed that II/1 binds in a similar orientation: the naphthalene core takes part in a π-π 
interaction with Phe221 and the amide makes an H-bond with Gln194 (Figure 17a). 
 
Figure 17. Hypothetical binding modes of compounds II/1 and II/2. a) Overlay of the proposed 
binding modes of II/C (grey) and II/1 (blue) in the PqsR effector binding site. b) Overlay of the 
proposed binding modes of II/C (grey) and II/2 (orange) in the PqsR effector binding site. 
Hydrogen bonds are represented in red dashed lines. For the sake of clarity π-π-interactions 
are not depicted. 
Thermodynamic analysis revealed that only Phe221 is involved in the binding of the oxadiazole 
II/2 but competition experiments confirmed that it occupies the same site as II/C. These 
interesting findings can be rationalized on the proposed binding mode of II/2, which is depicted 
in Figure 17b. Possibly, the phenyl moiety of 2 makes a π-π interaction with F221 that is 
favored by the presence of the electron withdrawing CF3-substituent (Lewis et al., 2012). 
Oxadiazoles are often used as replacements for carbonyl containing compounds such as esters, 
amides, and hydroxamic acids and the two nitrogen atoms in the 1,3,4-isomers are described to 
be very favorable hydrogen bond acceptors (Boström et al., 2012). However, in this case the 
oxadiazole ring of II/2 is not able to take over the H-bond acceptor ability of the carbonyl 
oxygen of II/C to interact with Gln194, as shown by the thermodynamic data (Table 2). Most 
likely, this is caused by an inappropriate geometrical orientation (distance, angle) of II/2 in the 
binding site. The fact that II/2 is a pure and potent PqsR antagonist, which does not interact 
with Gln194 underpins the above stated hypothesis that Gln194 is not important for antagonism. 
The combination of site-directed mutagenesis with thermodynamic analysis has led to the 
identification of fragments with different scaffolds (II/C and II/2) that bind to the same site but 
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do not occupy exactly the same space. Thus, the gained structural information can be used to 
elaborate them by growing or merging while an attempt to link both fragments can be excluded. 
Accordingly, the here-applied approach to preserve structural information is a valuable strategy 
to direct fragment progressing. However, it is limited to the ability of identifying binding sites 
and interacting amino acids but it does not deliver a detailed structure of the protein-fragment 
complex including the targetable amino acids, which can be used to identify how and where to 
grow or modify the fragment. Crystallization of the complexes is a reliable method to obtain 
such information. 
In the present study, ITC was also employed to derive and understand SAR. It was found 
that the CF3 moiety plays an important role for the binding of II/2. Replacing it by a methyl 
group (compound II/6) reduced the affinity toward PqsR (II/6, KD = 12.4 µM vs. II/2, KD = 1.3 
µM) as result of a significant loss in ΔH of 4.4 kcal/mol (Figure 18). 
 
 
Figure 18. Relative thermodynamic contributions of functional groups to PqsR binding. ΔΔG, 
ΔΔH, and –TΔΔS are ΔGII/2 – ΔGII/6; II/7, ΔHII/2 – ΔHII/6; II/7, and –T(ΔS2 – ΔS6/7), respectively. 
Negative values indicate a loss; positive values, a gain compared to compound 2. Errors 
indicate SD calculated via Gaussian error propagation. Significance: thermodynamic 
contribution of the functional group on the binding of 2 to PqsR. ☆ p < 0.003; ★ p < 0.05. 
This finding is in accordance with the hypothetical binding mode of II/2 proposing a π-π 
interaction between the phenyl ring of II/2 and Phe221 (Figure 17a). Electron withdrawing 
substituents such as CF3 promote π-π interactions while the introduction of electron-donating 
groups such as alkyl moieties are predicted to induce ever more unfavorable effects on π-π 
interactions. The latter can be attributed to repulsion of the increasingly negative electron 
densities forming on the aromatic centre (Lewis et al., 2012).  
In comparison to II/2 (KD = 1.3 µM) compound II/7 (KD = 6.5 µM), which does not have an 
amino group in 2-position of the oxadiazole ring, shows a lower binding affinity. But what is 
even more important is the fact, that the enthalpic contribution is rather constant for both ligands 
(Figure 18). Thus, it can be assumed that the amino group of II/2 is not involved in a specific 
interaction like an H-bond. This interesting observation would not have been made using 
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different technologies or assay formats monitoring only affinity. In view of that, ITC, which 
allows dissecting free energy of binding into its enthalpic and entropic contributions, is a helpful 
tool to to analyze and understand SAR. The low throughput and the high amounts of protein, 
which are required, though, prevent thermodynamic profiling from being performed 
routineously. 
In summary, thermodynamic analysis together with site-directed mutagesesis were used for 
hit characterization, as guidepost for candidate selection, and to understand SAR. The structural 
information obtained by this strategy led to the identification of fragments (II/C and II/2) that 
have the potential to be optimized by the application of fragment growing or merging. The 
relative importances of functional groups of II/2 were investigated by ITC. The obtained results 
are of great relevance for the imminent optimization steps. Besides synthetic modifications 
future experiments should address the crystallization of PqsR-fragment complexes to get 
detailed information how and where to grow or modify the fragments. As alternative NMR 
spectroscopy could be used that also is a standard method for macromolecular three-
dimensional structure determination (Pellecchia et al., 2002). 
In the chapters 3.1 and 3.2 the comparison of thermodynamic signatures obtained for PqsR 
ligands towards the wild-type protein and site-directed mutants was successfully applied to 
increase the knowledge of protein–ligand interactions. As alternative to this laborious site-
directed mutagenesis experiments, proteins from various species, which are highly conserved in 
sequence and differ only in few residues, might be considered. This latter approach was applied 
in subproject 3.3 employing human and marmoset monkey 17β-HSD1. The present study aimed 
at increasing the information of active site topologies and protein-ligand interactions to facilitate 
structure-based design and optimization of 17β-HSD1 inhibitors. The inhibitory potencies of 
selected members of different non-steroidal inhibitor classes toward marmoset 17β-HSD1 were 
determined and the data were compared with the values obtained for the human enzyme. While 
among other inhibitor classes the bicyclic substituted hydroxyphenylmethanones (representative 
structure: III/12) showed comparable inhibition data for both enzymes, a species specific 
inhibition profile was observed in the class of the (hydroxyphenyl)naphthols (representative 
structure: III/19; Figure 19). A combination of computational methods, including homology 
modelling, molecular docking, MD simulation, and binding energy calculation, was used to 
develop a reasonable model of the three-dimensional structure of marmoset 17β-HSD1 and 
inhibition data of compunds III/12 and III/19 were rationalized on the structural basis. 
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Figure 19. Inhibition of human and marmoset 17β-HSD1 by compounds III/12 and III/19. IC50 
values toward marmoset 17β-HSD1 are Logit transformed values calculated from % inhibition at 
50 nM inhibitor concentration, for inhibition values <30% or >70%, a trend is given. 
When the three-dimensional structures of marmoset and human 17β-HSD1 are compared, one 
of the most striking features is the small α-helix including the residues 190 to 196 (Figure 20a). 
It is formed in the segment between the βF-sheet and the αG’-helix starting from the interface 
residue Thr190, which is half in and half out of the helix (N-cap position). In contrast to the 
human enzyme, where this region is highly flexible, as suggested by the different crystal 
structures, the α-helix stayed stable during the MD simulation in both the holoform and the 
ternary complex (Figure 20b).  
 
Figure 20. a) Three-dimensional structure superimposition of marmoset and human 17β-HSD1. 
Low energy structure of marmoset 17β-HSD1 (green) in complex with E1 and NADPH (orange) 
from MD simulation superimposed onto the x-ray structure of human 17β-HSD1 (grey, PDB 
code: 1fdtB). When two residues are indicated, the first corresponds to marmoset 17β-HSD1 
and the second to human 17β-HSD1. b) RMSD analysis of the MD simulations of the marmoset 
17β-HSD1 model. Time-dependent Cα-RMSD for all residues of the secondary (orange) and 
ternary (green) complex.  
The observed conformational stability might be explained by the presence of a proline in 
position 191 instead of an alanine. Proline is a favorable candidate for N1 position because of its 
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own conformational properties: with only one rotatable angle it loses less entropy than other 
amino acids in forming an α-helix and thereby it should have some stabilizing influence 
(Richardson and Richardson, 1988). Furthermore, in an analysis of sequence-structural 
characteristics in protein crystal structures, proline was found to be a favoured residue at N1 
position. Especially the residue pair involving threonine at N-cap and proline at N1 position, 
which is observed for marmoset 17β-HSD1, has a high prevalence (Kumar and Bansal, 1998). 
In order to analyze the influence of the conformational changes in marmoset 17β-HSD1 on 
the binding of ligands III/12 and III/19, docking studies with subsequent MD simulations, free 
energy calculations, and energy decomposition analyzes were carried out. While the 
conformational differences between the marmoset and the human enzyme did not affect the 
binding mode of III/12 remarkably, the suggested binding mode of III/19 differed strongly in 
17β-HSD1 of both species (Figure 21). 
 
Figure 21. Hypothetical binding modes of compounds III/12 and III/19. A) Superimposition of 
lowest energy structures of III/12 (orange) and III/19 (cyan) obtained by docking into the x-ray 
structure of human 17β-HSD1 (magenta, PDB code: 1fdtB). B) Superimposition of lowest 
energy structures of III/12 (light green) and III/19 (yellow) obtained by docking into the 
marmoset 17β-HSD1 homology model (green). C) Superimposition of lowest energy structures 
of III/12 (light green) docked into the marmoset 17β-HSD1 model (green) and of III/12 (orange) 
docked into the x-ray structure of human 17β-HSD1 (magenta, PDB code: 1fdtB). D) 
Superimposition of lowest energy structures of III/19 (yellow) docked into the marmoset 17β-
HSD1 model (green) and of III/19 (cyan) docked into the x-ray structure of human 17β-HSD1 
(magenta, PDB code: 1fdtB).  
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One possible explanation for that might be the lower sterical demand of III/12 compared to 
III/19. However, the energy contribution of the interaction between III/12 and the marmoset 
Asn152 (-1.6 kcal/mol) is reduced, whereas it was outstanding in complex with the human 
enzyme (-4.1 kcal/mol). Due to the minimal shift of III/12 in the marmoset binding pocket, the 
geometric parameters for the H-bond with Asn152 are no longer optimal. Interestingly, in the 
marmoset enzyme an additional interaction of III/12 with Asn222 is observed, which seems to 
compensate the deficit in interaction energy due to the absent interaction with Asn152 resulting 
in comparable binding energies for III/12 in complex with human (-4.7 kcal/mol) and marmoset 
(-5.8 kcal/mol) 17β-HSD1. The latter finding is in accordance with the inhibition data observed 
for compound III/12 (Figure 19) and validates the marmoset 17β-HSD1 model. 
Considering compound III/19, no particular interactions with the subpocket residues of the 
marmoset enzyme exist. Although weak interactions between III/19 and the C-terminal region 
of marmoset 17β-HSD1 are observed, the binding free energy (-3.2 kcal/mol) is less favorable 
compared to that calculated for the human 17β-HSD1-III/19 complex (-7.3 kcal/mol). As the C-
terminal part of the enzyme has already been discussed as a potential product exit gate of the 
enzyme (Negri et al., 2010), inhibitor III/19 might be solvent exposed. This is consistent with 
the unfavorable entropy term of this complex resulting in the least favorable free energy. 
Obviously, the presence of a proline in the flexible loop region and the thereby induced 
conformational changes in marmoset 17β-HSD1 are decisive for the species specific inhibition 
of III/19. On one hand interactions with subpocket residues like Asn152, recently discussed as 
relevant interaction partner (Lilienkampf et al., 2009), are prevented and on the other hand the 
inhibitor is forced in an unfavorable solvent exposed conformation. 
The validity of the presented homology model is further substantiated by its ability to 
explain the reduced inhibitory potency of C-15 substituted estrone derivatives toward marmoset 
17β-HSD1 (Möller et al., 2010). The substituents in 15-position of the steroid were designed to 
occupy the hole between the flexible βFαG’-loop and the αG’-helix in the human enzyme 
(Messinger et al., 2009). Together with the helix formation and the conformational changes in 
the βD/αE- segment, the S222N mutation limits the size of the hole in marmoset 17β-HSD1 and 
thereby might reduce the inhibitory potency toward the marmoset enzyme. 
In summary, comparison of inhibitory potencies toward human and marmoset 17β-HSD1 
and their rationalization on the structural level increased the knowledge of active site topologies 
and protein-ligand interactions. Thus, the applied approach can be a valid alternative to site-
directed mutagenesis. This work could not only offer a better understanding of the active site 
topologies and of the protein-ligand interactions, but also provides novel structural clues that 
will help to design and optimize potent human 17β-HSD1 inhibitors with improved inhibitory 
potency toward marmoset 17β-HSD1. This is an important step to turn compounds, which show 
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a promising pharmaceutical profile, into candidates for in vivo evaluation. Hence, our combined 
computational approach could also be considered as a valuable tool to achieve this goal. 
However, the explanatory power of the three-dimensional structure of marmoset 17β-HSD1 and 
the proposed ligand binding modes should not be overestimated keeping in mind that they are 
models. But using theses models in addition to complementary experimental methods such as in 
vitro enzyme assays or NMR spectroscopy that is a dynamic method to explore the structure of 
macromolecules, in particular of flexible proteins like 17β-HSD1, can aid drug discovery. 
The proposed binding mode of III/12 (=IV/B3) was used to elaborate the bicyclic 
substituted hydroxyphenylmethanone type inhibitors of 17β-HSD1. According to the suggested 
binding mode the bicyclic moiety of IV/B3 occupies the C-terminal region of 17β-HSD1. Given 
that several highly active steroidal inhibitors have extensions in position 2 with the most potent 
derivatives of them bearing an additional phenyl ring connected by a C2 linker (Gege et al., 
2006) there is space for additional substituents in this region. Therefore this subproject aimed at 
investigating the role of the bicyclic moiety to gain further interactions and is described in 
chapter 3.4. The design concept of the bicyclic substituted hydroxyphenylmethanones that was 
reported in a preceding study (Oster et al., 2010a) expected the hydroxyl group of the phenyl 
ring to form hydrogen bonds with His221 and Glu282 in the C-terminal region of the steroid 
binding pocket. In the proposed binding mode compound IV/B3 is stabilized by four H-bonds: 
the meta-hydroxyphenyl moiety forms an H-bond with Asn152, the carbonyl group interacts 
with Ser142 as well as with Tyr155 and the OH group in para position of the phenyl ring 
adjacent to the thiophene interacts with His221 (Figure 22).  
 
Figure 22. a) Hypothetical binding mode of compound IV/B3 (orange) obtained by docking into 
17β-HSD1 (PDB-ID: 1FDT). Co-factor NADPH (light green) and interacting residues (dark 
green) of the active site are shown. Hydrogen bonds are represented in black dashed lines. b) 
Chemical structure of compound IV/B3. 
However no interaction with Glu282 was observed. The proposed binding model is confirmed 
by the inhibitory potencies of the methoxy derivatives (IV/2-IV/4), which indicate that the 
hydrogen-bond donor property is not necessary for strong inhibitory activity (Table 3). 
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In general, the relevance of Glu282 for ligand binding is discussed controversially. While site-
directed mutagenesis studies indicated no significant interaction between Glu282 and the 3-OH 
group of the substrate (Puranen et al., 1997), hydrogen bonding between both was found in 
several independent crystal structures (Azzi et al., 1996; Sawicki et al., 1999). The hydrogen-
bond acceptor property of the phenol might play a more important role since compound IV/1, 
without hydroxy functionality on the phenyl ring, showed reduced 17β-HSD1 inhibition (Table 
3). Thus, the potential hydrogen-bond donor His221, which is known as an important factor for 
substrate interaction (Mazza et al., 1998), appears to be involved in the binding of our inhibitors 
although it is also described to be implicated in enzyme stabilization by interacting with Glu282 
(Mazumdar et al., 2009). 
Table 3. Inhibition of human 17β-HSD1 and 17β-HSD2 by compounds IV/B3 and IV/1-IV/4 
 
Compd. X 
IC50 [nM][a] 
17β-HSD1[b] 17β-HSD2[c] 
IV/B3 4-hydroxy 33 478 
IV/1 H 155 128 
IV/2 2-methoxy 86 196 
IV/3 3-methoxy 95 342 
IV/4 4-methoxy 220 507 
[a] Mean value of three determinations, standard deviation less then 26 %; [b] Human placenta, cytosolic fraction, 
substrate E1 (500 nM), cofactor NADH (500 µM); [c] Human placenta, microsomal fraction, substrate E2 (500 nM), 
cofactor NAD+ (1500 µM). 
Regarding the mono-methoxy and ethoxy derivatives (IV/2–IV/5 and IV/9–IV/11), 
respectively, it becomes apparent that the para position seems to be less favorable than meta 
and ortho. Moreover, di- and trimethoxy derivatives (IV/6–IV/8) showed a strong decrease in 
activity as well, indicating that the space around this phenyl ring is sterically restricted. This 
finding is in accordance with the docking results. According to the orientation of the phenyl 
ring, the disubstitution of IV/6 compels the methoxy groups to adopt a conformation leading to 
steric clashes with either Tyr218 or Phe259. Indeed, taking into account that the 1,3-
benzodioxol compound IV/26 showed a much higher affinity than the corresponding dimethoxy 
compound IV/6, it can be concluded that the binding pocket is very restricted. 
The sulfonamide IV/23 (IC50 = 12 nM) turned out to be the most potent inhibitor of this 
study. Compared to its methanesulfonamide analogue IV/21, the introduction of the phenyl led 
to 12-fold higher 17β-HSD1 inhibition. The docking study revealed the benzene ring of IV/23 
to be implicated in a π–π interaction with Phe259 (Figure 23).  
S
O
OH
IV/B3, IV/1-IV/4
X
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Figure 23. a) Hypothetical binding mode of compound IV/23 (orange) obtained by docking into 
17β-HSD1 (PDB-ID: 1FDT). Co-factor NADPH (light green) and interacting residues (dark 
green) of the active site are shown. Hydrogen bonds are represented in black dashed lines. For 
the sake of clarity π-π-interactions are not depicted. b) Chemical structure of compound IV/23. 
Comparing IV/B3 and IV/23, both compounds interact with Asn152. The relevance of this 
amino acid for ligand binding was already proposed in chapter 3.3 and is confirmed by a co-
crystal structure of a highly potent, steroidal 17β-HSD1 inhibitor (Mazumdar et al., 2009). 
IV/B3 and IV/23 showed similar IC50 values although the hydrogen-bonding interaction of 
IV/23 with Ser142 was not present in the observed binding mode. The π–π interactions found 
for compound IV/23 might be able to compensate the loss of the hydrogen bond between the 
ketone and Ser142. 
In summary, guided by in silico structural data further developments in the class of bicyclic 
substituted hydroxyphenylmethanones were achieved by organic synthesis and biological 
evaluation. The high inhibitory activities of compounds bearing large substituents like 
benzylsulfonamide or benzyloxy revealed that these groups take advantage of the additional 
space in the C-terminal region. Despite the good inhibitory potencies, they have to be 
considered critically in terms of ligand efficiency. However, further bio-isosteric replacements 
of the phenolic hydroxy group might lead to compounds combining high potency with good 
selectivity and intracellular activity. The most promising compound of this study, 
methylbenzenesulfonamide IV/23, shows strong inhibitory activity in both cellular and cell-free 
assays, as well as no affinity toward estrogen receptors α and β. It might be a candidate for 
further optimization, especially regarding its selectivity and cellular activity. 
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